{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {},
   "outputs": [],
   "source": [
    "from app.utils import download_patent_text\n",
    "import requests\n",
    "\n",
    "url = \"https://patents.google.com/patent/{patent_number}/en\"\n",
    "patent_number = \"US7615532\"\n",
    "patent_number = \"US20210008212A1\"\n",
    "patent_number = \"US777194\"\n",
    "patent_number = \"US6099803\"\n",
    "\n",
    "# response = requests.get(url.format(patent_number=patent_number))\n",
    "patent_text, soup =  download_patent_text(url.format(patent_number=patent_number))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 190,
   "metadata": {},
   "outputs": [],
   "source": [
    "from bs4 import BeautifulSoup\n",
    "res = requests.get(url.format(patent_number=patent_number))\n",
    "res.content\n",
    "soup = BeautifulSoup(res.content, \"html.parser\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 191,
   "metadata": {},
   "outputs": [],
   "source": [
    "title = soup.head.title.string\n",
    "abstract = soup.find_all(\"section\", {\"itemprop\": \"abstract\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 184,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 184,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "abstract"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 185,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "h2 Links\n"
     ]
    },
    {
     "ename": "IndexError",
     "evalue": "list index out of range",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[185], line 14\u001b[0m\n\u001b[0;32m     12\u001b[0m         html \u001b[38;5;241m+\u001b[39m\u001b[38;5;241m=\u001b[39m \u001b[38;5;28mstr\u001b[39m(tag)\n\u001b[0;32m     13\u001b[0m info \u001b[38;5;241m=\u001b[39m sections[\u001b[38;5;241m0\u001b[39m]\n\u001b[1;32m---> 14\u001b[0m links \u001b[38;5;241m=\u001b[39m \u001b[43msections\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m1\u001b[39;49m\u001b[43m]\u001b[49m\n\u001b[0;32m     15\u001b[0m sections \u001b[38;5;241m=\u001b[39m soup\u001b[38;5;241m.\u001b[39mfind_all(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124msection\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "\u001b[1;31mIndexError\u001b[0m: list index out of range"
     ]
    }
   ],
   "source": [
    "description = soup.find(\"section\", {\"itemprop\": \"description\"})\n",
    "classification = soup.find(\"h2\", {\"itemprop\": \"classifications\"})\n",
    "claims = soup.find(\"section\", {\"itemprop\": \"claims\"})\n",
    "sections = []\n",
    "html = u\"\" + str(soup.find(\"h2\"))\n",
    "for tag in soup.find(\"h2\").next_siblings:\n",
    "    if tag.name == \"h2\":\n",
    "        sections.append(html)\n",
    "        html = u\"\" + str(tag)\n",
    "        print(tag.name, tag.string)\n",
    "    else:\n",
    "        html += str(tag)\n",
    "info = sections[0]\n",
    "links = sections[1]\n",
    "sections = soup.find_all(\"section\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 186,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "h2 Links\n",
      "section None\n"
     ]
    }
   ],
   "source": [
    "sections = []\n",
    "for tag in soup.find(\"h2\").next_siblings:\n",
    "    if tag.name == \"h2\" or tag.name == \"section\":\n",
    "        sections.append(html)\n",
    "        html = u\"\" + str(tag)\n",
    "        print(tag.name, tag.string)\n",
    "        if tag.name == \"section\":\n",
    "            break\n",
    "    else:\n",
    "        html += str(tag)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'<section>\\n<h2>Images</h2>\\n<ul>\\n<li itemprop=\"images\" itemscope=\"\" repeat=\"\">\\n<img itemprop=\"thumbnail\" src=\"https://patentimages.storage.googleapis.com/67/92/f4/23e5856d442174/US20210008212A1-20210114-D00001.png\"/>\\n<meta content=\"https://patentimages.storage.googleapis.com/70/10/da/f0e18739f178d1/US20210008212A1-20210114-D00001.png\" itemprop=\"full\"/>\\n<ul>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"0\" itemprop=\"figurePage\"/>\\n<meta content=\"20\" itemprop=\"id\"/>\\n<meta content=\"Water\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"132\" itemprop=\"left\"/>\\n<meta content=\"990\" itemprop=\"top\"/>\\n<meta content=\"210\" itemprop=\"right\"/>\\n<meta content=\"1029\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"0\" itemprop=\"figurePage\"/>\\n<meta content=\"40\" itemprop=\"id\"/>\\n<meta content=\"Distilled monoglycerides\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"136\" itemprop=\"left\"/>\\n<meta content=\"668\" itemprop=\"top\"/>\\n<meta content=\"228\" itemprop=\"right\"/>\\n<meta content=\"706\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"0\" itemprop=\"figurePage\"/>\\n<meta content=\"80\" itemprop=\"id\"/>\\n<meta content=\"Deoxycholic acid\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"156\" itemprop=\"left\"/>\\n<meta content=\"21\" itemprop=\"top\"/>\\n<meta content=\"214\" itemprop=\"right\"/>\\n<meta content=\"57\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"images\" itemscope=\"\" repeat=\"\">\\n<img itemprop=\"thumbnail\" src=\"https://patentimages.storage.googleapis.com/6a/7a/e2/55d57a93a19ae9/US20210008212A1-20210114-D00002.png\"/>\\n<meta content=\"https://patentimages.storage.googleapis.com/fe/a9/32/389890293ced44/US20210008212A1-20210114-D00002.png\" itemprop=\"full\"/>\\n<ul>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"1\" itemprop=\"figurePage\"/>\\n<meta content=\"100\" itemprop=\"id\"/>\\n<meta content=\"hydrogenated castor oil\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"134\" itemprop=\"left\"/>\\n<meta content=\"25\" itemprop=\"top\"/>\\n<meta content=\"220\" itemprop=\"right\"/>\\n<meta content=\"66\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"1\" itemprop=\"figurePage\"/>\\n<meta content=\"20\" itemprop=\"id\"/>\\n<meta content=\"Water\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"132\" itemprop=\"left\"/>\\n<meta content=\"959\" itemprop=\"top\"/>\\n<meta content=\"190\" itemprop=\"right\"/>\\n<meta content=\"995\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"1\" itemprop=\"figurePage\"/>\\n<meta content=\"80\" itemprop=\"id\"/>\\n<meta content=\"Deoxycholic acid\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"151\" itemprop=\"left\"/>\\n<meta content=\"264\" itemprop=\"top\"/>\\n<meta content=\"223\" itemprop=\"right\"/>\\n<meta content=\"306\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"images\" itemscope=\"\" repeat=\"\">\\n<img itemprop=\"thumbnail\" src=\"https://patentimages.storage.googleapis.com/85/91/ce/021689700d0501/US20210008212A1-20210114-D00003.png\"/>\\n<meta content=\"https://patentimages.storage.googleapis.com/32/fa/02/2b3cab679e2d6a/US20210008212A1-20210114-D00003.png\" itemprop=\"full\"/>\\n<ul>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"2\" itemprop=\"figurePage\"/>\\n<meta content=\"10\" itemprop=\"id\"/>\\n<meta content=\"Glycerol monolaurate\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"136\" itemprop=\"left\"/>\\n<meta content=\"795\" itemprop=\"top\"/>\\n<meta content=\"222\" itemprop=\"right\"/>\\n<meta content=\"836\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"2\" itemprop=\"figurePage\"/>\\n<meta content=\"20\" itemprop=\"id\"/>\\n<meta content=\"Water\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"142\" itemprop=\"left\"/>\\n<meta content=\"404\" itemprop=\"top\"/>\\n<meta content=\"228\" itemprop=\"right\"/>\\n<meta content=\"443\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"2\" itemprop=\"figurePage\"/>\\n<meta content=\"30\" itemprop=\"id\"/>\\n<meta content=\"Glycerol monolaurate\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"150\" itemprop=\"left\"/>\\n<meta content=\"19\" itemprop=\"top\"/>\\n<meta content=\"245\" itemprop=\"right\"/>\\n<meta content=\"60\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"images\" itemscope=\"\" repeat=\"\">\\n<img itemprop=\"thumbnail\" src=\"https://patentimages.storage.googleapis.com/91/55/4f/9145bd9232ade5/US20210008212A1-20210114-D00004.png\"/>\\n<meta content=\"https://patentimages.storage.googleapis.com/01/1e/29/a567f987b20f22/US20210008212A1-20210114-D00004.png\" itemprop=\"full\"/>\\n<ul>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"3\" itemprop=\"figurePage\"/>\\n<meta content=\"100\" itemprop=\"id\"/>\\n<meta content=\"hydrogenated castor oil\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"118\" itemprop=\"left\"/>\\n<meta content=\"18\" itemprop=\"top\"/>\\n<meta content=\"237\" itemprop=\"right\"/>\\n<meta content=\"59\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"3\" itemprop=\"figurePage\"/>\\n<meta content=\"15\" itemprop=\"id\"/>\\n<meta content=\"Pioglitazone\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"584\" itemprop=\"left\"/>\\n<meta content=\"1166\" itemprop=\"top\"/>\\n<meta content=\"640\" itemprop=\"right\"/>\\n<meta content=\"1203\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"3\" itemprop=\"figurePage\"/>\\n<meta content=\"20\" itemprop=\"id\"/>\\n<meta content=\"Water\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"129\" itemprop=\"left\"/>\\n<meta content=\"897\" itemprop=\"top\"/>\\n<meta content=\"214\" itemprop=\"right\"/>\\n<meta content=\"938\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"3\" itemprop=\"figurePage\"/>\\n<meta content=\"30\" itemprop=\"id\"/>\\n<meta content=\"Glycerol monolaurate\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"977\" itemprop=\"left\"/>\\n<meta content=\"1163\" itemprop=\"top\"/>\\n<meta content=\"1038\" itemprop=\"right\"/>\\n<meta content=\"1204\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"3\" itemprop=\"figurePage\"/>\\n<meta content=\"40\" itemprop=\"id\"/>\\n<meta content=\"Distilled monoglycerides\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"130\" itemprop=\"left\"/>\\n<meta content=\"683\" itemprop=\"top\"/>\\n<meta content=\"193\" itemprop=\"right\"/>\\n<meta content=\"724\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n<li itemprop=\"callouts\" itemscope=\"\" repeat=\"\">\\n<meta content=\"3\" itemprop=\"figurePage\"/>\\n<meta content=\"80\" itemprop=\"id\"/>\\n<meta content=\"Deoxycholic acid\" itemprop=\"label\"/>\\n<span itemprop=\"bounds\" itemscope=\"\">\\n<meta content=\"146\" itemprop=\"left\"/>\\n<meta content=\"234\" itemprop=\"top\"/>\\n<meta content=\"233\" itemprop=\"right\"/>\\n<meta content=\"278\" itemprop=\"bottom\"/>\\n</span>\\n</li>\\n</ul>\\n</li>\\n</ul>\\n</section>'"
      ]
     },
     "execution_count": 145,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "html"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2"
      ]
     },
     "execution_count": 144,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(sections)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "12"
      ]
     },
     "execution_count": 192,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sections = soup.find_all(\"section\")\n",
    "len(sections)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 215,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<h2>Images</h2>\n",
      "<h2>Classifications</h2>\n",
      "<h2>Definitions</h2>\n",
      "<h2>Abstract</h2>\n",
      "<h2>Description</h2>\n",
      "<h2>Claims (<span itemprop=\"count\">38</span>)</h2>\n",
      "<h2>Priority Applications (21)</h2>\n",
      "<section itemprop=\"metadata\" itemscope=\"\">\n",
      "<span itemprop=\"applicationNumber\">US09/026,618</span>\n",
      "<span itemprop=\"priorityDate\">1993-11-01</span>\n",
      "<span itemprop=\"filingDate\">1998-02-20</span>\n",
      "<span itemprop=\"title\">Advanced active electronic devices for molecular biological analysis and diagnostics \n",
      "       </span>\n",
      "<span itemprop=\"ifiStatus\">Expired - Fee Related</span>\n",
      "<a href=\"/patent/US6099803A/en\">\n",
      "<span itemprop=\"representativePublication\">US6099803A</span>\n",
      "        (<span itemprop=\"primaryLanguage\">en</span>)\n",
      "      </a>\n",
      "</section>\n",
      "<section itemprop=\"metadata\" itemscope=\"\">\n",
      "<span itemprop=\"applicationNumber\">US09/026,618</span>\n",
      "<span itemprop=\"priorityDate\">1993-11-01</span>\n",
      "<span itemprop=\"filingDate\">1998-02-20</span>\n",
      "<span itemprop=\"title\">Advanced active electronic devices for molecular biological analysis and diagnostics \n",
      "       </span>\n",
      "<span itemprop=\"ifiStatus\">Expired - Fee Related</span>\n",
      "<a href=\"/patent/US6099803A/en\">\n",
      "<span itemprop=\"representativePublication\">US6099803A</span>\n",
      "        (<span itemprop=\"primaryLanguage\">en</span>)\n",
      "      </a>\n",
      "</section>\n",
      "<h2>ID=27574953</h2>\n",
      "<h2>Patent Citations (2)</h2>\n",
      "<h2>Similar Documents</h2>\n",
      "<h2>Legal Events</h2>\n"
     ]
    }
   ],
   "source": [
    "patent = {\n",
    "    \"Images\": None,\n",
    "    \"Info\": None,\n",
    "    \"Links\": None,\n",
    "    \"Classifications\": None,\n",
    "    \"Definitions\": None,\n",
    "    \"Abstract\": None,\n",
    "    \"Description\": None,\n",
    "    \"Claims\": None,\n",
    "    \"Applications\": None,\n",
    "    \"Metadata\": None,\n",
    "    \"ID\": None,    \n",
    "    \"Published as\": None,\n",
    "    \"Similar Documents\": None,\n",
    "    \"Legal Events\": None\n",
    "}\n",
    "for section in sections:\n",
    "    if section.h2:\n",
    "        for key in patent.keys():\n",
    "            if key in str(section.h2):\n",
    "                patent[key] = section\n",
    "        print(section.h2)\n",
    "    else:\n",
    "        print(section)\n",
    "        if \"metadata\" in str(section):\n",
    "            patent[\"Metadata\"] = section\n",
    "            print(section)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 204,
   "metadata": {},
   "outputs": [],
   "source": [
    "claims = \"\".join(list(patent[\"Claims\"].find(\"div\", {\"itemprop\": \"content\"}).strings)).replace(\"\\n\", \"\").split(\"  \")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 218,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<generator object Tag._all_strings at 0x00000139965CA880>"
      ]
     },
     "execution_count": 218,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patent[\"Description\"].find(\"div\", {\"itemprop\": \"content\"}).strings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 217,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "'NoneType' object is not iterable",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[217], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m description \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;241m.\u001b[39mjoin(\u001b[38;5;28;43mlist\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mpatent\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mDescription\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfind\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdiv\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitemprop\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mtexts\u001b[49m\u001b[43m)\u001b[49m)\u001b[38;5;241m.\u001b[39mreplace(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m)\u001b[38;5;241m.\u001b[39msplit(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m  \u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m      2\u001b[0m description \u001b[38;5;241m=\u001b[39m [d \u001b[38;5;28;01mfor\u001b[39;00m d \u001b[38;5;129;01min\u001b[39;00m description \u001b[38;5;28;01mif\u001b[39;00m d \u001b[38;5;241m!=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m]\n\u001b[0;32m      3\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m i,des \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28menumerate\u001b[39m(description):\n",
      "\u001b[1;31mTypeError\u001b[0m: 'NoneType' object is not iterable"
     ]
    }
   ],
   "source": [
    "description = \"\".join(list(patent[\"Description\"].find(\"div\", {\"itemprop\": \"content\"}))).replace(\"\\n\", \"\").split(\"  \")\n",
    "description = [d for d in description if d != \"\"]\n",
    "for i,des in enumerate(description):\n",
    "    if len(des) < 50:\n",
    "        description[i-1] += des\n",
    "        description.pop(i)\n",
    "description = [d.encode(\"utf-8\").decode(\"utf-8\") for d in description if d != \"\"]\n",
    "\n",
    "description"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 207,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "74"
      ]
     },
     "execution_count": 207,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patent_content = description + claims\n",
    "len(patent_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 158,
   "metadata": {},
   "outputs": [],
   "source": [
    "patent[\"Claims\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<h2>Claims (<span itemprop=\"count\">13</span>)</h2>"
      ]
     },
     "execution_count": 118,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sections[5].h2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<section itemprop=\"abstract\" itemscope=\"\">\n",
       "<h2>Abstract</h2>\n",
       "<div html=\"\" itemprop=\"content\"><abstract lang=\"EN\" load-source=\"docdb\" mxw-id=\"PA431605677\" source=\"national office\">\n",
       "<div class=\"abstract\">The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.</div>\n",
       "</abstract>\n",
       "</div>\n",
       "</section>"
      ]
     },
     "execution_count": 113,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sections[3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "12"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(sections)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [],
   "source": [
    "classification"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "no_sections = soup.section.decompose()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "no_sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "h2 Links\n",
      "h2 Cited By (30)\n"
     ]
    }
   ],
   "source": [
    "# info section\n",
    "sections = []\n",
    "html = u\"\" + str(no_sections.find(\"h2\"))\n",
    "for tag in no_sections.find(\"h2\").next_siblings:\n",
    "    if tag.name == \"h2\":\n",
    "        sections.append(html)\n",
    "        html = u\"\" + str(tag)\n",
    "        print(tag.name, tag.string)\n",
    "    else:\n",
    "        html += str(tag)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "25"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list(soup.find(\"section\").next_siblings))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<section>\n",
       "<h2>Classifications</h2>\n",
       "<ul>\n",
       "<li>\n",
       "<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">C</span>—<span itemprop=\"Description\">CHEMISTRY; METALLURGY</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">C07</span>—<span itemprop=\"Description\">ORGANIC CHEMISTRY</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">C07K</span>—<span itemprop=\"Description\">PEPTIDES</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">C07K14/00</span>—<span itemprop=\"Description\">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">C07K14/435</span>—<span itemprop=\"Description\">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">C07K14/575</span>—<span itemprop=\"Description\">Hormones</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">C07K14/62</span>—<span itemprop=\"Description\">Insulins</span>\n",
       "<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"FirstCode\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "</ul>\n",
       "</li>\n",
       "<li>\n",
       "<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A</span>—<span itemprop=\"Description\">HUMAN NECESSITIES</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61</span>—<span itemprop=\"Description\">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K</span>—<span itemprop=\"Description\">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K38/00</span>—<span itemprop=\"Description\">Medicinal preparations containing peptides</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K38/16</span>—<span itemprop=\"Description\">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K38/17</span>—<span itemprop=\"Description\">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K38/22</span>—<span itemprop=\"Description\">Hormones</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K38/28</span>—<span itemprop=\"Description\">Insulins</span>\n",
       "<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "</ul>\n",
       "</li>\n",
       "<li>\n",
       "<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A</span>—<span itemprop=\"Description\">HUMAN NECESSITIES</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61</span>—<span itemprop=\"Description\">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K</span>—<span itemprop=\"Description\">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K47/00</span>—<span itemprop=\"Description\">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K47/50</span>—<span itemprop=\"Description\">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K47/51</span>—<span itemprop=\"Description\">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K47/54</span>—<span itemprop=\"Description\">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61K47/542</span>—<span itemprop=\"Description\">Carboxylic acids, e.g. a fatty acid or an amino acid</span>\n",
       "<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "</ul>\n",
       "</li>\n",
       "<li>\n",
       "<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A</span>—<span itemprop=\"Description\">HUMAN NECESSITIES</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61</span>—<span itemprop=\"Description\">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61P</span>—<span itemprop=\"Description\">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61P3/00</span>—<span itemprop=\"Description\">Drugs for disorders of the metabolism</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61P3/08</span>—<span itemprop=\"Description\">Drugs for disorders of the metabolism for glucose homeostasis</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61P3/10</span>—<span itemprop=\"Description\">Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics</span>\n",
       "<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "</ul>\n",
       "</li>\n",
       "<li>\n",
       "<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A</span>—<span itemprop=\"Description\">HUMAN NECESSITIES</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61</span>—<span itemprop=\"Description\">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61P</span>—<span itemprop=\"Description\">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61P5/00</span>—<span itemprop=\"Description\">Drugs for disorders of the endocrine system</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61P5/48</span>—<span itemprop=\"Description\">Drugs for disorders of the endocrine system of the pancreatic hormones</span>\n",
       "<meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\n",
       "<span itemprop=\"Code\">A61P5/50</span>—<span itemprop=\"Description\">Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin</span>\n",
       "<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\n",
       "</li>\n",
       "</ul>\n",
       "</li>\n",
       "</ul>\n",
       "</section>"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "soup.find(\"section\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['<section>\\n<h2>Classifications</h2>\\n<ul>\\n<li>\\n<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">C</span>—<span itemprop=\"Description\">CHEMISTRY; METALLURGY</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">C07</span>—<span itemprop=\"Description\">ORGANIC CHEMISTRY</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">C07K</span>—<span itemprop=\"Description\">PEPTIDES</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">C07K14/00</span>—<span itemprop=\"Description\">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">C07K14/435</span>—<span itemprop=\"Description\">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">C07K14/575</span>—<span itemprop=\"Description\">Hormones</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">C07K14/62</span>—<span itemprop=\"Description\">Insulins</span>\\n<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"FirstCode\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n</ul>\\n</li>\\n<li>\\n<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A</span>—<span itemprop=\"Description\">HUMAN NECESSITIES</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61</span>—<span itemprop=\"Description\">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K</span>—<span itemprop=\"Description\">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K38/00</span>—<span itemprop=\"Description\">Medicinal preparations containing peptides</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K38/16</span>—<span itemprop=\"Description\">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K38/17</span>—<span itemprop=\"Description\">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K38/22</span>—<span itemprop=\"Description\">Hormones</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K38/28</span>—<span itemprop=\"Description\">Insulins</span>\\n<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n</ul>\\n</li>\\n<li>\\n<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A</span>—<span itemprop=\"Description\">HUMAN NECESSITIES</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61</span>—<span itemprop=\"Description\">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K</span>—<span itemprop=\"Description\">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K47/00</span>—<span itemprop=\"Description\">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K47/50</span>—<span itemprop=\"Description\">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K47/51</span>—<span itemprop=\"Description\">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K47/54</span>—<span itemprop=\"Description\">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61K47/542</span>—<span itemprop=\"Description\">Carboxylic acids, e.g. a fatty acid or an amino acid</span>\\n<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n</ul>\\n</li>\\n<li>\\n<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A</span>—<span itemprop=\"Description\">HUMAN NECESSITIES</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61</span>—<span itemprop=\"Description\">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61P</span>—<span itemprop=\"Description\">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61P3/00</span>—<span itemprop=\"Description\">Drugs for disorders of the metabolism</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61P3/08</span>—<span itemprop=\"Description\">Drugs for disorders of the metabolism for glucose homeostasis</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61P3/10</span>—<span itemprop=\"Description\">Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics</span>\\n<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n</ul>\\n</li>\\n<li>\\n<ul itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A</span>—<span itemprop=\"Description\">HUMAN NECESSITIES</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61</span>—<span itemprop=\"Description\">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61P</span>—<span itemprop=\"Description\">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61P5/00</span>—<span itemprop=\"Description\">Drugs for disorders of the endocrine system</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61P5/48</span>—<span itemprop=\"Description\">Drugs for disorders of the endocrine system of the pancreatic hormones</span>\\n<meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n<li itemprop=\"classifications\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"Code\">A61P5/50</span>—<span itemprop=\"Description\">Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin</span>\\n<meta content=\"true\" itemprop=\"Leaf\"/><meta content=\"true\" itemprop=\"IsCPC\"/>\\n</li>\\n</ul>\\n</li>\\n</ul>\\n</section>\\n',\n",
       " '<section>\\n<h2>Definitions</h2>\\n<ul>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the present invention</span>\\n<span itemprop=\"definition\">relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action.</span>\\n<meta content=\"0002\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the invention</span>\\n<span itemprop=\"definition\">also relates to methods of providing such derivatives, to pharmaceutical compositions containing them, to a method of treating diabetes and hyperglycemia using the insulin derivatives of the invention and to the use of such insulin derivatives in the treatment of diabetes and hyperglycemia.</span>\\n<meta content=\"0002\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the treatment of diabetes</span>\\n<span itemprop=\"definition\">both type 1 diabetes and type 2 diabetes, relies to an increasing extent on the so-called intensive insulin treatment.</span>\\n<meta content=\"0003\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the patients</span>\\n<span itemprop=\"definition\">are treated with multiple daily insulin injections comprising one or two daily injections of a long acting insulin to cover the basal insulin requirement supplemented by bolus injections of a rapid acting insulin to cover the insulin requirement related to meals.</span>\\n<meta content=\"0003\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Long acting insulin compositions</span>\\n<span itemprop=\"definition\">are well known in the art.</span>\\n<meta content=\"0004\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">one main type of long acting insulin compositions</span>\\n<span itemprop=\"definition\">comprises injectable aqueous suspensions of insulin crystals or amorphous insulin.</span>\\n<meta content=\"0004\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin compounds utilized</span>\\n<span itemprop=\"definition\">typically are protamine insulin, zinc insulin or protamine zinc insulin.</span>\\n<meta content=\"0004\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">protamines</span>\\n<span itemprop=\"definition\">While it was earlier believed that protamines were non-immunogenic, it has now turned out that protamines can be immunogenic in man and that their use for medical purposes may lead to formation of antibodies. Also, evidence has been found that the protamine-insulin complex is itself immunogenic. Therefore, with some patients the use of long acting insulin compositions containing protamines must be avoided.</span>\\n<meta content=\"0006\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Another type of long acting insulin compositions</span>\\n<span itemprop=\"definition\">are solutions having a pH value below physiological pH from which the insulin will precipitate because of the rise in the pH value when the solution is injected.</span>\\n<meta content=\"0007\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a drawback with these solutions</span>\\n<span itemprop=\"definition\">is that the particle size distribution of the precipitate formed in the tissue on injection, and thus the release profile of the medication, depends on the blood flow at the injection site and other parameters in a somewhat unpredictable manner.</span>\\n<meta content=\"0007\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a further drawback</span>\\n<span itemprop=\"definition\">is that the solid particles of the insulin may act as a local irritant causing inflammation of the tissue at the site of injection.</span>\\n<meta content=\"0007\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">WO 91/12817</span>\\n<span itemprop=\"definition\">discloses soluble insulin compositions comprising insulin complexes of cobalt(III). The action profile of these complexes is only moderately prolonged and the bioavailability is reduced relative to human insulin.</span>\\n<meta content=\"0008\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Human insulin</span>\\n<span itemprop=\"definition\">has three primary amino groups: the N-terminal group of the A-chain and of the B-chain and the  ⁇ -amino group of Lys B29 .</span>\\n<meta content=\"0009\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Several insulin derivatives which are substituted in one or more of these groups</span>\\n<span itemprop=\"definition\">are known in the prior art.</span>\\n<meta content=\"0009\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">U.S. Pat. No. 3,528,960</span>\\n<span itemprop=\"definition\">(Eli Lilly) relates to N-carboxyaroyl insulins in which one, two or three primary amino groups of the insulin molecule has a carboxyaroyl group.</span>\\n<meta content=\"0009\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">JP laid-open patent application No. 1-254699</span>\\n<span itemprop=\"definition\">discloses insulin wherein a fatty acid is bound to the amino group of Phe B1 or to the  ⁇ -amino group of LyS B29 or to both of these.</span>\\n<meta content=\"0011\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the stated purpose of the derivatisation</span>\\n<span itemprop=\"definition\">is to obtain a pharmacologically acceptable, stable insulin preparation.</span>\\n<meta content=\"0011\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Insulins</span>\\n<span itemprop=\"definition\">which in the B30 position have an amino acid having at least five carbon atoms which cannot necessarily be coded for by a triplet of nucleotides, are described in JP laid-open patent application No. 57-067548 (Shionogi).</span>\\n<meta content=\"0012\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin analogues</span>\\n<span itemprop=\"definition\">are claimed to be useful in the treatment of diabetes mellitus, particularly in patients who are insulin resistant due to generation of bovine or porcine insulin antibodies.</span>\\n<meta content=\"0012\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">WO 95/07931</span>\\n<span itemprop=\"definition\">discloses human insulin derivatives wherein the  ⁇ -amino group of LyS B29 has a lipophilic substituent. These insulin derivatives have a prolonged profile of action and are soluble at physiological pH values.</span>\\n<meta content=\"0013\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">EP 894095</span>\\n<span itemprop=\"definition\">discloses insulin derivatives wherein the N-terminal group of the B-chain and/or the  ⁇ -amino group of Lys in position B28, B29 or B30 has a substituent of the formula —CO—W—COOH where W can be a long chain hydrocarbon group. These insulin derivatives have a prolonged profile of action and are soluble at physiological pH values.</span>\\n<meta content=\"0014\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the present invention</span>\\n<span itemprop=\"definition\">is based on the recognition that the overall hydrophobicity of an insulin derivative molecule plays an important role for the in vivo potency of the derivative.</span>\\n<meta content=\"0016\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the present invention</span>\\n<span itemprop=\"definition\">relates to an insulin derivative which is a naturally occurring insulin or an analogue thereof which has a side chain attached either to the  ⁇ -amino group of the N-terminal amino acid residue of the B chain or to the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: -W-X—Y-Z wherein W is:</span>\\n<meta content=\"0017\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the side chain -W-X—Y-Z</span>\\n<span itemprop=\"definition\">is attached to the  ⁇ -amino group of the N-terminal amino acid residue of the B chain of the parent insulin.</span>\\n<meta content=\"0044\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">side chain -W-X—Y-Z</span>\\n<span itemprop=\"definition\">is attached to the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0045\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the side chain —W 13 X—Y-Z</span>\\n<span itemprop=\"definition\">is attached to the  ⁇ -amino group of a Lys residue present in position 28 of the B chain.</span>\\n<meta content=\"0045\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the side chain -W-X—Y-Z</span>\\n<span itemprop=\"definition\">is attached to the  ⁇ -amino group of a Lys residue present in position 29 of the B chain.</span>\\n<meta content=\"0045\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the side chain -W-X—Y-Z</span>\\n<span itemprop=\"definition\">is attached to the  ⁇ -amino group of a Lys residue present in position 30 of the B chain.</span>\\n<meta content=\"0045\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure W of the side chain -W-X—Y-Z</span>\\n<span itemprop=\"definition\">can be a covalent bond.</span>\\n<meta content=\"0046\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">can be a residue of an  ⁇ -amino acid having a carboxylic acid group in the side chain and comprising a total of from 4 to 10 carbon atoms.</span>\\n<meta content=\"0046\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">can be the residue of an  ⁇ -amino acid, that can be coded for by the genetic code.</span>\\n<meta content=\"0046\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">can, for example, be selected from the group consisting of  ⁇ -Asp,  ⁇ -Asp,  ⁇ -Glu, and  ⁇ -Glu. Further options for W are for example  ⁇ -hGlu and  ⁇ -hGlu.</span>\\n<meta content=\"0046\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">is a chain composed of two  ⁇ -amino acid residues of which one has from 4 to 10 carbon atoms and a carboxylic acid group in the side chain while the other has from 2 to 11 carbon atoms but no free carboxylic acid group.</span>\\n<meta content=\"0047\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the  ⁇ -amino acid residue with no free carboxylic acid group</span>\\n<span itemprop=\"definition\">can be a neutral, codable  ⁇ -amino acid residue.</span>\\n<meta content=\"0047\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">examples are:  ⁇ -Asp-Gly; Gly- ⁇ -Asp;  ⁇ -Asp-Gly; Gly- ⁇ -Asp;  ⁇ -Glu-Gly; Gly- ⁇ -Glu;  ⁇ -Glu-Gly; Gly- ⁇ -Glu;  ⁇ -hGlu-Gly; Gly- ⁇ -hGlu;  ⁇ -hGlu-Gly; and Gly- ⁇ -hGlu.</span>\\n<meta content=\"0047\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">is a chain composed of two  ⁇ -amino acid residues, independently having from 4 to 10 carbon atoms, and both having a carboxylic acid group in the side chain.</span>\\n<meta content=\"0048\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">One of these  ⁇ -amino acid residues or both of them</span>\\n<span itemprop=\"definition\">can be codable  ⁇ -amino acid residues.</span>\\n<meta content=\"0048\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">examples are:  ⁇ -Asp- ⁇ -Asp;  ⁇ -Asp- ⁇ -Glu;  ⁇ -Asp- ⁇ -hGlu;  ⁇ -Asp- ⁇ -Asp;  ⁇ -Asp- ⁇ -Glu;  ⁇ -Asp- ⁇ -hGlu;  ⁇ -Asp- ⁇ -Asp;  ⁇ -Asp- ⁇ -hGlu;  ⁇ -Asp- ⁇ -Asp;  ⁇ -Asp- ⁇ -hGlu;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Glu;  ⁇ -Glu- ⁇ -hGlu;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Asp;  ⁇ -Glu- ⁇ -Asp</span>\\n<meta content=\"0048\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">is a chain composed of three  ⁇ -amino acid residues, independently having from 4 to 10 carbon atoms, the amino acid residues of the chain being selected from the group of residues having a neutral side chain and residues having a carboxylic acid group in the side chain so that the chain has at least one residue which has a carboxylic acid group in the side chain.</span>\\n<meta content=\"0049\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acid residues</span>\\n<span itemprop=\"definition\">are codable residues.</span>\\n<meta content=\"0049\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">is a chain composed of four  ⁇ -amino acid residues, independently having from 4 to 10 carbon atoms, the amino acid residues of the chain being selected from the group having a neutral side chain and residues having a carboxylic acid group in the side chain so that the chain has at least one residue which has a carboxylic acid group in the side chain.</span>\\n<meta content=\"0050\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acid residues</span>\\n<span itemprop=\"definition\">are codable residues.</span>\\n<meta content=\"0050\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">can be connected to the  ⁇ -amino group of the Lys residue in the B-chain via an urea derivative.</span>\\n<meta content=\"0051\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure X of the side chain -W-X—Y-Z</span>\\n<span itemprop=\"definition\">can be a group of the formula — C O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal  ⁇ -amino group in the B chain or with the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0052\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure X of the side chain</span>\\n<span itemprop=\"definition\">can be a group of the formula —CH(COOH) C O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal  ⁇ -amino group in the B chain or with the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0053\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure X of the side chain</span>\\n<span itemprop=\"definition\">can be a group of the formula —N(CH 2 COOH)CH 2 C O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal  ⁇ -amino group in the B chain or with the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0054\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure X of the side chain</span>\\n<span itemprop=\"definition\">can be a group of the formula —N(CH 2 CH 2 COOH)CH 2 C O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal  ⁇ -amino group in the B chain or with the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0055\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure X of the side chain</span>\\n<span itemprop=\"definition\">can be a group of the formula —N(CH 2 COOH)CH 2 CH 2 C O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal  ⁇ -amino group in the B chain or with the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0056\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure X of the side chain</span>\\n<span itemprop=\"definition\">can be a group of the formula —N(CH 2 COOH)CH 2 CON(CH 2 COOH)CH 2 C O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal  ⁇ -amino group in the B chain or with the f-amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0057\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure X of the side chain</span>\\n<span itemprop=\"definition\">can be a group of the formula —N(CH 2 CH 2 COOH)CH 2 CH 2 C O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal  ⁇ -amino group in the B chain or with the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0058\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure X of the side chain</span>\\n<span itemprop=\"definition\">can be a group of the formula —N(CH 2 CH 2 COOH)CH 2 CH 2 CON(CH 2 CH 2 COOH)CH 2 CH 2 C O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal  ⁇ -amino group in the B chain or with the  ⁇ -amino group of a Lys residue present in the B chain of the parent insulin.</span>\\n<meta content=\"0059\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure Y of the side chain -W-X—Y-Z</span>\\n<span itemprop=\"definition\">can be a group of the formula —(CH 2 ) m — where m is an integer in the range of from 6 to 32, from 8 to 20, from 12 to 20, or from 12-16.</span>\\n<meta content=\"0060\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Y</span>\\n<span itemprop=\"definition\">is a divalent hydrocarbon chain comprising 1, 2 or 3—CH ⁇ CH— groups and a number of —CH 2 — groups sufficient to give a total number of carbon atoms in the chain in the range of from 6 to 32, from 10 to 32, from 12 to 20, or from 12-16.</span>\\n<meta content=\"0061\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Y</span>\\n<span itemprop=\"definition\">is a divalent hydrocarbon chain of the formula —(CH 2 ) v C 6 H 4 (CH 2 ) w — wherein v and w are integers or one of them is zero so that the sum of v and w is in the range of from 6 to 30, from 10 to 20, or from 12-16.</span>\\n<meta content=\"0062\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the substructure Z of the side chain -W-X—Y-Z</span>\\n<span itemprop=\"definition\">is —COOH provided that when W is a covalent bond and X is —CO—, then Z is different from —COOH.</span>\\n<meta content=\"0063\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Z</span>\\n<span itemprop=\"definition\">is —CO-Asp.</span>\\n<meta content=\"0064\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Z</span>\\n<span itemprop=\"definition\">is —CO-Glu</span>\\n<meta content=\"0065\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Z</span>\\n<span itemprop=\"definition\">is —CO-Gly.</span>\\n<meta content=\"0066\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Z</span>\\n<span itemprop=\"definition\">is —CO-Sar.</span>\\n<meta content=\"0067\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Z</span>\\n<span itemprop=\"definition\">is —CH(COOH) 2 .</span>\\n<meta content=\"0068\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Z</span>\\n<span itemprop=\"definition\">is —N(CH 2 COOH) 2 .</span>\\n<meta content=\"0069\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Z</span>\\n<span itemprop=\"definition\">is —SO 3 H.</span>\\n<meta content=\"0070\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Z</span>\\n<span itemprop=\"definition\">is —PO 3 H.</span>\\n<meta content=\"0071\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">W</span>\\n<span itemprop=\"definition\">is selected from the group consisting of  ⁇ -Asp,  ⁇ -Asp,  ⁇ -Glu, and  ⁇ -Glu;</span>\\n<meta content=\"0072\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">X</span>\\n<span itemprop=\"definition\">is —CO— or —CH(COOH)CO;</span>\\n<meta content=\"0072\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Y</span>\\n<span itemprop=\"definition\">is —(CH 2 ) m — where m is an integer in the range of 12-18 and Z is —COOH or —CH(COOH) 2 .</span>\\n<meta content=\"0072\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin moiety—in the present text also referred to as the parent insulin—of an insulin derivative according to the invention</span>\\n<span itemprop=\"definition\">can be a naturally occurring insulin such as human insulin or porcine insulin.</span>\\n<meta content=\"0073\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the parent insulin</span>\\n<span itemprop=\"definition\">can be an insulin analogue.</span>\\n<meta content=\"0073\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acid residue at position A21</span>\\n<span itemprop=\"definition\">is Asn.</span>\\n<meta content=\"0074\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acid residue at position A21</span>\\n<span itemprop=\"definition\">is Gly.</span>\\n<meta content=\"0075\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Specific examples from this group of analogues</span>\\n<span itemprop=\"definition\">are Gly A21 human insulin, Gly A21 des(B30) human insulin; and Gly A21 Arg B31 Arg B32 human insulin.</span>\\n<meta content=\"0075\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">amino acid residue at position B1</span>\\n<span itemprop=\"definition\">has been deleted.</span>\\n<meta content=\"0076\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a specific example from this group of parent insulin analogues</span>\\n<span itemprop=\"definition\">is des(B1) human insulin.</span>\\n<meta content=\"0076\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">amino acid residue at position B30</span>\\n<span itemprop=\"definition\">has been deleted.</span>\\n<meta content=\"0077\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a specific example from this group of parent insulin analogues</span>\\n<span itemprop=\"definition\">is des(B30) human insulin.</span>\\n<meta content=\"0077\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acid residue at position B28</span>\\n<span itemprop=\"definition\">is Asp.</span>\\n<meta content=\"0078\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a specific example from this group of parent insulin analogues</span>\\n<span itemprop=\"definition\">is Asp B28 human insulin.</span>\\n<meta content=\"0078\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acid residue at position B28</span>\\n<span itemprop=\"definition\">is Lys and the amino acid residue at position B29 is Pro.</span>\\n<meta content=\"0079\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a specific example from this group of parent insulin analogues</span>\\n<span itemprop=\"definition\">is Lys B28 Pro B29 human insulin.</span>\\n<meta content=\"0079\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acid residue in position B30</span>\\n<span itemprop=\"definition\">is Lys and the amino acid residue in position B29 is any codable amino acid except Cys, Met, Arg and Lys.</span>\\n<meta content=\"0080\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">An example</span>\\n<span itemprop=\"definition\">is an insulin analogue where the amino acid residue at position B29 is Thr and the amino acid residue at position B30 is Lys.</span>\\n<meta content=\"0080\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a specific example from this group of parent insulin analogues</span>\\n<span itemprop=\"definition\">is Thr B29 LyS B30 human insulin.</span>\\n<meta content=\"0080\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acid residue at position B3</span>\\n<span itemprop=\"definition\">is Lys and the amino acid residue at position B29 is Glu.</span>\\n<meta content=\"0081\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a specific example from this group of parent insulin analogues</span>\\n<span itemprop=\"definition\">is Lys B3 Glu B29 human insulin.</span>\\n<meta content=\"0081\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">insulin derivatives according to the invention</span>\\n<span itemprop=\"definition\">are the following compounds:</span>\\n<meta content=\"0082\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 14 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0083\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 15 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0084\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 16 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0085\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 17 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0086\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 18 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0087\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 16 CO)- ⁇ -Glu-N-( ⁇ -Glu)) des(B30) human insulin;</span>\\n<meta content=\"0088\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(Asp-OC(CH 2 ) 16 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0089\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(Glu-OC(CH 2 ) 14 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0090\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(Glu-OC(CH 2 ) 14 CO—) des(B30) human insulin;</span>\\n<meta content=\"0091\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(Asp-OC(CH 2 ) 16 CO—) des(B30) human insulin;</span>\\n<meta content=\"0092\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 16 CO)- ⁇ -Glu-N-( ⁇ -Asp)) des(B30) human insulin;</span>\\n<meta content=\"0093\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(Gly-OC(CH 2 ) 13 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0094\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(Sar-OC(CH 2 ) 13 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0095\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 13 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0096\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 13 CO)- ⁇ -Glu) des(B30) human insulin;</span>\\n<meta content=\"0098\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 16 CO)- ⁇ -D-Glu) des(B30) human insulin;</span>\\n<meta content=\"0099\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N  ⁇  —(HOOC(CH 2 ) 14 CO- ⁇ -D-Asp) des(B30) human insulin;</span>\\n<meta content=\"0100\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">(N—HOOC(CH 2 ) 16 CO- ⁇ -D-Asp) des(B30) human insulin;</span>\\n<meta content=\"0101\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">[N—(HOOC(CH 2 ) 16 CO—N-(carboxyethyl)-Gly] des(B30) human insulin;</span>\\n<meta content=\"0103\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N  ⁇ B29</span>\\n<span itemprop=\"definition\">[N—(HOOC(CH 2 ) 14 CO)—N-(carboxymethyl)- ⁇ -Ala] des(B30) human insulin.</span>\\n<meta content=\"0105\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Insulin derivatives according to the invention</span>\\n<span itemprop=\"definition\">may be provided in the form of essentially zinc free compounds or in the form of zinc complexes.</span>\\n<meta content=\"0106\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">zinc complexes of an insulin derivative according to the invention</span>\\n<span itemprop=\"definition\">two Zn 2+ ions, three Zn 2+ ions or four Zn 2+ ions can be bound to each insulin hexamer. Solutions of zinc complexes of the insulin derivatives will contain mixtures of such species.</span>\\n<meta content=\"0106\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a pharmaceutical composition</span>\\n<span itemprop=\"definition\">comprising a therapeutically effective amount of an insulin derivative according to the invention together with a pharmaceutically acceptable carrier can be provided for the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycemia in patients in need of such a treatment.</span>\\n<meta content=\"0107\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">An insulin derivative according to the invention</span>\\n<span itemprop=\"definition\">can be used for the manufacture of a pharmaceutical composition for use in the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia.</span>\\n<meta content=\"0107\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a pharmaceutical composition for treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment</span>\\n<span itemprop=\"definition\">comprising a therapeutically effective amount of an insulin derivative according to the invention in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with pharmaceutically acceptable carriers and additives.</span>\\n<meta content=\"0108\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the invention</span>\\n<span itemprop=\"definition\">provides a pharmaceutical composition being a mixture of an insulin derivative according to the invention and a rapid acting insulin analogue selected group consisting of Asp B28 human insulin; Lys B28 Pro B29 human insulin and LyS B3 Glu B29 human insulin.</span>\\n<meta content=\"0109\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the invention</span>\\n<span itemprop=\"definition\">provides a pharmaceutical composition</span>\\n<meta content=\"0110\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a pharmaceutical composition</span>\\n<span itemprop=\"definition\">comprising N  ⁇ B29 —N  ⁇  —(HOOC(CH 2 ) 14 CO)- ⁇ -Glu) des(B30) human insulin and AspB28 human insulin together with pharmaceutically acceptable carriers and additives.</span>\\n<meta content=\"0110\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin derivative according to the invention and the rapid acting insulin analogue</span>\\n<span itemprop=\"definition\">can be mixed in a ratio from about 90/10%; about 70/30% or about 50/50%.</span>\\n<meta content=\"0111\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment</span>\\n<span itemprop=\"definition\">comprising administering to the patient a therapeutically effective amount of an insulin derivative according to the invention together with a pharmaceutically acceptable carrier and pharmaceutical acceptable additives.</span>\\n<meta content=\"0112\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment</span>\\n<span itemprop=\"definition\">comprising administering to the patient a therapeutically effective amount of an insulin derivative according to the invention in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier and pharmaceutical acceptable additives.</span>\\n<meta content=\"0113\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the present invention</span>\\n<span itemprop=\"definition\">relates to insulin derivatives which have an overall hydrophobicity which is essentially similar to that of human insulin.</span>\\n<meta content=\"0114\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the present invention</span>\\n<span itemprop=\"definition\">relates to insulin derivatives which have a hydrophobic index, k′ rel , which is in the range of from about 2 to about 200.</span>\\n<meta content=\"0115\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin derivatives of the present invention</span>\\n<span itemprop=\"definition\">have a hydrophobic index, k′ rel , which is in the range from about 0.02 to about 10, from about 0.1 to about 5; from about 0.5 to about 5; or from about 0.5 to about 2.</span>\\n<meta content=\"0116\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin derivatives</span>\\n<span itemprop=\"definition\">will comprise a side chain -W-X—Y-Z as defined above which has at least one hydrophilic and at least one hydrophobic region.</span>\\n<meta content=\"0117\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin derivatives</span>\\n<span itemprop=\"definition\">will comprise a side chain -W-X—Y-Z as defined above which has at least one free carboxylic acid group and according to a further embodiment, the side chain will have at least two free carboxylic acid groups.</span>\\n<meta content=\"0118\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the invention</span>\\n<span itemprop=\"definition\">relates to a pharmaceutical composition</span>\\n<meta content=\"0119\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a pharmaceutical composition</span>\\n<span itemprop=\"definition\">comprising an insulin derivative according to the invention which is soluble at physiological pH values.</span>\\n<meta content=\"0119\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the invention</span>\\n<span itemprop=\"definition\">relates to a pharmaceutical composition</span>\\n<meta content=\"0120\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a pharmaceutical composition</span>\\n<span itemprop=\"definition\">comprising an insulin derivative according to the invention which is soluble at pH values in the interval from about 6.5 to about 8.5.</span>\\n<meta content=\"0120\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the invention</span>\\n<span itemprop=\"definition\">relates to a pharmaceutical composition with a prolonged profile of action which comprises an insulin derivative according to the invention.</span>\\n<meta content=\"0121\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the invention</span>\\n<span itemprop=\"definition\">in another embodiment, relates to a pharmaceutical composition which is a solution containing from about 120 nmol/ml to about 2400 nmol/ml, from about 400 nmol/ml to about 2400 nmol/ml, from about 400 nmol/ml to about 1200 nmol/ml, from about 600 nmol/ml to about 2400 nmol/ml, or from about 600 nmol/ml to about 1200 nmol/ml of an insulin derivative according to the invention or of a mixture of the insulin derivative according to the invention with a rapid acting insulin analogue.</span>\\n<meta content=\"0122\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">hydrophobicity (hydrophobic index) of the insulin derivatives of the invention relative to human insulin, k′ rel</span>\\n<span itemprop=\"definition\">was measured on a LiChrosorb RP18 (5  ⁇ m, 250 ⁇ 4 mm) HPLC column by isocratic elution at 40° C. using mixtures of A) 0.1 M sodium phosphate buffer, pH 7.3, containing 10% acetonitrile, and B) 50% acetonitrile in water as eluents. The elution was monitored by following the UV absorption of the eluate at 214 nm. Void time, t 0 , was found by injecting 0.1 mM sodium nitrate.</span>\\n<meta content=\"0123\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">k′ rel</span>\\n<span itemprop=\"definition\">(t derivative  ⁇ t 0 )/(t human  ⁇ t 0 ).</span>\\n<meta content=\"0123\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">k′ rel found for a number of insulin derivatives according to the invention</span>\\n<span itemprop=\"definition\">are given in Table 1.</span>\\n<meta content=\"0123\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">compositions containing an insulin derivative according to the present invention</span>\\n<span itemprop=\"definition\">may be administered parenterally to patients in need of such a treatment.</span>\\n<meta content=\"0125\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Parenteral administration</span>\\n<span itemprop=\"definition\">may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe.</span>\\n<meta content=\"0125\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">parenteral administration</span>\\n<span itemprop=\"definition\">can be performed by means of an infusion pump.</span>\\n<meta content=\"0125\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Further options</span>\\n<span itemprop=\"definition\">are to administer the insulin nasally or pulmonally, preferably in compositions, powders or liquids, specifically designed for the purpose.</span>\\n<meta content=\"0125\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">compositions of the insulin derivatives of the invention</span>\\n<span itemprop=\"definition\">can be prepared using the conventional techniques of the pharmaceutical industry which involve dissolving and mixing the ingredients as appropriate to give the desired end product.</span>\\n<meta content=\"0126\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">an insulin derivative according to the invention</span>\\n<span itemprop=\"definition\">is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared.</span>\\n<meta content=\"0126\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">An isotonic agent, a preservative and a buffer</span>\\n<span itemprop=\"definition\">is added as required and the pH value of the solution is adjusted—if necessary—using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxide as needed.</span>\\n<meta content=\"0126\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the volume of the solution</span>\\n<span itemprop=\"definition\">is adjusted with water to give the desired concentration of the ingredients.</span>\\n<meta content=\"0126\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the buffer</span>\\n<span itemprop=\"definition\">is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof.</span>\\n<meta content=\"0127\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Each one of these specific buffers</span>\\n<span itemprop=\"definition\">constitutes an alternative embodiment of the invention.</span>\\n<meta content=\"0127\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the formulation</span>\\n<span itemprop=\"definition\">further comprises a pharmaceutically acceptable preservative which may be selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, benzethonium chloride, chlorphenesine (3p-chlorphenoxypropane-1,2-diol) or mixtures thereof.</span>\\n<meta content=\"0128\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a pharmaceutically acceptable preservative</span>\\n<span itemprop=\"definition\">which may be selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol</span>\\n<meta content=\"0128\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the preservative</span>\\n<span itemprop=\"definition\">is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific preservatives constitutes an alternative embodiment of the invention.</span>\\n<meta content=\"0128\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the use of a preservative in pharmaceutical compositions</span>\\n<span itemprop=\"definition\">is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.</span>\\n<meta content=\"0128\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the formulation</span>\\n<span itemprop=\"definition\">further comprises an isotonic agent which may be selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), an alditol (e.g. glycerol (glycerine), 1,2-propanediol (propyleneglycol), 1,3-propanediol, 1,3-butanediol) polyethyleneglycol (e.g. PEG400), or mixtures thereof.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a salt</span>\\n<span itemprop=\"definition\">e.g. sodium chloride</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a sugar or sugar alcohol</span>\\n<span itemprop=\"definition\">e.g. L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">an alditol</span>\\n<span itemprop=\"definition\">e.g.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Any sugar</span>\\n<span itemprop=\"definition\">such as mono-, di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the sugar additive</span>\\n<span itemprop=\"definition\">is sucrose.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Sugar alcohol</span>\\n<span itemprop=\"definition\">is defined as a C4-C8 hydrocarbon having at least one —OH group and includes, for example, mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the sugar alcohol additive</span>\\n<span itemprop=\"definition\">is mannitol.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the sugars or sugar alcohols mentioned above</span>\\n<span itemprop=\"definition\">may be used individually or in combination. There is no fixed limit to the amount used, as long as the sugar or sugar alcohol is soluble in the liquid preparation and does not adversely effect the stabilizing effects achieved using the methods of the invention.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the sugar or sugar alcohol concentration</span>\\n<span itemprop=\"definition\">is between about 1 mg/ml and about 150 mg/ml.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the isotonic agent</span>\\n<span itemprop=\"definition\">is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 24 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 25 mg/ml to 50 mg/ml. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the use of an isotonic agent in pharmaceutical compositions</span>\\n<span itemprop=\"definition\">is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.</span>\\n<meta content=\"0129\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Typical isotonic agents</span>\\n<span itemprop=\"definition\">are sodium chloride, mannitol, dimethyl sulfone and glycerol and typical preservatives are phenol, m-cresol, methyl p-hydroxybenzoate and benzyl alcohol.</span>\\n<meta content=\"0130\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">buffers</span>\\n<span itemprop=\"definition\">examples include sodium acetate, glycylglycine, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and sodium phosphate.</span>\\n<meta content=\"0131\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a composition for nasal administration of an insulin derivative according to the present invention</span>\\n<span itemprop=\"definition\">may, for example, be prepared as described in European Patent No. 272097 (to Novo Nordisk A/S).</span>\\n<meta content=\"0132\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">compositions containing insulins of this invention</span>\\n<span itemprop=\"definition\">can be used in the treatment of states which are sensitive to insulin. Thus, they can be used in the treatment of type 1 diabetes, type 2 diabetes and hyperglycaemia for example as sometimes seen in seriously injured persons and persons who have undergone major surgery.</span>\\n<meta content=\"0133\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the optimal dose level for any patient</span>\\n<span itemprop=\"definition\">will depend on a variety of factors including the efficacy of the specific insulin derivative employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the state to be treated. It is recommended that the daily dosage of the insulin derivative of this invention be determined for each individual patient by those skilled in the art in a similar way as for known insulin compositions.</span>\\n<meta content=\"0133\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin derivatives of this invention</span>\\n<span itemprop=\"definition\">may be used in mixture with other types of insulin, e.g. insulin analogues with a more rapid onset of action.</span>\\n<meta content=\"0134\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">insulin analogues</span>\\n<span itemprop=\"definition\">e.g. in the European patent applications having the publication Nos. EP 214826 (Novo Nordisk A/S), EP 375437 (Novo Nordisk A/S) and EP 383472 (Eli Lilly &amp; Co.).</span>\\n<meta content=\"0134\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">insulin analogue</span>\\n<span itemprop=\"definition\">as used herein is meant a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring insulin, for example that of human insulin, by deleting and/or exchanging at least one amino acid residue occurring in the naturally occurring insulin and/or adding at least one amino acid residue.</span>\\n<meta content=\"0136\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the added and/or exchanged amino acid residues</span>\\n<span itemprop=\"definition\">can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues</span>\\n<meta content=\"0136\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the insulin analogues</span>\\n<span itemprop=\"definition\">may be such wherein position 28 of the B chain may be modified from the natural Pro residue to one of Asp, Lys, or lie.</span>\\n<meta content=\"0136\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Lys at position B29</span>\\n<span itemprop=\"definition\">is modified to Pro.</span>\\n<meta content=\"0136\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">B30</span>\\n<span itemprop=\"definition\">may be Lys and then B29 can be any codable amino acid except Cys, Met, Arg and Lys.</span>\\n<meta content=\"0136\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Asn at position A21</span>\\n<span itemprop=\"definition\">may be modified to Ala, Gln, Glu, Gly, His, lie, Leu, Met, Ser, Thr, Trp, Tyr or Val, in particular to Gly, Ala, Ser, or Thr and preferably to Gly.</span>\\n<meta content=\"0137\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Asn at position B3</span>\\n<span itemprop=\"definition\">may be modified to Lys or Asp.</span>\\n<meta content=\"0137\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Further examples of insulin analogues</span>\\n<span itemprop=\"definition\">are des(B30) human insulin; des(B30) human insulin analogues; insulin analogues wherein PheB1 has been deleted; insulin analogues wherein the A-chain and/or the B-chain have an N-terminal extension and insulin analogues wherein the A-chain and/or the B-chain have a C-terminal extension.</span>\\n<meta content=\"0137\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">one or two Arg</span>\\n<span itemprop=\"definition\">may be added to position B1.</span>\\n<meta content=\"0137\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">insulin derivative</span>\\n<span itemprop=\"definition\">as used herein is meant a naturally occurring insulin or an insulin analogue which has been chemically modified, e.g. by introducing a side chain in one or more positions of the insulin backbone or by oxidizing or reducing groups of the amino acid residues in the insulin or by converting a free carboxylic group to an ester group or acylating a free amino group or a hydroxy group.</span>\\n<meta content=\"0138\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a codable amino acid</span>\\n<span itemprop=\"definition\">or “a codable amino acid residue” is used to indicate an amino acid or amino acid residue which can be coded for by a triplet (“codon”) of nucleotides.</span>\\n<meta content=\"0139\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">hGlu</span>\\n<span itemprop=\"definition\">is homoglutamic acid.</span>\\n<meta content=\"0140\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">⁇ -Asp</span>\\n<span itemprop=\"definition\">is the L-form of —HNCH(CO—)CH 2 COOH.</span>\\n<meta content=\"0141\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">⁇ -Asp</span>\\n<span itemprop=\"definition\">is the L-form of —HNCH(COOH)CH 2 CO—.</span>\\n<meta content=\"0142\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">⁇ -Glu</span>\\n<span itemprop=\"definition\">is the L-form of —HNCH(CO—)CH 2 CH 2 COOH.</span>\\n<meta content=\"0143\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">⁇ -Glu</span>\\n<span itemprop=\"definition\">is the L-form of —HNCH(COOH)CH 2 CH 2 CO—.</span>\\n<meta content=\"0144\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">⁇ -hGlu</span>\\n<span itemprop=\"definition\">is the L-form of —HNCH(CO—)CH 2 CH 2 CH 2 COOH.</span>\\n<meta content=\"0145\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">⁇ -hGlu</span>\\n<span itemprop=\"definition\">is the L-form of —HNCH(COOH)CH 2 CH 2 CH 2 CO—.</span>\\n<meta content=\"0146\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">⁇ -Ala</span>\\n<span itemprop=\"definition\">is —NH—CH 2 —CH 2 —COOH.</span>\\n<meta content=\"0147\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Sar</span>\\n<span itemprop=\"definition\">is sarcosine (N-methylglycine).</span>\\n<meta content=\"0148\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">an amino acid residue having a carboxylic acid group in the side chain</span>\\n<span itemprop=\"definition\">designates amino acid residues like Asp, Glu and hGlu.</span>\\n<meta content=\"0149\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the amino acids</span>\\n<span itemprop=\"definition\">can be in either the L- or D-configuration. If nothing is specified it is understood that the amino acid residue is in the L configuration.</span>\\n<meta content=\"0149\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">an amino acid residue having a neutral side chain</span>\\n<span itemprop=\"definition\">designates amino acid residues like Gly, Ala, Val, Leu, Ile, Phe, Pro, Ser, Thr, Cys, Met, Tyr, Asn and Gln.</span>\\n<meta content=\"0150\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">an insulin derivative according to the invention</span>\\n<span itemprop=\"definition\">is stated to be “soluble at physiological pH values” it means that the insulin derivative can be used for preparing injectable insulin compositions that are fully dissolved at physiological pH values.</span>\\n<meta content=\"0151\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Such favourable solubility</span>\\n<span itemprop=\"definition\">may either be due to the inherent properties of the insulin derivative alone or a result of a favourable interaction between the insulin derivative and one or more ingredients contained in the vehicle.</span>\\n<meta content=\"0151\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Aad</span>\\n<span itemprop=\"definition\">Alpha-amino-adipic acid (homoglutamic acid)</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Bzl</span>\\n<span itemprop=\"definition\">Bn: benzyl</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">DIEA</span>\\n<span itemprop=\"definition\">N,N-diisopropylethylamine</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">DMF</span>\\n<span itemprop=\"definition\">N,N-dimethylformamide</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">IDA</span>\\n<span itemprop=\"definition\">Iminodiacetic acid</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Sar</span>\\n<span itemprop=\"definition\">Sarcosine (N-methyl-glycine)</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">tBu</span>\\n<span itemprop=\"definition\">tert-butyl</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">TSTU</span>\\n<span itemprop=\"definition\">O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">THF</span>\\n<span itemprop=\"definition\">Tetrahydrofuran EtOAc: Ethyl acetate</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">DIPEA</span>\\n<span itemprop=\"definition\">Diisopropylethylamine</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">HOAt</span>\\n<span itemprop=\"definition\">1-Hydroxy-7-azabenzotriazole</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">TEA</span>\\n<span itemprop=\"definition\">triethyl amine</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">succinimidyl</span>\\n<span itemprop=\"definition\">2,5-dioxo-pyrrolidin-1-yl</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">TFA</span>\\n<span itemprop=\"definition\">trifluoracetic acid</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">DCM</span>\\n<span itemprop=\"definition\">dichloromethane</span>\\n<meta content=\"0153\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the precipitate</span>\\n<span itemprop=\"definition\">was then dissolved in 10 ml of water at pH 8 and placed in ice. To this solution was added 10 ml of ice cold 0.2 M NaOH for saponification and the mixture was incubated for 40 min with ice cooling and then adjusted to pH 5.5 to precipitate the product.</span>\\n<meta content=\"0154\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the precipitate</span>\\n<span itemprop=\"definition\">was isolated and dissolved in 5 ml of A-buffer (see below) and diluted with 33 ml of 42.5% w/w aqueous ethanol divided in three and subjected to anion exchange chromatography employing a ResourceTM 6 ml anion exchange column eluted with a buffer system consisting of A-buffer: Tris 0.24% w/w, NH4Ac 0.25%, 42% ethanol w/w, pH 7.5 and B-buffer: Tris 0.24% w/w, NH4Ac 1.25%, 42% ethanol w/w pH 7.5.</span>\\n<meta content=\"0154\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the sample</span>\\n<span itemprop=\"definition\">was eluted by a flow of 6 ml/min in a gradient from 0 to 100% of B-buffer in 30 min.</span>\\n<meta content=\"0154\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the fractions containing the desired compound</span>\\n<span itemprop=\"definition\">were identified by RP-HPLC.</span>\\n<meta content=\"0154\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the yield of the desired product</span>\\n<span itemprop=\"definition\">was 15.3 mg (purity: 72.9%).</span>\\n<meta content=\"0154\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the volume of the pooled fractions containing the desired compound</span>\\n<span itemprop=\"definition\">was reduced to 20 ml under vacuum and this solution was then subjected to purification by RP-HPLC employing a reversed phase HPLC column Nucleosil, C4 250/10 mm, 10  ⁇ m, 300  ⁇ .</span>\\n<meta content=\"0154\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the buffer system</span>\\n<span itemprop=\"definition\">consisted of A-buffer: 10 mM Tris, 15 mM (NH4)2SO4, 10% ethanol, pH 7.3 and B-buffer: 70% vol/vol ethanol.</span>\\n<meta content=\"0154\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the product</span>\\n<span itemprop=\"definition\">was eluted with a gradient of from 10% to 60% of B-buffer in 120 min at a flow of 2 ml/min. The appropriate fractions were pooled and the compound was precipitated and lyophilized. The yield was 7.7 mg (purity: 99.4%).</span>\\n<meta content=\"0155\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Dimethyl hexadecandioate</span>\\n<span itemprop=\"definition\">was saponified in MeOH using 1.0 equivalent of NaOH, and the mono-methyl ester was isolated upon HCl acidification by recrystallisation from heptane.</span>\\n<meta content=\"0157\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Methyl succinimidyl hexadecandioate</span>\\n<span itemprop=\"definition\">(240 mg, 0.58 mmol) in dimethylformamide (5 ml) was treated with GluOMe (93 mg, 0.58 mmol) and N,N-diisopropylethylamine (200  ⁇ L, 1.16 mmol). The mixture was stirred for 20 hours and then evaporated in vacuo. The residue was redissolved in ethyl acetate. Washing with 0.1 M HCl and water, followed by drying (MgSO4) and evaporation in vacuo, gave 226 mg (88%) of methyl hexadecandioyl-Glu-OMe.</span>\\n<meta content=\"0160\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Methyl hexadecandioyl-Glu-OMe</span>\\n<span itemprop=\"definition\">200 mg, 0.45 mmol was dissolved in dichloromethane (4 ml), cooled with an ice-bath and treated with dicyclohexylcarbodiimide (93 mg, 0.45 mmol) and N-hydroxysuccinimide (52 mg, 0.45 mmol). The mixture was stirred for 20 hours, filtered and evaporated in vacuo, to give 243 mg (100%) of the desired intermediate.</span>\\n<meta content=\"0162\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared from dimethyl octadecandioate in analogy with the hexadecandioyl derivative described in Example 1.</span>\\n<meta content=\"0165\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the buffer system</span>\\n<span itemprop=\"definition\">consisted of A-buffer: 0.1% TFA, 10% vol/vol ethanol and B-buffer: 80% vol/vol ethanol.</span>\\n<meta content=\"0167\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the sample</span>\\n<span itemprop=\"definition\">was eluted by a gradient from 40% to 60% B-buffer at 40° C. for 120 min at a flow of 2 ml/min.</span>\\n<meta content=\"0167\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the appropriate fractions</span>\\n<span itemprop=\"definition\">were pooled and lyophilized and 31.1 mg of the title compound was obtained (purity: 94%).</span>\\n<meta content=\"0167\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Methyl octadecandioyl-Glu(OSu)-OMe</span>\\n<span itemprop=\"definition\">(prepared as described in Example 2, 200 mg, 0.35 mmol) in dimethylformamide (5 ml) was treated with GluOMe (62 mg, 0.39 mmol) and N,N-diisopropylethylamine (90  ⁇ L, 53 mmol), and the mixture was stirred for 20 hours. The solvent was removed in vacuo, and the residue was dissolved in ethyl acetate and washed twice with 0.2 M HCl, water and brine. Drying over MgSO 4 and evaporation gave methyl octadecandioyl-Glu(Glu-OMe)-OMe, 180 mg (83%).</span>\\n<meta content=\"0169\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Methyl octadecandioyl-Glu(Glu-OMe)-OMe</span>\\n<span itemprop=\"definition\">180 mg, 0.29 mmol was dissolved in THF (9 ml) and treated with succinimidyl tetramethyluroniumtetrafluoroborate (106 mg, 0.35 mmol) and N,N-diisopropylethylamine (60  ⁇ L, 0.35 mmol). The mixture was stirred overnight, evaporated, redissolved in ethyl acetate, and washed with 2 ⁇ 0.1 M HCl and water. Drying over MgSO 4 and evaporation gave 190 mg (93%) of the desired intermediate.</span>\\n<meta content=\"0170\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Des(B30) human insulin</span>\\n<span itemprop=\"definition\">500 mg, 0.088 mmol was dissolved in 100 mM Na 2 CO 3 (5 ml, pH 10.2) at room temperature.</span>\\n<meta content=\"0172\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Tert-butyl hexadecandioyl-Glu(OSu)-OtBu</span>\\n<span itemprop=\"definition\">66 mg, 0.105 mmol, prepared as described below</span>\\n<meta content=\"0172\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">acetonitrile</span>\\n<span itemprop=\"definition\">5 ml</span>\\n<meta content=\"0172\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">0.2 M methylamine</span>\\n<span itemprop=\"definition\">0.5 ml was added. pH was adjusted by HCl to 5.5, and the isoelectric precipitate was collected by centrifugation and dried in vacuo to give 525 mg.</span>\\n<meta content=\"0172\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the coupling yield</span>\\n<span itemprop=\"definition\">was 78% (RP-HPLC, C4 column; Buffer A: 10% MeCN in 0.1% TFA-water, Buffer B: 80% MeCN in 0.1% TFA-water; gradient 20% to 90% B in 16 minutes).</span>\\n<meta content=\"0172\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the protected product</span>\\n<span itemprop=\"definition\">was dissolved in TFA (10 ml), left 30 mins, and evaporated in vacuo.</span>\\n<meta content=\"0172\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the crude product</span>\\n<span itemprop=\"definition\">was dissolved in water and lyophilized (610 mg).</span>\\n<meta content=\"0172\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Hexadecadioic acid</span>\\n<span itemprop=\"definition\">(40.0 g, 140 mmol) was suspended in toluene (250 ml) and the mixture was heated to reflux. N,N-dimethylformamide di-tert-butyl acetal (76.3 g, 375 mmol) was added drop-wise over 4 hours. The mixture was refluxed overnight. The solvent was removed in vacuo at 50° C., and the crude material was suspended in DCM/AcOEt (500 ml, 1:1) and stirred for 15 mins. The solids were collected by filtration and triturated with DCM (200 ml). The filtrated were evaporated in vacuo to give crude mono-tert-butyl hexadecandioate, 30 grams.</span>\\n<meta content=\"0173\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the mono tert-butyl ester (2 g, 5.8 mmol)</span>\\n<span itemprop=\"definition\">was dissolved in THF (20 ml) and treated with TSTU (2.1 g, 7.0 mmol) and DIEA (1.2 ml, 7.0 mmol) and stirred overnight. The mixture was filtered, and the filtrate was evaporated in vacuo. The residue was dissolved in AcOEt and washed twice with cold 0.1 M HCl and water. Drying over MgSO 4 and evaporation in vacuo gave succinimidyl tert-butyl hexadecandioate, 2.02 g (79%).</span>\\n<meta content=\"0175\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">DesB30 insulin</span>\\n<span itemprop=\"definition\">50 mg, 9  ⁇ mol was dissolved in 0.1 M aqueous Na 2 CO 3 (0.65 ml), pH 10.5.</span>\\n<meta content=\"0181\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Octadecandioyl-L-Glu(OSu)</span>\\n<span itemprop=\"definition\">50.1 mg, 9.9  ⁇ mol, prepared as described below was dissolved in acetonitrile (0.65 ml) and added to the insulin solution; pH was 10.3.</span>\\n<meta content=\"0181\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">0.2 M methylamine</span>\\n<span itemprop=\"definition\">50  ⁇ l was added. pH was adjusted by HCl to 5.5, and the isoelectric precipitate was collected by centrifugation and dried in vacuo.</span>\\n<meta content=\"0181\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">HPLC</span>\\n<span itemprop=\"definition\">showed the crude coupling yield to be 52% (not optimized); C4 column; Buffer A: 10% MeCN in 0.1% TFA-water, Buffer B: 80% MeCN in 0.1% TFA-water; gradient 20% to 90% B in 16 minutes).</span>\\n<meta content=\"0181\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Octadecanedioic acid</span>\\n<span itemprop=\"definition\">(2.5 g, 8.0 mmol) was suspended in DCM (60 mL), treated with triethylamine (1.16 mL, 8.3 mmol) and ice-cooled. Benzylchloroformate (1.14 mL) was added drop-wise under nitrogen and the mixture was stirred for 10 min, when DMAP (0,097 g, 0.80 mmol) was added. After stirring for 20 min at 4° C. (TLC, 1:1 AcOEt:heptane), the reaction was evaporated to dryness. The crude material (3.9 g) was dissolved in DCM (60 ml), treated with silica (15 g) and evaporated.</span>\\n<meta content=\"0182\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the silica</span>\\n<span itemprop=\"definition\">was loaded on a silica column (175 g), and the product was eluted with AcOEt/heptane 1:7 to 1:1. Evaporation of the desired fractions gave mono-benzyl octadecandioate (1.15 g, 36%).</span>\\n<meta content=\"0182\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">BzlO-octadecandioyl-L-Glu-OBzl</span>\\n<span itemprop=\"definition\">(110 g, 0.18 mmol) was dissolved in THF (2 ml) and treated with TSTU (64 mg, 0.21 mmol) and DIEA (36  ⁇ l, 0.21 mmol) and stirred overnight. The mixture was filtered, and the filtrate was evaporated in vacuo. The residue was dissolved in AcOEt and washed twice with cold 0.1 M HCl and water. Drying over MgSO 4 and evaporation in vacuo gave BzlO-octadecandioyl-L-Glu(OSu)-OBzl, 119 g (94%).</span>\\n<meta content=\"0188\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared in analogy with example 4, via reaction of L-Asp(OtBu)-OtBu with succinimidyl octadecandioate followed by activation with TSTU, reaction with L-GluOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA.</span>\\n<meta content=\"0192\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with L-AadOtBu (prepared from commercial L-Aad(OMe) by tert-butylation with AcOtBu/BF 3 .OEt 2 and saponification of the methyl ester), followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA.</span>\\n<meta content=\"0210\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">LCMS 6116.9</span>\\n<span itemprop=\"definition\">calculated 6118.1.</span>\\n<meta content=\"0210\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">A1N, B1N-diBoc DesB30 Human insulin</span>\\n<span itemprop=\"definition\">(Kurtzhals P; Havelund S; Jonassen I; Kiehr B; Larsen U D; Ribel U; Markussen J Biochemical Journal, 1995, 312, 725-731) (186 mg, 0.031 mmol) was dissolved in DMSO (1.8 ml).</span>\\n<meta content=\"0216\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a solution of tert-butyl octadecandioyl-N-(tert-butoxycarbonylmethyl)- ⁇ -Ala-OSu</span>\\n<span itemprop=\"definition\">(27 mg, 0.04 mmol) in THF (1.8 ml) and triethylamine (0.045 ml, 0.31 mmol) was added (pH was 10).</span>\\n<meta content=\"0216\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the diacid can</span>\\n<span itemprop=\"definition\">was removed by filtration.</span>\\n<meta content=\"0218\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the filtrate</span>\\n<span itemprop=\"definition\">was concentrated on silica gel (40 g) and purified on a 1.5 L silicagel column using DCM/MeOH 14:1.</span>\\n<meta content=\"0218\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Octadecanedioic acid mono-tert-butyl ester</span>\\n<span itemprop=\"definition\">was isolated in 53% yield (3.52 g).</span>\\n<meta content=\"0218\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Succinimidyl tert-butyl octadecandioate</span>\\n<span itemprop=\"definition\">(0,15 g, 0.32 mmol) and N-(tert-butoxycarbonylmethyl)- ⁇ -Ala-OBn (0.10 g, 0,32 mmol) were dissolved in dry DMF (2.5 ml) and DIEA (0,070 ml, 0.38 mmol) was added. After stirring under nitrogen for 30 min HOAt (0,045 g, 0.32 mmol) was added and the mixture turned yellow. Stirring was continued at RT under nitrogen for convenience reasons for 13 days. The reaction mixture was concentrated.</span>\\n<meta content=\"0225\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">A1N, B1N-diBoc DesB30 Human insulin</span>\\n<span itemprop=\"definition\">(Kurtzhals P; Havelund S; Jonassen I; Kiehr B; Larsen U D; Ribel U; Markussen J Biochemical Journal, 1995, 312, 725-731) (120 mg, 0.020 mmol) was dissolved in DMSO (1.2 ml).</span>\\n<meta content=\"0231\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the crude product</span>\\n<span itemprop=\"definition\">was purified by RP-HPLC on C4-column, buffer A: 0.1% TFA, buffer B: MeCN+0.1% TFA; gradient 10-80% B, and by RP-HPLC on C4-column, buffer A: 20% EtOH+0.1% TFA, buffer B: 80% EtOH+0.1% TFA; gradient 15-60% B, followed by HPLC on C4-column, buffer A: 10 mM Tris+15 mM ammonium sulphate in 20% EtOH, pH 7.3, buffer B: 80% EtOH, gradient 15-60% B.</span>\\n<meta content=\"0231\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the collected fractions</span>\\n<span itemprop=\"definition\">were desalted on Sep-Pak with 70% acetonitrile+0.1% TFA, neutralized by addition of ammonia and freeze-dried. The unoptimized yield was 1.8 mg, 13%.</span>\\n<meta content=\"0231\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the purity as evaluated by HPLC</span>\\n<span itemprop=\"definition\">was 96.4%.</span>\\n<meta content=\"0231\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">N-(2-(Tert-butoxycarbonyl)ethyl)-Gly-OBn</span>\\n<span itemprop=\"definition\">(0.030 g, 0.1 mmol) and succinimidyl tertbutyloctadecanedioate (described in example 29, 0.050 mg, 0.1 mmol) was suspended in dry DMF (1 ml). HOAt (0.014 g, 0.1 mmol) and DIEA (0.21 ml, 1.2 mmol) was added. The yellow reaction mixture was stirred under nitrogen for 42 h. The reaction mixture was concentrated.</span>\\n<meta content=\"0235\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared in analogy with example 30, via reaction of N-(2-(tertbutoxycarbonyl)ethyl)-Gly-OBn with succinimidyl hexadecandioate (described in example 4) followed by debenzylation, activation with TSTU, coupling with A1N, B1N-diBOC-Des(B30) human insulin and deprotection by TFA.</span>\\n<meta content=\"0241\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared in analogy with example 29 via reaction of N-(tertbutoxycarbonylmethyl)- ⁇ -Ala-OBn with succinimidyl hexadecandioate (described in example 4) followed by debenzylation, activation with TSTU, coupling with A1N, B1N-diBOC-Des(B30) human insulin and deprotection by TFA.</span>\\n<meta content=\"0243\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared similarly as described in example 1 using (MeOOC(CH 2 ) 11 )NHCO(CH 2 ) 3 CO)-Glu(OSu)-OMe, prepared as described below, as acylating agent.</span>\\n<meta content=\"0245\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the 12-aminododecanoic acid methyl ester hydrochloride</span>\\n<span itemprop=\"definition\">(1 g, 3.8 mmol) was suspended in THF (15 ml) and added glutaric acid anhydride (1.29 g, 3.8 mmol) and TEA (0.52 ml, 3.8 mmol) and the resulting mixture (suspension) was stirred at room temperature for 16 hours. Water (75 ml) was added gradually. After 25 ml, a solution was obtained and later a suspension appeared. The mixture was stirred at room temperature for 1 hour and filtered. The solid was washed with water and dried in vacuo. This afforded 1.02 g (80%) of 12-(4-carboxybutyrylamino)dodecanoic acid methyl ester.</span>\\n<meta content=\"0250\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the 12-(4-carboxybutyrylamino)dodecanoic acid methyl ester</span>\\n<span itemprop=\"definition\">(0.33 g, 0.95 mmol) was dissolved in a mixture of THF and DMF (2:1, 6 ml), and added DIEA (0.178 ml, 1.04 mmol). The mixture was cooled to 0-5° C. and TSTU (0.314 g, 1.04 mmol) was added. The mixture was stirred at 0-5° C. for 1 hour and at room temperature for 16 hours. The mixture was concentrated to dryness in vacuo.</span>\\n<meta content=\"0252\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared similarly as described in example 1 using (MeOOC(CH 2 ) 11 )NHCO(CH 2 ) 2 CO)-Glu(OSu)-OMe, which in turn was prepared similarly as described in example 33 using succinic acid anhydride instead of glutaric acid anhydride, as acylating agent.</span>\\n<meta content=\"0256\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared similarly as described in example 4 using tert-butyl octadecandioyl-Gly-Glu(OSu)-OtBu, prepared as described below as acylating agent.</span>\\n<meta content=\"0258\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">H-Gly-Glu-O t Bu</span>\\n<span itemprop=\"definition\">(0.15 g, 0.58 mmol) was suspended in DMF (5 ml) and DIEA (0.15 ml, 0.86 mmol) and succinimidyl tert-butyl octadecandioate (0.27 g, 0.58 mmol) were added and the resulting mixture was stirred at room temperature for 16 hours.</span>\\n<meta content=\"0266\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">AcOEt</span>\\n<span itemprop=\"definition\">50 ml was added and the mixture was washed with 0.2N hydrochloric acid (100 ml) and water (3 ⁇ 100 ml). The organic phase was dried (Na 2 SO 4 ) and concentrated in vacuo to afford 0.34 g (quant.) of tert-butyl octadecandioyl-Gly-Glu-O t Bu.</span>\\n<meta content=\"0266\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared in analogy with example 1, via coupling of 15-[[2-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-ethyl]-(2-methoxycarbonyl-ethyl)-carbamoyl]-pentadecanoic acid methyl ester with Des(B30) human insulin and deprotection by NaOH.</span>\\n<meta content=\"0270\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">H ⁇ -Ala-OMe hydrochloride</span>\\n<span itemprop=\"definition\">(5.45 g, 39 mmol) was dissolved in DMSO (100 ml) and tert-butyl acrylate (5.71 ml, 39 mmol) and DIEA (13.4 ml, 78 mmol) were added, and the resulting mixture was stirred at room temperature for 6 days. The mixture was partitioned between water (500 ml) and AcOEt (2 ⁇ 250 ml). The combined organic phases were washed with saturated aqueous NH 4 Cl, dried (MgSO 4 ) and concentrated in vacuo. This afforded 7.24 g (80%) of N-(2-(methoxycarbonyl)ethyl)- ⁇ -Ala-OtBu.</span>\\n<meta content=\"0272\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Hexadecanedioic acid monomethyl ester</span>\\n<span itemprop=\"definition\">150 mg, 0.5 mmol was dissolved in DMF (5 mL). HOAt (102 mg, 0.75 mmol) and EDAC (143 mg, 0.75 mmol) was added and the reaction was stirred at 50° C. for 1 hour. After cooling to room temperature, DIEA (0.256 mL, 1.5 mmol) and N-(2-(methoxycarbonyl)ethyl)- ⁇ -Ala-OtBu (139 mg, 0.6 mmol) was added. The reaction was stirred overnight at room temperature. The mixture was partitioned between water (2 ⁇ 50 mL) and AcOEt (100 mL).</span>\\n<meta content=\"0274\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Methyl hexadecandioyl N-(2-(methoxycarbonyl)ethyl- ⁇ -Ala-OH</span>\\n<span itemprop=\"definition\">(161 mg, 0.351 mmol) was dissolved in THF (10 mL) DIEA (0.073 mL, 0.42 mmol) and TSTU (127 mg, 0.42 mmol) was added. The mixture was stirred while cooled on an icebath for 30 min, followed by stirring for 2 hours at room temperature. The mixture was partitioned between and AcOEt (100 mL) and aqueous HCl (0.2 N, 2 ⁇ 80 mL). The organic phase was dried (Na 2 SO 4 ) and concentrated in vacuo. This afforded 140 mg (72%) of methyl hexadecandioyl N-(2-(methoxycarbonyl)ethyl)- ⁇ -Ala-OSu as an oil.</span>\\n<meta content=\"0276\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was prepared in analogy with example 1 and 36 via coupling of methyl octadecandioyl N-(2-(methoxycarbonyl)ethyl)- ⁇ -Ala-OSu with Des(B30) human insulin and deprotection by NaOH.</span>\\n<meta content=\"0278\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">This compound</span>\\n<span itemprop=\"definition\">was synthesized in analogy with methyl hexadecandioyl N-(2-(methoxycarbonyl)ethyl)- ⁇ -Ala-OSu using octadecanedioic acid mono methyl ester.</span>\\n<meta content=\"0279\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the affinity of the insulin analogues of the invention for the human insulin receptor</span>\\n<span itemprop=\"definition\">was determined by a SPA assay (Scintillation Proximity Assay) microtiterplate antibody capture assay.</span>\\n<meta content=\"0282\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">SPA-PVT antibody-binding beads, anti-mouse reagent</span>\\n<span itemprop=\"definition\">(Amersham Biosciences, Cat No. PRNQ0017) were mixed with 25 ml of binding buffer (100 mM HEPES pH 7.8; 100 mM sodium chloride, 10 mM MgSO 4 , 0.025% Tween-20).</span>\\n<meta content=\"0282\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">binding buffer</span>\\n<span itemprop=\"definition\">100 mM HEPES pH 7.8; 100 mM sodium chloride, 10 mM MgSO 4 , 0.025% Tween-20.</span>\\n<meta content=\"0282\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">6005190</span>\\n<span itemprop=\"definition\">is composed of 2.4  ⁇ l of a 1:5000 diluted purified recombinant human insulin receptor—exon 11, an amount of a stock solution of A14 Tyr[ 125 I]-human insulin corresponding to 5000 cpm per 100  ⁇ l of reagent mix, 12  ⁇ l of a 1:1000 dilution of F12 antibody, 3 ml of SPA-beads and binding buffer to a total of 12 ml. A total of 100  ⁇ l was then added and a dilution series is made from appropriate samples. To the dilution series was then added 100  ⁇ l of reagent mix and the samples were incubated for 16 hours while gently shaken. The phases were the then separated by centrifugation for 1 min and the plates counted in a Topcounter. The binding data were fitted using the nonlinear regression algorithm in the GraphPad Prism 2.01 (GraphPad Software, San Diego, Calif.).</span>\\n<meta content=\"0282\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">mice</span>\\n<span itemprop=\"definition\">were immunized by injecting 50  ⁇ g of purified mIR in FCA subcutaneously followed by two injections with 20  ⁇ g of mIR in FIA. Highresponder mice were boosted intravenously with 25  ⁇ g of mIR and the spleens were harvested after 3 days. Spleen cells were fused with the myeloma Fox cell line (Köhler, G &amp; Milstein C. (1976), European J. Immunology, 6:511-19; Taggart R T et al (1983), Science 219:1228-30). Supernatants were screened for antibody production in a mIR specific ELISA. Positive wells were cloned and tested in Western blotting.</span>\\n<meta content=\"0283\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Sprague Dawley male rats weighing 238-383 g on the experimental day</span>\\n<span itemprop=\"definition\">were used for the clamp experiment.</span>\\n<meta content=\"0285\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the rats</span>\\n<span itemprop=\"definition\">had free access to feed under controlled ambient conditions and were fasted overnight (from 3 pm) prior to the clamp experiment.</span>\\n<meta content=\"0285\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">the rats</span>\\n<span itemprop=\"definition\">were acclimatized in the animal facilities for at least 1 week prior to the surgical procedure. Approximately 1 week prior to the clamp experiment Tygon catheters were inserted under halothane anaesthesia into the jugular vein (for infusion) and the carotid artery (for blood sampling) and exteriorised and fixed on the back of the neck. The rats were given Streptocilin vet. (Boehringer Ingelheim; 0.15 ml/rat, i.m.) post-surgically and placed in an animal care unit (25° C.) during the recovery period.</span>\\n<meta content=\"0286\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Anorphin</span>\\n<span itemprop=\"definition\">(0.06 mg/rat, s.c.) was administered during anaesthesia and Rimadyl (1.5 mg/kg, s.c.) was administered after full recovery from the anaesthesia (2-3 h) and again once daily for 2 days.</span>\\n<meta content=\"0286\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Plasma glucose levels</span>\\n<span itemprop=\"definition\">were measured at 10 min intervals throughout and infusion of 20% aqueous glucose was adjusted accordingly in order to maintain euglyceamia. Samples of re-suspended erythrocytes were pooled from each rat and returned in about 1 ⁇ 2 ml volumes via the carotid catheter.</span>\\n<meta content=\"0287\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Insulins to be tested</span>\\n<span itemprop=\"definition\">were diluted from a stock solution containing 97  ⁇ M of the insulin derivative in 5 mM phosphate pH 7.7. The final concentration in the solution ready for use was 0.45  ⁇ M of the insulin derivative, 5 mM of phosphate, 100 mM of sodium chloride, 0.007% of polysorbate 20. The pH was 7.7 and the i.v. infusion rate was 15 and 20 pmol ⁇ min  ⁇ 1  ⁇ kg  ⁇ 1 .</span>\\n<meta content=\"0289\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">a stock solution of human insulin that was used as reference compound</span>\\n<span itemprop=\"definition\">was formulated in a similar medium and infused i.v. at 6, 15 or 30 pmol ⁇ min  ⁇ 1  ⁇ kg  ⁇ 1 .</span>\\n<meta content=\"0290\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">T 50%</span>\\n<span itemprop=\"definition\">is the time when 50% of an injected amount of the A14 Tyr[ 125 I] labelled derivative of an insulin to be tested has disappeared from the injection site as measured with an external  ⁇ -counter.</span>\\n<meta content=\"0293\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">Formulated preparations of insulin derivatives labelled in Tyr A14 with 125 I</span>\\n<span itemprop=\"definition\">were injected sc. in pigs as previously described (Ribel, U., Jorgensen, K, Brange, J, and Henriksen, U. The pig as a model for subcutaneous insulin absorption in man. Serrano-Rios, M and Lefèbvre, P. J. 891-896. 1985. Amsterdam; New York; Oxford, Elsevier Science Publishers. 1985 (Conference Proceeding)).</span>\\n<meta content=\"0295\" itemprop=\"num_attr\"/>\\n</li>\\n<li itemprop=\"definitions\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"subject\">test/detemir</span>\\n<span itemprop=\"definition\">shows the T 50% found for each of the compounds tested (“test”) and the T 50% found for insulin detemir (“detemir”) in the same experiment.</span>\\n<meta content=\"0298\" itemprop=\"num_attr\"/>\\n</li>\\n</ul>\\n</section>\\n',\n",
       " '<section itemprop=\"abstract\" itemscope=\"\">\\n<h2>Abstract</h2>\\n<div html=\"\" itemprop=\"content\"><abstract lang=\"EN\" load-source=\"docdb\" mxw-id=\"PA66892516\" source=\"national office\">\\n<div class=\"abstract\">The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to the epsilon-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: -W-X-Y-Z wherein W, X, Y and Z are as defined in the disclosure.</div>\\n</abstract>\\n</div>\\n</section>\\n',\n",
       " '<section itemprop=\"description\" itemscope=\"\">\\n<h2>Description</h2>\\n<div html=\"\" itemprop=\"content\"><div class=\"description\" lang=\"EN\" load-source=\"patent-office\" mxw-id=\"PDES33222580\">\\n<heading id=\"h-0001\">CROSS-REFERENCE TO RELATED APPLICATIONS</heading>\\n<div class=\"description-paragraph\" id=\"p-0002\" num=\"0001\">This application is a continuation of International Application No. PCT/DK2004/000511, filed Jul. 22, 2004, which claims priority from Danish Patent Application No. PA 2003 01129 filed Aug. 5, 2003 and to U.S. Patent Application No. 60/495,451 filed Aug. 14, 2003.</div>\\n<heading id=\"h-0002\">FIELD OF THE INVENTION</heading>\\n<div class=\"description-paragraph\" id=\"p-0003\" num=\"0002\">The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action. The invention also relates to methods of providing such derivatives, to pharmaceutical compositions containing them, to a method of treating diabetes and hyperglycemia using the insulin derivatives of the invention and to the use of such insulin derivatives in the treatment of diabetes and hyperglycemia.</div>\\n<heading id=\"h-0003\">BACKGROUND OF THE INVENTION</heading>\\n<div class=\"description-paragraph\" id=\"p-0004\" num=\"0003\">Currently, the treatment of diabetes, both type 1 diabetes and type 2 diabetes, relies to an increasing extent on the so-called intensive insulin treatment. According to this regimen, the patients are treated with multiple daily insulin injections comprising one or two daily injections of a long acting insulin to cover the basal insulin requirement supplemented by bolus injections of a rapid acting insulin to cover the insulin requirement related to meals.</div>\\n<div class=\"description-paragraph\" id=\"p-0005\" num=\"0004\">Long acting insulin compositions are well known in the art. Thus, one main type of long acting insulin compositions comprises injectable aqueous suspensions of insulin crystals or amorphous insulin. In these compositions, the insulin compounds utilized typically are protamine insulin, zinc insulin or protamine zinc insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0006\" num=\"0005\">Certain drawbacks are associated with the use of insulin suspensions. Thus, in order to secure an accurate dosing, the insulin particles must be suspended homogeneously by gentle shaking before a defined volume of the suspension is withdrawn from a vial or expelled from a cartridge. Also, for the storage of insulin suspensions, the temperature must be kept within more narrow limits than for insulin solutions in order to avoid lump formation or coagulation.</div>\\n<div class=\"description-paragraph\" id=\"p-0007\" num=\"0006\">While it was earlier believed that protamines were non-immunogenic, it has now turned out that protamines can be immunogenic in man and that their use for medical purposes may lead to formation of antibodies. Also, evidence has been found that the protamine-insulin complex is itself immunogenic. Therefore, with some patients the use of long acting insulin compositions containing protamines must be avoided.</div>\\n<div class=\"description-paragraph\" id=\"p-0008\" num=\"0007\">Another type of long acting insulin compositions are solutions having a pH value below physiological pH from which the insulin will precipitate because of the rise in the pH value when the solution is injected. A drawback with these solutions is that the particle size distribution of the precipitate formed in the tissue on injection, and thus the release profile of the medication, depends on the blood flow at the injection site and other parameters in a somewhat unpredictable manner. A further drawback is that the solid particles of the insulin may act as a local irritant causing inflammation of the tissue at the site of injection.</div>\\n<div class=\"description-paragraph\" id=\"p-0009\" num=\"0008\">WO 91/12817 (Novo Nordisk ANS) discloses soluble insulin compositions comprising insulin complexes of cobalt(III). The action profile of these complexes is only moderately prolonged and the bioavailability is reduced relative to human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0010\" num=\"0009\">Human insulin has three primary amino groups: the N-terminal group of the A-chain and of the B-chain and the ε-amino group of Lys<sup>B29</sup>. Several insulin derivatives which are substituted in one or more of these groups are known in the prior art. Thus, U.S. Pat. No. 3,528,960 (Eli Lilly) relates to N-carboxyaroyl insulins in which one, two or three primary amino groups of the insulin molecule has a carboxyaroyl group.</div>\\n<div class=\"description-paragraph\" id=\"p-0011\" num=\"0010\">According to GB Patent No. 1.492.997 (Nat. Res. Dev. Corp.), it has been found that insulin with a carbamyl substitution at N<sup>εB29 </sup>has an improved profile of hypoglycaemic effect.</div>\\n<div class=\"description-paragraph\" id=\"p-0012\" num=\"0011\">JP laid-open patent application No. 1-254699 (Kodama Co., Ltd.) discloses insulin wherein a fatty acid is bound to the amino group of Phe<sup>B1 </sup>or to the ε-amino group of LyS<sup>B29 </sup>or to both of these. The stated purpose of the derivatisation is to obtain a pharmacologically acceptable, stable insulin preparation.</div>\\n<div class=\"description-paragraph\" id=\"p-0013\" num=\"0012\">Insulins, which in the B30 position have an amino acid having at least five carbon atoms which cannot necessarily be coded for by a triplet of nucleotides, are described in JP laid-open patent application No. 57-067548 (Shionogi). The insulin analogues are claimed to be useful in the treatment of diabetes mellitus, particularly in patients who are insulin resistant due to generation of bovine or porcine insulin antibodies.</div>\\n<div class=\"description-paragraph\" id=\"p-0014\" num=\"0013\">WO 95/07931 (Novo Nordisk A/S) discloses human insulin derivatives wherein the ε-amino group of LyS<sup>B29 </sup>has a lipophilic substituent. These insulin derivatives have a prolonged profile of action and are soluble at physiological pH values.</div>\\n<div class=\"description-paragraph\" id=\"p-0015\" num=\"0014\">EP 894095 discloses insulin derivatives wherein the N-terminal group of the B-chain and/or the ε-amino group of Lys in position B28, B29 or B30 has a substituent of the formula —CO—W—COOH where W can be a long chain hydrocarbon group. These insulin derivatives have a prolonged profile of action and are soluble at physiological pH values.</div>\\n<div class=\"description-paragraph\" id=\"p-0016\" num=\"0015\">However, there is still a need for insulins having a more prolonged profile of action than the insulin derivatives known up till now and which at the same time are soluble at physiological pH values and have a potency which is comparable to that of human insulin.</div>\\n<heading id=\"h-0004\">SUMMARY OF THE INVENTION</heading>\\n<div class=\"description-paragraph\" id=\"p-0017\" num=\"0016\">The present invention is based on the recognition that the overall hydrophobicity of an insulin derivative molecule plays an important role for the in vivo potency of the derivative.</div>\\n<div class=\"description-paragraph\" id=\"p-0018\" num=\"0017\">In one aspect the present invention relates to an insulin derivative which is a naturally occurring insulin or an analogue thereof which has a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula:\\n<br/>\\n-W-X—Y-Z\\n<br/>\\nwherein W is:\\n</div> <ul> <li id=\"ul0001-0001\" num=\"0000\"> <ul> <li id=\"ul0002-0001\" num=\"0018\">an α-amino acid residue having a carboxylic acid group in the side chain which residue forms, with one of its carboxylic acid groups, an amide group together with the α-amino group of the N-terminal amino acid residue of the B chain or together with the ε-amino group of a Lys residue present in the B chain of the parent insulin;</li> <li id=\"ul0002-0002\" num=\"0019\">a chain composed of two, three or four α-amino acid residues linked together via amide bonds, which chain—via an amide bond—is linked to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin, the amino acid residues of W being selected from the group of amino acid residues having a neutral side chain and amino acid residues having a carboxylic acid group in the side chain so that W has at least one amino acid residue which has a carboxylic acid group in the side chain; or</li> <li id=\"ul0002-0003\" num=\"0020\">a covalent bond from X to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin;\\n<br/>\\nX is:\\n</li> <li id=\"ul0002-0004\" num=\"0021\">—<u>C</u>O—;</li> <li id=\"ul0002-0005\" num=\"0022\">—CH(COOH) <u>C</u>O—;</li> <li id=\"ul0002-0006\" num=\"0023\">—N(CH<sub>2</sub>COOH)CH<sub>2</sub> <u>C</u>O—;</li> <li id=\"ul0002-0007\" num=\"0024\">—N(CH<sub>2</sub>COOH)CH<sub>2</sub>CON(CH<sub>2</sub>COOH)CH<sub>2</sub> <u>C</u>O—;</li> <li id=\"ul0002-0008\" num=\"0025\">—N(CH<sub>2</sub>CH<sub>2</sub>COOH)CH<sub>2</sub>CH<sub>2</sub> <u>C</u>O—;</li> <li id=\"ul0002-0009\" num=\"0026\">—N(CH<sub>2</sub>CH<sub>2</sub>COOH)CH<sub>2</sub>CH<sub>2</sub>CON(CH<sub>2</sub>CH<sub>2</sub>COOH)CH<sub>2</sub>CH<sub>2</sub> <u>C</u>O—;</li> <li id=\"ul0002-0010\" num=\"0027\">—NHCH(COOH)(CH<sub>2</sub>)<sub>4</sub>NH<u>C</u>O—;</li> <li id=\"ul0002-0011\" num=\"0028\">—N(CH<sub>2</sub>CH<sub>2</sub>COOH)CH<sub>2</sub> <u>C</u>O—; or</li> <li id=\"ul0002-0012\" num=\"0029\">—N(CH<sub>2</sub>COOH)CH<sub>2</sub>CH<sub>2</sub> <u>C</u>O—.\\n<br/>\\nthat\\n</li> </ul> </li> <li id=\"ul0001-0002\" num=\"0030\">a) when W is an amino acid residue or a chain of amino acid residues, via a bond from the underscored carbonyl carbon forms an amide bond with an amino group in W, or</li> <li id=\"ul0001-0003\" num=\"0031\">b) when W is a covalent bond, via a bond from the underscored carbonyl carbon forms an amide bond with the N-terminal α-amino group in the B chain or with the ε-amino group of a Lys residue present in the B chain of the parent insulin;\\n<br/>\\nY is:\\n    <ul> <li id=\"ul0003-0001\" num=\"0032\">—(CH<sub>2</sub>)<sub>m</sub>— where m is an integer in the range of 6 to 32;</li> <li id=\"ul0003-0002\" num=\"0033\">a divalent hydrocarbon chain comprising 1, 2 or 3-CH═CH— groups and a number of —CH<sub>2</sub>— groups sufficient to give a total number of carbon atoms in the chain in the range of 10 to 32;</li> <li id=\"ul0003-0003\" num=\"0034\">a divalent hydrocarbon chain of the formula —(CH<sub>2</sub>)<sub>v</sub>C<sub>6</sub>H<sub>4</sub>(CH<sub>2</sub>)<sub>w</sub>— wherein v and w are integers or one of them is zero so that the sum of v and w is in the range of 6 to 30; and\\n<br/>\\nZ is:\\n</li> <li id=\"ul0003-0004\" num=\"0035\">—COOH;</li> <li id=\"ul0003-0005\" num=\"0036\">—CO-Asp;</li> <li id=\"ul0003-0006\" num=\"0037\">—CO-Glu;</li> <li id=\"ul0003-0007\" num=\"0038\">—CO-Gly;</li> <li id=\"ul0003-0008\" num=\"0039\">—CO-Sar;</li> <li id=\"ul0003-0009\" num=\"0040\">—CH(COOH)<sub>2</sub>;</li> <li id=\"ul0003-0010\" num=\"0041\">—N(CH<sub>2</sub>COOH)<sub>2</sub>;</li> <li id=\"ul0003-0011\" num=\"0042\">—SO<sub>3</sub>H; or</li> <li id=\"ul0003-0012\" num=\"0043\">—PO<sub>3</sub>H;\\n<br/>\\nand any Zn<sup>2+</sup> complexes thereof, provided that when W is a covalent bond and X is —CO—, then Z is different from —COOH.\\n</li> </ul>\\n</li> </ul>\\n<div class=\"description-paragraph\" id=\"p-0019\" num=\"0044\">In one embodiment of the invention, the side chain -W-X—Y-Z is attached to the α-amino group of the N-terminal amino acid residue of the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0020\" num=\"0045\">In another embodiment of the invention, side chain -W-X—Y-Z is attached to the ε-amino group of a Lys residue present in the B chain of the parent insulin. In one more specific aspect of this embodiment, the side chain —W<b>13</b> X—Y-Z is attached to the ε-amino group of a Lys residue present in position 28 of the B chain. In a further more specific aspect of this embodiment, the side chain -W-X—Y-Z is attached to the ε-amino group of a Lys residue present in position 29 of the B chain. In a further more specific aspect of this embodiment, the side chain -W-X—Y-Z is attached to the ε-amino group of a Lys residue present in position 30 of the B chain.</div>\\n<div class=\"description-paragraph\" id=\"p-0021\" num=\"0046\">The substructure W of the side chain -W-X—Y-Z can be a covalent bond. Alternatively, W can be a residue of an α-amino acid having a carboxylic acid group in the side chain and comprising a total of from 4 to 10 carbon atoms. Specifically, W can be the residue of an α-amino acid, that can be coded for by the genetic code. Thus, W can, for example, be selected from the group consisting of α-Asp, β-Asp, α-Glu, and γ-Glu. Further options for W are for example α-hGlu and δ-hGlu.</div>\\n<div class=\"description-paragraph\" id=\"p-0022\" num=\"0047\">In a further embodiment, W is a chain composed of two α-amino acid residues of which one has from 4 to 10 carbon atoms and a carboxylic acid group in the side chain while the other has from 2 to 11 carbon atoms but no free carboxylic acid group. The α-amino acid residue with no free carboxylic acid group can be a neutral, codable α-amino acid residue. Examples of W according to this embodiment are: α-Asp-Gly; Gly-α-Asp; β-Asp-Gly; Gly-β-Asp; α-Glu-Gly; Gly-α-Glu; γ-Glu-Gly; Gly-γ-Glu; α-hGlu-Gly; Gly-α-hGlu; δ-hGlu-Gly; and Gly-δ-hGlu.</div>\\n<div class=\"description-paragraph\" id=\"p-0023\" num=\"0048\">In a further embodiment, W is a chain composed of two α-amino acid residues, independently having from 4 to 10 carbon atoms, and both having a carboxylic acid group in the side chain. One of these α-amino acid residues or both of them can be codable α-amino acid residues. Examples of W according to this embodiment are: α-Asp-α-Asp; α-Asp-α-Glu; α-Asp-α-hGlu; α-Asp-β-Asp; α-Asp-γ-Glu; α-Asp-δ-hGlu; β-Asp-α-Asp; β-Asp-α-Glu; β-Asp-α-hGlu; β-Asp-β-Asp; β-Asp-γ-Glu; β-Asp-δ-hGlu; α-Glu-α-Asp; α-Glu-α-Glu; α-Glu-α-hGlu; α-Glu-β-Asp; α-Glu-γ-Glu; α-Glu-δ-hGlu; γ-Glu-α-Asp; γ-Glu-α-Glu; γ-Glu-α-hGlu; γ-Glu-β-Asp; γ-Glu-γ-Glu; γ-Glu-δ-hGlu; α-hGlu-α-Asp; α-hGlu-α-Glu; α-hGlu-α-hGlu; α-hGlu-β-Asp; α-hGlu-γ-Glu; α-hGlu-δ-hGlu; δ-hGlu-α-Asp; δ-hGlu-α-Glu; δ-hGlu-α-hGlu; δ-hGlu-β-Asp; δ-hGlu-γ-Glu; and δ-hGlu-δ-hGlu.</div>\\n<div class=\"description-paragraph\" id=\"p-0024\" num=\"0049\">In a further embodiment, W is a chain composed of three α-amino acid residues, independently having from 4 to 10 carbon atoms, the amino acid residues of the chain being selected from the group of residues having a neutral side chain and residues having a carboxylic acid group in the side chain so that the chain has at least one residue which has a carboxylic acid group in the side chain. In one embodiment, the amino acid residues are codable residues.</div>\\n<div class=\"description-paragraph\" id=\"p-0025\" num=\"0050\">In a further embodiment, W is a chain composed of four α-amino acid residues, independently having from 4 to 10 carbon atoms, the amino acid residues of the chain being selected from the group having a neutral side chain and residues having a carboxylic acid group in the side chain so that the chain has at least one residue which has a carboxylic acid group in the side chain. In one embodiment, the amino acid residues are codable residues.</div>\\n<div class=\"description-paragraph\" id=\"p-0026\" num=\"0051\">In one embodiment W can be connected to the ε-amino group of the Lys residue in the B-chain via an urea derivative.</div>\\n<div class=\"description-paragraph\" id=\"p-0027\" num=\"0052\">The substructure X of the side chain -W-X—Y-Z can be a group of the formula —<u>C</u>O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal α-amino group in the B chain or with the ε-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0028\" num=\"0053\">In a further embodiment, the substructure X of the side chain can be a group of the formula —CH(COOH)<u>C</u>O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal α-amino group in the B chain or with the ε-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0029\" num=\"0054\">In a further embodiment, the substructure X of the side chain can be a group of the formula —N(CH<sub>2</sub>COOH)CH<sub>2</sub> <u>C</u>O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal α-amino group in the B chain or with the ε-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0030\" num=\"0055\">In a further embodiment, the substructure X of the side chain can be a group of the formula —N(CH<sub>2</sub>CH<sub>2</sub>COOH)CH<sub>2</sub> <u>C</u>O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal α-amino group in the B chain or with the ε-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0031\" num=\"0056\">In a further embodiment, the substructure X of the side chain can be a group of the formula —N(CH<sub>2</sub>COOH)CH<sub>2</sub>CH<sub>2</sub> <u>C</u>O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal α-amino group in the B chain or with the ε-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0032\" num=\"0057\">In a further embodiment, the substructure X of the side chain can be a group of the formula —N(CH<sub>2</sub>COOH)CH<sub>2</sub>CON(CH<sub>2</sub>COOH)CH<sub>2</sub> <u>C</u>O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal α-amino group in the B chain or with the f-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0033\" num=\"0058\">In a further embodiment, the substructure X of the side chain can be a group of the formula —N(CH<sub>2</sub>CH<sub>2</sub>COOH)CH<sub>2</sub>CH<sub>2</sub> <u>C</u>O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal α-amino group in the B chain or with the ε-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0034\" num=\"0059\">In a further embodiment, the substructure X of the side chain can be a group of the formula —N(CH<sub>2</sub>CH<sub>2</sub>COOH)CH<sub>2</sub>CH<sub>2</sub>CON(CH<sub>2</sub>CH<sub>2</sub>COOH)CH<sub>2</sub>CH<sub>2</sub> <u>C</u>O— that, via a bond from the underscored carbonyl carbon, forms an amide bond with an amino group in W or, when W is a covalent bond, with the N-terminal α-amino group in the B chain or with the ε-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0035\" num=\"0060\">The substructure Y of the side chain -W-X—Y-Z can be a group of the formula —(CH<sub>2</sub>)<sub>m</sub>— where m is an integer in the range of from 6 to 32, from 8 to 20, from 12 to 20, or from 12-16.</div>\\n<div class=\"description-paragraph\" id=\"p-0036\" num=\"0061\">In another embodiment, Y is a divalent hydrocarbon chain comprising 1, 2 or 3—CH═CH— groups and a number of —CH<sub>2</sub>— groups sufficient to give a total number of carbon atoms in the chain in the range of from 6 to 32, from 10 to 32, from 12 to 20, or from 12-16.</div>\\n<div class=\"description-paragraph\" id=\"p-0037\" num=\"0062\">In another embodiment, Y is a divalent hydrocarbon chain of the formula —(CH<sub>2</sub>)<sub>v</sub>C<sub>6</sub>H<sub>4</sub>(CH<sub>2</sub>)<sub>w</sub>— wherein v and w are integers or one of them is zero so that the sum of v and w is in the range of from 6 to 30, from 10 to 20, or from 12-16.</div>\\n<div class=\"description-paragraph\" id=\"p-0038\" num=\"0063\">In one embodiment, the substructure Z of the side chain -W-X—Y-Z is —COOH provided that when W is a covalent bond and X is —CO—, then Z is different from —COOH.</div>\\n<div class=\"description-paragraph\" id=\"p-0039\" num=\"0064\">In another embodiment, Z is —CO-Asp.</div>\\n<div class=\"description-paragraph\" id=\"p-0040\" num=\"0065\">In another embodiment, Z is —CO-Glu.</div>\\n<div class=\"description-paragraph\" id=\"p-0041\" num=\"0066\">In another embodiment, Z is —CO-Gly.</div>\\n<div class=\"description-paragraph\" id=\"p-0042\" num=\"0067\">In another embodiment, Z is —CO-Sar.</div>\\n<div class=\"description-paragraph\" id=\"p-0043\" num=\"0068\">In another embodiment, Z is —CH(COOH)<sub>2</sub>.</div>\\n<div class=\"description-paragraph\" id=\"p-0044\" num=\"0069\">In another embodiment, Z is —N(CH<sub>2</sub>COOH)<sub>2</sub>.</div>\\n<div class=\"description-paragraph\" id=\"p-0045\" num=\"0070\">In another embodiment, Z is —SO<sub>3</sub>H.</div>\\n<div class=\"description-paragraph\" id=\"p-0046\" num=\"0071\">In another embodiment, Z is —PO<sub>3</sub>H.</div>\\n<div class=\"description-paragraph\" id=\"p-0047\" num=\"0072\">In a further embodiment W is selected from the group consisting of α-Asp, β-Asp, α-Glu, and γ-Glu; X is —CO— or —CH(COOH)CO; Y is —(CH<sub>2</sub>)<sub>m</sub>— where m is an integer in the range of 12-18 and Z is —COOH or —CH(COOH)<sub>2</sub>.</div>\\n<div class=\"description-paragraph\" id=\"p-0048\" num=\"0073\">The insulin moiety—in the present text also referred to as the parent insulin—of an insulin derivative according to the invention can be a naturally occurring insulin such as human insulin or porcine insulin. Alternatively, the parent insulin can be an insulin analogue.</div>\\n<div class=\"description-paragraph\" id=\"p-0049\" num=\"0074\">In one group of parent insulin analogues, the amino acid residue at position A21 is Asn.</div>\\n<div class=\"description-paragraph\" id=\"p-0050\" num=\"0075\">In another group of parent insulin analogues, the amino acid residue at position A21 is Gly. Specific examples from this group of analogues are Gly<sup>A21 </sup>human insulin, Gly<sup>A21 </sup>des(B30) human insulin; and Gly<sup>A21</sup>Arg<sup>B31</sup>Arg<sup>B32 </sup>human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0051\" num=\"0076\">In another group of parent insulin analogues, the amino acid residue at position B1 has been deleted. A specific example from this group of parent insulin analogues is des(B1) human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0052\" num=\"0077\">In another group of parent insulin analogues, the amino acid residue at position B30 has been deleted. A specific example from this group of parent insulin analogues is des(B30) human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0053\" num=\"0078\">In another group of parent insulin analogues, the amino acid residue at position B28 is Asp. A specific example from this group of parent insulin analogues is Asp<sup>B28 </sup>human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0054\" num=\"0079\">In another group of parent insulin analogues, the amino acid residue at position B28 is Lys and the amino acid residue at position B29 is Pro. A specific example from this group of parent insulin analogues is Lys<sup>B28</sup>Pro<sup>B29 </sup>human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0055\" num=\"0080\">In another group of parent insulin analogues the amino acid residue in position B30 is Lys and the amino acid residue in position B29 is any codable amino acid except Cys, Met, Arg and Lys. An example is an insulin analogue where the amino acid residue at position B29 is Thr and the amino acid residue at position B30 is Lys. A specific example from this group of parent insulin analogues is Thr<sup>B29</sup>LyS<sup>B30 </sup>human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0056\" num=\"0081\">In another group of parent insulin analogues, the amino acid residue at position B3 is Lys and the amino acid residue at position B29 is Glu. A specific example from this group of parent insulin analogues is Lys<sup>B3</sup>Glu<sup>B29 </sup>human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0057\" num=\"0082\">Examples of insulin derivatives according to the invention are the following compounds:</div>\\n<div class=\"description-paragraph\" id=\"p-0058\" num=\"0083\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0059\" num=\"0084\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>15</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0060\" num=\"0085\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0061\" num=\"0086\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>17</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0062\" num=\"0087\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>18</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0063\" num=\"0088\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-Glu-N-(γ-Glu)) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0064\" num=\"0089\">N<sup>εB29</sup>—(N<sup>α</sup>—(Asp-OC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0065\" num=\"0090\">N<sup>εB29</sup>—(N<sup>α</sup>—(Glu-OC(CH<sub>2</sub>)<sub>14</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0066\" num=\"0091\">N<sup>εB29</sup>—(N<sup>α</sup>—(Glu-OC(CH<sub>2</sub>)<sub>14</sub>CO—) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0067\" num=\"0092\">N<sup>εB29</sup>—(N<sup>α</sup>—(Asp-OC(CH<sub>2</sub>)<sub>16</sub>CO—) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0068\" num=\"0093\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)-α-Glu-N-(β-Asp)) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0069\" num=\"0094\">N<sup>εB29</sup>—(N<sup>α</sup>—(Gly-OC(CH<sub>2</sub>)<sub>13</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0070\" num=\"0095\">N<sup>εB29</sup>—(N<sup>α</sup>—(Sar-OC(CH<sub>2</sub>)<sub>13</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0071\" num=\"0096\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>13</sub>CO)-γ-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0072\" num=\"0097\">(N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>13</sub>CO)-β-Asp) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0073\" num=\"0098\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>13</sub>CO)-α-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0074\" num=\"0099\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-D-Glu) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0075\" num=\"0100\">N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO-β-D-Asp) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0076\" num=\"0101\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-β-D-Asp) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0077\" num=\"0102\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-IDA) des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0078\" num=\"0103\">N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO—N-(carboxyethyl)-Gly] des(B30) human insulin;</div>\\n<div class=\"description-paragraph\" id=\"p-0079\" num=\"0104\">N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)—N-(carboxyethyl)-Gly] des(B30) human insulin; and</div>\\n<div class=\"description-paragraph\" id=\"p-0080\" num=\"0105\">N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)—N-(carboxymethyl)-β-Ala] des(B30) human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0081\" num=\"0106\">Insulin derivatives according to the invention may be provided in the form of essentially zinc free compounds or in the form of zinc complexes. When zinc complexes of an insulin derivative according to the invention are provided, two Zn<sup>2+</sup> ions, three Zn<sup>2+</sup> ions or four Zn<sup>2+</sup> ions can be bound to each insulin hexamer. Solutions of zinc complexes of the insulin derivatives will contain mixtures of such species.</div>\\n<div class=\"description-paragraph\" id=\"p-0082\" num=\"0107\">In a further aspect of the invention, a pharmaceutical composition comprising a therapeutically effective amount of an insulin derivative according to the invention together with a pharmaceutically acceptable carrier can be provided for the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycemia in patients in need of such a treatment. An insulin derivative according to the invention can be used for the manufacture of a pharmaceutical composition for use in the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia.</div>\\n<div class=\"description-paragraph\" id=\"p-0083\" num=\"0108\">In a further aspect of the invention, there is provided a pharmaceutical composition for treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment, comprising a therapeutically effective amount of an insulin derivative according to the invention in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with pharmaceutically acceptable carriers and additives.</div>\\n<div class=\"description-paragraph\" id=\"p-0084\" num=\"0109\">In one embodiment the invention provides a pharmaceutical composition being a mixture of an insulin derivative according to the invention and a rapid acting insulin analogue selected group consisting of Asp<sup>B28 </sup>human insulin; Lys<sup>B28</sup>Pro<sup>B29 </sup>human insulin and LyS<sup>B3</sup>Glu<sup>B29 </sup>human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0085\" num=\"0110\">In one embodiment the invention provides a pharmaceutical composition comprising N<sup>εB29</sup>—N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)-γ-Glu) des(B30) human insulin and AspB28 human insulin together with pharmaceutically acceptable carriers and additives.</div>\\n<div class=\"description-paragraph\" id=\"p-0086\" num=\"0111\">The insulin derivative according to the invention and the rapid acting insulin analogue can be mixed in a ratio from about 90/10%; about 70/30% or about 50/50%.</div>\\n<div class=\"description-paragraph\" id=\"p-0087\" num=\"0112\">In a further aspect of the invention, there is provided a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of an insulin derivative according to the invention together with a pharmaceutically acceptable carrier and pharmaceutical acceptable additives.</div>\\n<div class=\"description-paragraph\" id=\"p-0088\" num=\"0113\">In a further aspect of the invention, there is provided a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of an insulin derivative according to the invention in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier and pharmaceutical acceptable additives.</div>\\n<div class=\"description-paragraph\" id=\"p-0089\" num=\"0114\">In a further aspect, the present invention relates to insulin derivatives which have an overall hydrophobicity which is essentially similar to that of human insulin.</div>\\n<div class=\"description-paragraph\" id=\"p-0090\" num=\"0115\">In further aspect, the present invention relates to insulin derivatives which have a hydrophobic index, k′<sub>rel</sub>, which is in the range of from about 2 to about 200.</div>\\n<div class=\"description-paragraph\" id=\"p-0091\" num=\"0116\">In a further aspect, the insulin derivatives of the present invention have a hydrophobic index, k′<sub>rel</sub>, which is in the range from about 0.02 to about 10, from about 0.1 to about 5; from about 0.5 to about 5; or from about 0.5 to about 2.</div>\\n<div class=\"description-paragraph\" id=\"p-0092\" num=\"0117\">According to one embodiment of the present invention the insulin derivatives will comprise a side chain -W-X—Y-Z as defined above which has at least one hydrophilic and at least one hydrophobic region.</div>\\n<div class=\"description-paragraph\" id=\"p-0093\" num=\"0118\">According to another embodiment of the present invention, the insulin derivatives will comprise a side chain -W-X—Y-Z as defined above which has at least one free carboxylic acid group and according to a further embodiment, the side chain will have at least two free carboxylic acid groups.</div>\\n<div class=\"description-paragraph\" id=\"p-0094\" num=\"0119\">In another embodiment, the invention relates to a pharmaceutical composition comprising an insulin derivative according to the invention which is soluble at physiological pH values.</div>\\n<div class=\"description-paragraph\" id=\"p-0095\" num=\"0120\">In another embodiment, the invention relates to a pharmaceutical composition comprising an insulin derivative according to the invention which is soluble at pH values in the interval from about 6.5 to about 8.5.</div>\\n<div class=\"description-paragraph\" id=\"p-0096\" num=\"0121\">In another embodiment, the invention relates to a pharmaceutical composition with a prolonged profile of action which comprises an insulin derivative according to the invention.</div>\\n<div class=\"description-paragraph\" id=\"p-0097\" num=\"0122\">In another embodiment, the invention relates to a pharmaceutical composition which is a solution containing from about 120 nmol/ml to about 2400 nmol/ml, from about 400 nmol/ml to about 2400 nmol/ml, from about 400 nmol/ml to about 1200 nmol/ml, from about 600 nmol/ml to about 2400 nmol/ml, or from about 600 nmol/ml to about 1200 nmol/ml of an insulin derivative according to the invention or of a mixture of the insulin derivative according to the invention with a rapid acting insulin analogue.</div>\\n<div class=\"description-paragraph\" id=\"h-0005\" num=\"0000\">Hydrophobicity Data on Insulin Derivatives According to the Invention.</div>\\n<div class=\"description-paragraph\" id=\"p-0098\" num=\"0123\">The hydrophobicity (hydrophobic index) of the insulin derivatives of the invention relative to human insulin, k′<sub>rel</sub>, was measured on a LiChrosorb RP18 (5 μm, 250×4 mm) HPLC column by isocratic elution at 40° C. using mixtures of A) 0.1 M sodium phosphate buffer, pH 7.3, containing 10% acetonitrile, and B) 50% acetonitrile in water as eluents. The elution was monitored by following the UV absorption of the eluate at 214 nm. Void time, t<sub>0</sub>, was found by injecting 0.1 mM sodium nitrate. Retention time for human insulin, t<sub>human</sub>, was adjusted to at least 2t<sub>0 </sub>by varying the ratio between the A and B solutions. k′<sub>rel</sub>=(t<sub>derivative</sub>−t<sub>0</sub>)/(t<sub>human</sub>−t<sub>0</sub>). k′<sub>rel </sub>found for a number of insulin derivatives according to the invention are given in Table 1.</div>\\n<div class=\"description-paragraph\" id=\"p-0099\" num=\"0124\"> <tables id=\"TABLE-US-00001\" num=\"00001\"> <patent-tables colsep=\"0\" frame=\"none\" pgwide=\"1\" rowsep=\"0\"> <table align=\"left\" class=\"description-table\" cols=\"2\" colsep=\"0\" rowsep=\"0\" width=\"100%\"> <thead> <tr class=\"description-tr\"> <td class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\">TABLE 1</td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">Insulin derivative</td> <td class=\"description-td\">k′<sub>rel</sub> </td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> </thead> <tbody><tr class=\"description-tr\"> <td class=\"description-td\"> </td> </tr> </tbody></table> <table align=\"left\" class=\"description-table\" cols=\"2\" colsep=\"0\" rowsep=\"0\" width=\"100%\"> <tbody><tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">0.87</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">1.15</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>8</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">0.45</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-Glu-N-(γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">1.17</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Asp-OC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">0.70</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Glu-OC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">0.33</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Glu-OC(CH<sub>2</sub>)<sub>14</sub>CO-) des(B30) human insulin</td> <td class=\"description-td\">1.17</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-Glu)-N-(β-Asp) des(B30) human insulin</td> <td class=\"description-td\">1.11</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>13</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">0.58</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Sar-OC(CH<sub>2</sub>)<sub>13</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">0.63</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-Glu)-N-(AspAsp) des(B30) human insulin</td> <td class=\"description-td\">1.07</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">0.88</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>15</sub>CO-γ-L-Glu) des(B30) human insulin</td> <td class=\"description-td\">1.13</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-β-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">0.69</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>13</sub>CO-β-L-Glu) des(B30) human insulin</td> <td class=\"description-td\">0.54</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>13</sub>CO-β-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">0.47</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-δ-L-Aad) des(B30) human insulin</td> <td class=\"description-td\">0.84</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-D-Glu) des(B30) human insulin</td> <td class=\"description-td\">1.4</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>15</sub>CO-β-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">1.09</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">1.49</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Glu) des(B30) human insulin</td> <td class=\"description-td\">1.51</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-ε-L-LysCO—) des(B30) human insulin</td> <td class=\"description-td\">0.90</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-β-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">1.54</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>16</sub>CO-γ-L-Glu) des(B30) human insulin</td> <td class=\"description-td\">1.57</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO-N-(carboxymethyl)-β-Ala] des(B30) human insulin</td> <td class=\"description-td\">1.13</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—[N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>3</sub>CO)-γ-L-Glu] des(B30) human insulin</td> <td class=\"description-td\">0.42</td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> </tbody></table> </patent-tables> </tables> <br/>\\nPharmaceutical Compositions\\n</div>\\n<div class=\"description-paragraph\" id=\"p-0100\" num=\"0125\">Pharmaceutical compositions containing an insulin derivative according to the present invention may be administered parenterally to patients in need of such a treatment. Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump. Further options are to administer the insulin nasally or pulmonally, preferably in compositions, powders or liquids, specifically designed for the purpose.</div>\\n<div class=\"description-paragraph\" id=\"p-0101\" num=\"0126\">Injectable compositions of the insulin derivatives of the invention can be prepared using the conventional techniques of the pharmaceutical industry which involve dissolving and mixing the ingredients as appropriate to give the desired end product. Thus, according to one procedure, an insulin derivative according to the invention is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared. An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted—if necessary—using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxide as needed. Finally, the volume of the solution is adjusted with water to give the desired concentration of the ingredients.</div>\\n<div class=\"description-paragraph\" id=\"p-0102\" num=\"0127\">In a further embodiment of the invention the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the invention.</div>\\n<div class=\"description-paragraph\" id=\"p-0103\" num=\"0128\">In a further embodiment of the invention the formulation further comprises a pharmaceutically acceptable preservative which may be selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, benzethonium chloride, chlorphenesine (3p-chlorphenoxypropane-1,2-diol) or mixtures thereof. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific preservatives constitutes an alternative embodiment of the invention. The use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: <i>The Science and Practice of Pharmacy, </i>19<sup>th </sup>edition, 1995.</div>\\n<div class=\"description-paragraph\" id=\"p-0104\" num=\"0129\">In a further embodiment of the invention the formulation further comprises an isotonic agent which may be selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), an alditol (e.g. glycerol (glycerine), 1,2-propanediol (propyleneglycol), 1,3-propanediol, 1,3-butanediol) polyethyleneglycol (e.g. PEG400), or mixtures thereof. Any sugar such as mono-, di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used. In one embodiment the sugar additive is sucrose. Sugar alcohol is defined as a C4-C8 hydrocarbon having at least one —OH group and includes, for example, mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol. In one embodiment the sugar alcohol additive is mannitol. The sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to the amount used, as long as the sugar or sugar alcohol is soluble in the liquid preparation and does not adversely effect the stabilizing effects achieved using the methods of the invention. In one embodiment, the sugar or sugar alcohol concentration is between about 1 mg/ml and about 150 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 24 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 25 mg/ml to 50 mg/ml. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention. The use of an isotonic agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: <i>The Science and Practice of Pharmacy, </i>19<sup>th </sup>edition, 1995.</div>\\n<div class=\"description-paragraph\" id=\"p-0105\" num=\"0130\">Typical isotonic agents are sodium chloride, mannitol, dimethyl sulfone and glycerol and typical preservatives are phenol, m-cresol, methyl p-hydroxybenzoate and benzyl alcohol.</div>\\n<div class=\"description-paragraph\" id=\"p-0106\" num=\"0131\">Examples of suitable buffers are sodium acetate, glycylglycine, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and sodium phosphate.</div>\\n<div class=\"description-paragraph\" id=\"p-0107\" num=\"0132\">A composition for nasal administration of an insulin derivative according to the present invention may, for example, be prepared as described in European Patent No. 272097 (to Novo Nordisk A/S).</div>\\n<div class=\"description-paragraph\" id=\"p-0108\" num=\"0133\">Compositions containing insulins of this invention can be used in the treatment of states which are sensitive to insulin. Thus, they can be used in the treatment of type 1 diabetes, type 2 diabetes and hyperglycaemia for example as sometimes seen in seriously injured persons and persons who have undergone major surgery. The optimal dose level for any patient will depend on a variety of factors including the efficacy of the specific insulin derivative employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the state to be treated. It is recommended that the daily dosage of the insulin derivative of this invention be determined for each individual patient by those skilled in the art in a similar way as for known insulin compositions.</div>\\n<div class=\"description-paragraph\" id=\"p-0109\" num=\"0134\">Where expedient, the insulin derivatives of this invention may be used in mixture with other types of insulin, e.g. insulin analogues with a more rapid onset of action. Examples of such insulin analogues are described e.g. in the European patent applications having the publication Nos. EP 214826 (Novo Nordisk A/S), EP 375437 (Novo Nordisk A/S) and EP 383472 (Eli Lilly &amp; Co.).</div>\\n<div class=\"description-paragraph\" id=\"p-0110\" num=\"0135\">The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection.</div>\\n<heading id=\"h-0006\">DEFINITIONS</heading>\\n<div class=\"description-paragraph\" id=\"p-0111\" num=\"0136\">By “insulin analogue” as used herein is meant a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring insulin, for example that of human insulin, by deleting and/or exchanging at least one amino acid residue occurring in the naturally occurring insulin and/or adding at least one amino acid residue. The added and/or exchanged amino acid residues can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues The insulin analogues may be such wherein position 28 of the B chain may be modified from the natural Pro residue to one of Asp, Lys, or lie. In another embodiment Lys at position B29 is modified to Pro. In one embodiment B30 may be Lys and then B29 can be any codable amino acid except Cys, Met, Arg and Lys.</div>\\n<div class=\"description-paragraph\" id=\"p-0112\" num=\"0137\">Also, Asn at position A21 may be modified to Ala, Gln, Glu, Gly, His, lie, Leu, Met, Ser, Thr, Trp, Tyr or Val, in particular to Gly, Ala, Ser, or Thr and preferably to Gly. Furthermore, Asn at position B3 may be modified to Lys or Asp. Further examples of insulin analogues are des(B30) human insulin; des(B30) human insulin analogues; insulin analogues wherein PheB1 has been deleted; insulin analogues wherein the A-chain and/or the B-chain have an N-terminal extension and insulin analogues wherein the A-chain and/or the B-chain have a C-terminal extension. Thus one or two Arg may be added to position B1.</div>\\n<div class=\"description-paragraph\" id=\"p-0113\" num=\"0138\">By “insulin derivative” as used herein is meant a naturally occurring insulin or an insulin analogue which has been chemically modified, e.g. by introducing a side chain in one or more positions of the insulin backbone or by oxidizing or reducing groups of the amino acid residues in the insulin or by converting a free carboxylic group to an ester group or acylating a free amino group or a hydroxy group.</div>\\n<div class=\"description-paragraph\" id=\"p-0114\" num=\"0139\">The expression “a codable amino acid” or “a codable amino acid residue” is used to indicate an amino acid or amino acid residue which can be coded for by a triplet (“codon”) of nucleotides.</div>\\n<div class=\"description-paragraph\" id=\"p-0115\" num=\"0140\">hGlu is homoglutamic acid.</div>\\n<div class=\"description-paragraph\" id=\"p-0116\" num=\"0141\">α-Asp is the L-form of —HNCH(CO—)CH<sub>2</sub>COOH.</div>\\n<div class=\"description-paragraph\" id=\"p-0117\" num=\"0142\">β-Asp is the L-form of —HNCH(COOH)CH<sub>2</sub>CO—.</div>\\n<div class=\"description-paragraph\" id=\"p-0118\" num=\"0143\">α-Glu is the L-form of —HNCH(CO—)CH<sub>2</sub>CH<sub>2</sub>COOH.</div>\\n<div class=\"description-paragraph\" id=\"p-0119\" num=\"0144\">γ-Glu is the L-form of —HNCH(COOH)CH<sub>2</sub>CH<sub>2</sub>CO—.</div>\\n<div class=\"description-paragraph\" id=\"p-0120\" num=\"0145\">α-hGlu is the L-form of —HNCH(CO—)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>COOH.</div>\\n<div class=\"description-paragraph\" id=\"p-0121\" num=\"0146\">δ-hGlu is the L-form of —HNCH(COOH)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO—.</div>\\n<div class=\"description-paragraph\" id=\"p-0122\" num=\"0147\">β-Ala is —NH—CH<sub>2</sub>—CH<sub>2</sub>—COOH.</div>\\n<div class=\"description-paragraph\" id=\"p-0123\" num=\"0148\">Sar is sarcosine (N-methylglycine).</div>\\n<div class=\"description-paragraph\" id=\"p-0124\" num=\"0149\">The expression “an amino acid residue having a carboxylic acid group in the side chain” designates amino acid residues like Asp, Glu and hGlu. The amino acids can be in either the L- or D-configuration. If nothing is specified it is understood that the amino acid residue is in the L configuration.</div>\\n<div class=\"description-paragraph\" id=\"p-0125\" num=\"0150\">The expression “an amino acid residue having a neutral side chain” designates amino acid residues like Gly, Ala, Val, Leu, Ile, Phe, Pro, Ser, Thr, Cys, Met, Tyr, Asn and Gln.</div>\\n<div class=\"description-paragraph\" id=\"p-0126\" num=\"0151\">When an insulin derivative according to the invention is stated to be “soluble at physiological pH values” it means that the insulin derivative can be used for preparing injectable insulin compositions that are fully dissolved at physiological pH values. Such favourable solubility may either be due to the inherent properties of the insulin derivative alone or a result of a favourable interaction between the insulin derivative and one or more ingredients contained in the vehicle.</div>\\n<div class=\"description-paragraph\" id=\"p-0127\" num=\"0152\">The following abbreviations have been used in the specification and examples:</div>\\n<div class=\"description-paragraph\" id=\"p-0128\" num=\"0153\">\\n<tables id=\"TABLE-US-00002\" num=\"00002\">\\n<patent-tables colsep=\"0\" frame=\"none\" rowsep=\"0\">\\n<table align=\"left\" class=\"description-table\" cols=\"3\" colsep=\"0\" rowsep=\"0\" width=\"100%\">\\n<thead>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td align=\"center\" class=\"description-td\" colspan=\"3\" nameend=\"2\" namest=\"offset\" rowsep=\"1\"> </td>\\n</tr>\\n</thead>\\n<tbody><tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">Aad:</td>\\n<td class=\"description-td\">Alpha-amino-adipic acid (homoglutamic acid)</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">Bzl = Bn:</td>\\n<td class=\"description-td\">benzyl</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">DIEA:</td>\\n<td class=\"description-td\">N,N-diisopropylethylamine</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">DMF:</td>\\n<td class=\"description-td\">N,N-dimethylformamide</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">IDA:</td>\\n<td class=\"description-td\">Iminodiacetic acid</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">Sar:</td>\\n<td class=\"description-td\">Sarcosine (N-methyl-glycine)</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">tBu:</td>\\n<td class=\"description-td\">tert-butyl</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">TSTU:</td>\\n<td class=\"description-td\">O-(N-succinimidyl)-1,1,3,3-tetramethyluronium</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">tetrafluoroborate</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">THF:</td>\\n<td class=\"description-td\">Tetrahydrofuran</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">EtOAc:</td>\\n<td class=\"description-td\">Ethyl acetate</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">DIPEA:</td>\\n<td class=\"description-td\">Diisopropylethylamine</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">HOAt:</td>\\n<td class=\"description-td\">1-Hydroxy-7-azabenzotriazole</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">TEA:</td>\\n<td class=\"description-td\">triethyl amine</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">Su:</td>\\n<td class=\"description-td\">succinimidyl = 2,5-dioxo-pyrrolidin-1-yl</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">TFA:</td>\\n<td class=\"description-td\">trifluoracetic acid</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">DCM:</td>\\n<td class=\"description-td\">dichloromethane</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">DMSO:</td>\\n<td class=\"description-td\">dimethyl sulphoxide</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">TLC:</td>\\n<td class=\"description-td\">Thin Layer Chromatography</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">RT:</td>\\n<td class=\"description-td\">room temperature</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td align=\"center\" class=\"description-td\" colspan=\"3\" nameend=\"2\" namest=\"offset\" rowsep=\"1\"> </td>\\n</tr>\\n</tbody></table>\\n</patent-tables>\\n</tables>\\n</div>\\n<heading id=\"h-0007\">EXAMPLES</heading>\\n<heading id=\"h-0008\">Example 1</heading>\\n<heading id=\"h-0009\">Synthesis of N<sup>εB29</sup>—N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)-γ-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0129\" num=\"0154\">200 mg of des(B30) human insulin was dissolved in 10 ml of 50 mM Na2CO3 (pH 10.2) contained in a tube which was placed in a water bath at 15° C. Methyl hexadecandioyl-Glu(OSu)-OMe (37.90 mg, prepared as described below), was dissolved in 10 ml of acetonitrile and subsequently added to the insulin solution. The reaction was stopped after 30 min by addition of 3.8 ml of 0.2 M ethanolamine adjusted to pH 9.0 with dilute HCl. The yield of the reaction was 37% as determined by RP-HPLC. The product precipitated after addition of 2.5 volumes of water and adjustment of pH to 5.5. The precipitate was then dissolved in 10 ml of water at pH 8 and placed in ice. To this solution was added 10 ml of ice cold 0.2 M NaOH for saponification and the mixture was incubated for 40 min with ice cooling and then adjusted to pH 5.5 to precipitate the product. The precipitate was isolated and dissolved in 5 ml of A-buffer (see below) and diluted with 33 ml of 42.5% w/w aqueous ethanol divided in three and subjected to anion exchange chromatography employing a Resource™ 6 ml anion exchange column eluted with a buffer system consisting of A-buffer: Tris 0.24% w/w, NH4Ac 0.25%, 42% ethanol w/w, pH 7.5 and B-buffer: Tris 0.24% w/w, NH4Ac 1.25%, 42% ethanol w/w pH 7.5. The sample was eluted by a flow of 6 ml/min in a gradient from 0 to 100% of B-buffer in 30 min. The fractions containing the desired compound were identified by RP-HPLC. The yield of the desired product was 15.3 mg (purity: 72.9%). The volume of the pooled fractions containing the desired compound was reduced to 20 ml under vacuum and this solution was then subjected to purification by RP-HPLC employing a reversed phase HPLC column Nucleosil, C4 250/10 mm, 10 μm, 300 Å. The buffer system consisted of A-buffer: 10 mM Tris, 15 mM (NH4)2SO4, 10% ethanol, pH 7.3 and B-buffer: 70% vol/vol ethanol.</div>\\n<div class=\"description-paragraph\" id=\"p-0130\" num=\"0155\">The product was eluted with a gradient of from 10% to 60% of B-buffer in 120 min at a flow of 2 ml/min. The appropriate fractions were pooled and the compound was precipitated and lyophilized. The yield was 7.7 mg (purity: 99.4%).</div>\\n<div class=\"description-paragraph\" id=\"p-0131\" num=\"0156\">Molecular weight, found by mass spectroscopy: 6097.2, calculated 6104.1. B-terminal peptide containing the side chain was obtained after digestion with <i>staphylococcus aureus </i>protease. Molecular weight, found by mass spectroscopy: 1413.1, calculated: 1413.5.</div>\\n<heading id=\"h-0010\">Preparation of Methyl hexadecandioyl-Glu(OSu)-OMe</heading>\\n<div class=\"description-paragraph\" id=\"p-0132\" num=\"0157\">Dimethyl hexadecandioate was saponified in MeOH using 1.0 equivalent of NaOH, and the mono-methyl ester was isolated upon HCl acidification by recrystallisation from heptane.</div>\\n<div class=\"description-paragraph\" id=\"p-0133\" num=\"0158\">Mono-methyl hexadecandioate (275 mg, 0.91 mmol) was dissolved in THF (3 ml) and treated with succinimidyl tetramethyluroniumtetrafluoroborate (331 mg, 1.1 mmol) and N,N-diisopropylethylamine (188 μL, 1.1 mmol), and the mixture was stirred for 20 hours. The solvent was removed in vacuo, and the residue was dissolved in ethyl acetate and washed with 0.1 M HCl (twice) and water. The organic phase was dried over MgSO4, filtered and evaporated in vacuo to give 350 mg (96%) of methyl succinimidyl hexadecandioate.</div>\\n<div class=\"description-paragraph\" id=\"p-0134\" num=\"0159\">1H-NMR (CDCl3) □: 3.66 (s, 3H), 2.83 (s, 4H), 2.60 (t, 2H), 2.30 (t, 2H), 1.74 (p, 2H), 1.62 (p, 2H), 1.40 (m, 2H), 1.35-1.22 (m, 18H).</div>\\n<div class=\"description-paragraph\" id=\"p-0135\" num=\"0160\">Methyl succinimidyl hexadecandioate (240 mg, 0.58 mmol) in dimethylformamide (5 ml) was treated with GluOMe (93 mg, 0.58 mmol) and N,N-diisopropylethylamine (200 μL, 1.16 mmol). The mixture was stirred for 20 hours and then evaporated in vacuo. The residue was redissolved in ethyl acetate. Washing with 0.1 M HCl and water, followed by drying (MgSO4) and evaporation in vacuo, gave 226 mg (88%) of methyl hexadecandioyl-Glu-OMe.</div>\\n<div class=\"description-paragraph\" id=\"p-0136\" num=\"0161\">1H-NMR □: 6.22 (d, 1H), 4.65 (m, 1H), 3.76 (s, 3H), 3.66 (s, 3H), 2.42 (t, 2H), 2.29 (m, 4H), 2.22 (t, 2H), 1.97 (m, 2H), 1.62 (m, 4H), 1.35-1.22 (m, 20H).</div>\\n<div class=\"description-paragraph\" id=\"p-0137\" num=\"0162\">Methyl hexadecandioyl-Glu-OMe (200 mg, 0.45 mmol) was dissolved in dichloromethane (4 ml), cooled with an ice-bath and treated with dicyclohexylcarbodiimide (93 mg, 0.45 mmol) and N-hydroxysuccinimide (52 mg, 0.45 mmol). The mixture was stirred for 20 hours, filtered and evaporated in vacuo, to give 243 mg (100%) of the desired intermediate.</div>\\n<div class=\"description-paragraph\" id=\"p-0138\" num=\"0163\">1H-NMR (CDCl3) □: 6.34 (d, 1H), 4.67 (m, 1H), 3.73 (s, 3H), 3.64 (s, 3H), 2.81 (s, 4H), 2.66 (m, 2H), 2.27 (m, 4H), 2.20 (t, 2H), 1.89 (m, 1H), 1.70 (m, 1H), 1.58 (m, 4H), 1.29-1.20 (m, 20H).</div>\\n<heading id=\"h-0011\">Example 2</heading>\\n<heading id=\"h-0012\">Synthesis of NεB29-(Nα-(HOOC(CH2)16CO)-γ-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0139\" num=\"0164\">300 mg of des(B30) human insulin was acylated, purified and isolated as described in Example 1, except that in the present example methyl octadecandioyl-Glu(OSu)-OMe (prepared as described below) was used as acylating agent instead of the methyl hexadecandioyl-Glu(OSu)-OMe used in Example 1. 25.5 mg of the title compound was obtained (purity: 97.4%). Molecular weight, found by mass spectroscopy: 6136.6, calculated: 6132. B-terminal peptide containing the ligand was obtained after digestion by <i>staphylococcus aureus </i>protease. Molecular weight, found by mass spectroscopy: 1439.1, Calculated: 1442.5.</div>\\n<heading id=\"h-0013\">Preparation of Methyl octadecandioyl-Glu(OSu)-OMe</heading>\\n<div class=\"description-paragraph\" id=\"p-0140\" num=\"0165\">This compound was prepared from dimethyl octadecandioate in analogy with the hexadecandioyl derivative described in Example 1.</div>\\n<div class=\"description-paragraph\" id=\"p-0141\" num=\"0166\">1H-NMR (CDCl3) □: 6.20 (d, 1H), 4.70 (m, 1H), 3.78 (s, 3H), 3.67 (s, 3H), 2.84 (s, 4H), 2.70 (m, 2H), 2.30 (m, 4H), 2.22 (t, 2H), 1.93 (m, 1H), 1.70 (m, 1H), 1.62 (m, 4H), 1.33-1.23 (m, 24H).</div>\\n<heading id=\"h-0014\">Example 3</heading>\\n<heading id=\"h-0015\">Synthesis of N<sup>εB29</sup>—N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-Glu-N-(γ-Glu)) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0142\" num=\"0167\">In a similar way as described in Example 1, 300 mg of des(B30) human insulin was acylated with methyl octadecandioyl-Glu(Glu(OSu)-OMe)-OMe. Purification by anion exchange was performed as described above. However, prolonged elution with 100% B-buffer was conducted in order to elute the desired product. The fractions containing the desired product were identified by RP-HPLC and 47.5 mg was obtained at a purity of 55%. The volume of the fractions containing the desired product was reduced in vacuo and the resulting solution was subjected to purification by RP-HPLC employing a reversed phase HPLC Jupiter column, C4 250/10 mm, 10 μm, 300 Å from Phenomerex. The buffer system consisted of A-buffer: 0.1% TFA, 10% vol/vol ethanol and B-buffer: 80% vol/vol ethanol. The sample was eluted by a gradient from 40% to 60% B-buffer at 40° C. for 120 min at a flow of 2 ml/min. The appropriate fractions were pooled and lyophilized and 31.1 mg of the title compound was obtained (purity: 94%).</div>\\n<div class=\"description-paragraph\" id=\"p-0143\" num=\"0168\">Molecular weight of the title compound found by mass spectroscopy: 6259.65, calculated: 6261.2. The molecular weight (by mass spectroscopy) of the B-terminal peptide containing the side chain, obtained after digestion with <i>staphylococcus aureus </i>protease was found to be 1569.88, calculated: 1569.88.</div>\\n<heading id=\"h-0016\">Preparation of Methyl octadecandioyl-Glu(Glu(OSu)-OMe)-OMe</heading>\\n<div class=\"description-paragraph\" id=\"p-0144\" num=\"0169\">Methyl octadecandioyl-Glu(OSu)-OMe (prepared as described in Example 2, 200 mg, 0.35 mmol) in dimethylformamide (5 ml) was treated with GluOMe (62 mg, 0.39 mmol) and N,N-diisopropylethylamine (90 μL, 53 mmol), and the mixture was stirred for 20 hours. The solvent was removed in vacuo, and the residue was dissolved in ethyl acetate and washed twice with 0.2 M HCl, water and brine. Drying over MgSO<sub>4 </sub>and evaporation gave methyl octadecandioyl-Glu(Glu-OMe)-OMe, 180 mg (83%).</div>\\n<div class=\"description-paragraph\" id=\"p-0145\" num=\"0170\">Methyl octadecandioyl-Glu(Glu-OMe)-OMe (180 mg, 0.29 mmol) was dissolved in THF (9 ml) and treated with succinimidyl tetramethyluroniumtetrafluoroborate (106 mg, 0.35 mmol) and N,N-diisopropylethylamine (60 μL, 0.35 mmol). The mixture was stirred overnight, evaporated, redissolved in ethyl acetate, and washed with 2×0.1 M HCl and water. Drying over MgSO<sub>4 </sub>and evaporation gave 190 mg (93%) of the desired intermediate.</div>\\n<div class=\"description-paragraph\" id=\"p-0146\" num=\"0171\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 6.73 (d, 1H), 6.43 (d, 1H), 4.69 (m, 1H), 4.56 (m, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 3.66 (s, 3H), 2.85 (s, 4H), 2.72 (m, 2H), 2.41-2.12 (m, 8H), 2.95 (m, 2H), 1.72-1.56 (m, 6H), 1.35-1.22 (m, 22H).</div>\\n<heading id=\"h-0017\">Example 4</heading>\\n<heading id=\"h-0018\">Synthesis of N<sup>εB29</sup>—N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0147\" num=\"0172\">Des(B30) human insulin (500 mg, 0.088 mmol) was dissolved in 100 mM Na<sub>2</sub>CO<sub>3 </sub>(5 ml, pH 10.2) at room temperature. Tert-butyl hexadecandioyl-Glu(OSu)-OtBu (66 mg, 0.105 mmol, prepared as described below), was dissolved in acetonitrile (5 ml) and subsequently added to the insulin solution. After 30 mins, 0.2 M methylamine (0.5 ml) was added. pH was adjusted by HCl to 5.5, and the isoelectric precipitate was collected by centrifugation and dried in vacuo to give 525 mg. The coupling yield was 78% (RP-HPLC, C4 column; Buffer A: 10% MeCN in 0.1% TFA-water, Buffer B: 80% MeCN in 0.1% TFA-water; gradient 20% to 90% B in 16 minutes). The protected product was dissolved in TFA (10 ml), left 30 mins, and evaporated in vacuo. The crude product was dissolved in water and lyophilized (610 mg). 0454 was purified by RP-HPLC on C4-column, buffer A: 20% EtOH+0.1% TFA, buffer B: 80% EtOH+0.1% TFA; gradient 15-60% B, followed by HPLC on C4-column, buffer A: 10 mM Tris+15 mM ammonium sulphate in 20% EtOH, pH 7.3, buffer B: 80% EtOH, gradient 15-60% B. The collected fractions were desalted on Sep-Pak with 70% acetonitrile+0.1% TFA, neutralized by addition of ammonia and freeze-dried. The unoptimized yield was 64 mg, 12%. The purity as evaluated by HPLC was 99.2%. LCMS 6102.9, C<sub>274</sub>H<sub>411</sub>N<sub>65</sub>O<sub>81</sub>S<sub>6 </sub>requires 6104.1. B-terminal peptide containing the side chain (RGFFYTPK(N<sup>ε</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)-γ-L-Glu) was obtained after digestion with <i>staphylococcus aureus </i>protease. MALDI-MS: 1413.1, calculated: 1412.7.</div>\\n<heading id=\"h-0019\">Preparation of tert-butyl hexadecandioyl-L-Glu(OSu)-OtBu</heading>\\n<div class=\"description-paragraph\" id=\"p-0148\" num=\"0173\">Hexadecadioic acid (40.0 g, 140 mmol) was suspended in toluene (250 ml) and the mixture was heated to reflux. N,N-dimethylformamide di-tert-butyl acetal (76.3 g, 375 mmol) was added drop-wise over 4 hours. The mixture was refluxed overnight. The solvent was removed in vacuo at 50° C., and the crude material was suspended in DCM/AcOEt (500 ml, 1:1) and stirred for 15 mins. The solids were collected by filtration and triturated with DCM (200 ml). The filtrated were evaporated in vacuo to give crude mono-tert-butyl hexadecandioate, 30 grams. This material was suspended in DCM (50 ml), cooled with ice for 10 mins, and filtered. The solvent was removed in vacuo to leave 25 gram crude mono-tert-butyl hexadecandioate, which was recrystallized from heptane (200 ml) to give mono-tert-butyl hexadecandioate, 15.9 g (33%). Alternatively to recrystallization, the mono-ester can be purified by silica chromatography in AcOEt/heptane.</div>\\n<div class=\"description-paragraph\" id=\"p-0149\" num=\"0174\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 2.35 (t, 2H), 2.20 (t, 2H), 1.65-1.55 (m, 4H), 1.44 (s, 9H), 1.34-1.20 (m, 20H).</div>\\n<div class=\"description-paragraph\" id=\"p-0150\" num=\"0175\">The mono tert-butyl ester (2 g, 5.8 mmol) was dissolved in THF (20 ml) and treated with TSTU (2.1 g, 7.0 mmol) and DIEA (1.2 ml, 7.0 mmol) and stirred overnight. The mixture was filtered, and the filtrate was evaporated in vacuo. The residue was dissolved in AcOEt and washed twice with cold 0.1 M HCl and water. Drying over MgSO<sub>4 </sub>and evaporation in vacuo gave succinimidyl tert-butyl hexadecandioate, 2.02 g (79%).</div>\\n<div class=\"description-paragraph\" id=\"p-0151\" num=\"0176\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 2.84 (s, 4H), 2.60 (t, 2H), 2.20 (t, 2H), 1.74 (p, 2H), 1.56 (m, 2H), 1.44 (s, 9H), 1.40 (m, 2H), 1.30-1.20 (m, 18H).</div>\\n<div class=\"description-paragraph\" id=\"p-0152\" num=\"0177\">Succinimidyl tert-butyl hexadecandioate (1 g, 2.27 mmol) was dissolved DMF (15 ml) and treated with L-Glu-OtBu (0.51 g, 2.5 mmol) and DIEA (0.58 ml, 3.41 mmol) and the mixture was stirred overnight. The solvent was evaporated in vacuo, and the crude product was dissolved in AcOEt, and washed twice with 0.2 M HCl, with water and brine. Drying over MgSO<sub>4 </sub>and evaporation in vacuo gave tert-butyl hexadecandioyl-L-Glu-OtBu, 1.2 g (100%).</div>\\n<div class=\"description-paragraph\" id=\"p-0153\" num=\"0178\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 6.25 (d, 1H), 4.53 (m, 1H), 2.42 (m, 2H), 2.21 (m, 4H), 1.92 (m, 1H), 1.58 (m, 4H), 1.47 (s, 9H), 1.43 (s, 9H), 1.43-1.22 (m, 18H).</div>\\n<div class=\"description-paragraph\" id=\"p-0154\" num=\"0179\">Tert-butyl hexadecandioyl-L-Glu-OtBu (1.2 g, 2.27 mmol) was dissolved in THF (15 ml) and treated with TSTU (0.82 g, 2.72 mmol) and DIEA (0.47 ml, 2.72 mmol) and stirred overnight. The mixture was filtered, and the filtrate was evaporated in vacuo. The residue was dissolved in AcOEt and washed twice with cold 0.1 M HCl and water. Drying over MgSO<sub>4 </sub>and evaporation in vacuo gave tert-butyl hexadecandioyl-L-Glu(OSu)-OtBu, 1.30 g (92%).</div>\\n<div class=\"description-paragraph\" id=\"p-0155\" num=\"0180\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 6.17 (d, 1H), 4.60 (m, 1H), 2.84 (s, 4H), 2.72 (m, 1H), 2.64 (m, 1H), 2.32 (m, 1H), 2.20 (m, 4H), 2.08 (m, 1H), 1.6 (m, 4H), 1.47 (s, 9H), 1.43 (s, 9H), 1.33-1.21 (m, 20H).</div>\\n<heading id=\"h-0020\">Example 5</heading>\\n<heading id=\"h-0021\">Synthesis of N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0156\" num=\"0181\">DesB30 insulin (50 mg, 9 μmol) was dissolved in 0.1 M aqueous Na<sub>2</sub>CO<sub>3 </sub>(0.65 ml), pH 10.5. Octadecandioyl-L-Glu(OSu) (50.1 mg, 9.9 μmol, prepared as described below) was dissolved in acetonitrile (0.65 ml) and added to the insulin solution; pH was 10.3. After 30 mins, 0.2 M methylamine (50 μl) was added. pH was adjusted by HCl to 5.5, and the isoelectric precipitate was collected by centrifugation and dried in vacuo. HPLC showed the crude coupling yield to be 52% (not optimized); C4 column; Buffer A: 10% MeCN in 0.1% TFA-water, Buffer B: 80% MeCN in 0.1% TFA-water; gradient 20% to 90% B in 16 minutes). LCMS 6133.2, C<sub>276</sub>H<sub>415</sub>N<sub>65</sub>O<sub>81</sub>S<sub>6 </sub>requires 6132.2.</div>\\n<heading id=\"h-0022\">Preparation of octadecandioyl-L-Glu(OSu)</heading>\\n<div class=\"description-paragraph\" id=\"p-0157\" num=\"0182\">Octadecanedioic acid (2.5 g, 8.0 mmol) was suspended in DCM (60 mL), treated with triethylamine (1.16 mL, 8.3 mmol) and ice-cooled. Benzylchloroformate (1.14 mL) was added drop-wise under nitrogen and the mixture was stirred for 10 min, when DMAP (0,097 g, 0.80 mmol) was added. After stirring for 20 min at 4° C. (TLC, 1:1 AcOEt:heptane), the reaction was evaporated to dryness. The crude material (3.9 g) was dissolved in DCM (60 ml), treated with silica (15 g) and evaporated. The silica was loaded on a silica column (175 g), and the product was eluted with AcOEt/heptane 1:7 to 1:1. Evaporation of the desired fractions gave mono-benzyl octadecandioate (1.15 g, 36%).</div>\\n<div class=\"description-paragraph\" id=\"p-0158\" num=\"0183\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 7.35 (m, 5H), 5.11 (s, 2H), 2.35 (t, 4H), 1.63 (t, 4H), 1.30-1.22 (m, 24).</div>\\n<div class=\"description-paragraph\" id=\"p-0159\" num=\"0184\">Mono-benzyl octadecandioate was dissolved in DMF (3.5 mL) and THF (7 mL) and cooled with ice bath. DIEA (0.103 mL) and TSTU were added and the mixture was stirred 1 h at ice bath and at RT overnight. The solvent was evaporated in vacuo and the residue was dissolved in AcOEt and washed twice with 0.2 N HCl, saturated NaHCO<sub>3</sub>, dried, filtered and evaporated to dryness to give succinimidyl mono-benzyl octadecandioate (0.25 g, 100%).</div>\\n<div class=\"description-paragraph\" id=\"p-0160\" num=\"0185\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 7.35 (m, 5H), 5.11 (s, 2H), 2.83 (s, 4H), 2.60 (t, 2H), 2.35 (t, 2H), 1.80-1.60 (m, 4H), 1.40-1.20 (m, 24).</div>\\n<div class=\"description-paragraph\" id=\"p-0161\" num=\"0186\">Succinimidyl mono-benzyl octadecandioate-(95 mg, 0.19 mmol) was dissolved DMF (1.5 ml) and treated with L-Glu-OBzl (49 mg, 0.21 mmol) and DIEA (50 □l, 0.28 mmol) and the mixture was stirred overnight. The solvent was evaporated in vacuo, and the crude product was dissolved in AcOEt, and washed twice with 0.2M HCl, with water and brine. Drying over MgSO<sub>4 </sub>and evaporation in vacuo gave BzlO-octadecandioyl-L-Glu-OBzl, 114 mg (97%).</div>\\n<div class=\"description-paragraph\" id=\"p-0162\" num=\"0187\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 7.35 (m, 5H), 6.22 (d, 2H), 5.17 (s, 2H), 5.11 (s, 2H), 4.71 (m, 1H), 2.37 (m, 4H), 2.22 (m, 3H), 1.98 (m, 1H), 1.63 (m, 4H), 1.31-1.20 (m, 24H).</div>\\n<div class=\"description-paragraph\" id=\"p-0163\" num=\"0188\">BzlO-octadecandioyl-L-Glu-OBzl (110 g, 0.18 mmol) was dissolved in THF (2 ml) and treated with TSTU (64 mg, 0.21 mmol) and DIEA (36 μl, 0.21 mmol) and stirred overnight. The mixture was filtered, and the filtrate was evaporated in vacuo. The residue was dissolved in AcOEt and washed twice with cold 0.1 M HCl and water. Drying over MgSO<sub>4 </sub>and evaporation in vacuo gave BzlO-octadecandioyl-L-Glu(OSu)-OBzl, 119 g (94%).</div>\\n<div class=\"description-paragraph\" id=\"p-0164\" num=\"0189\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 7.36 (m, 5H), 6.40 (d, 2H), 5.19 (s, 2H), 5.11 (s, 2H), 4.75 (m, 1H), 2.82 (s, 4H), 2.68 (m, 1H), 2.59 (m, 1H), 2.35 (t, 2H), 2.19 (t, 2H), 1.62 (m, 4H), 1.32-1.21 (m, 24H).</div>\\n<div class=\"description-paragraph\" id=\"p-0165\" num=\"0190\">BzlO-octadecandioyl-L-Glu(OSu)-OBzl (59 mg, 0.082 mmol) was dissolved in acetone/0.1% TFA (1 ml). Pd/C was added (20 mg). The flask was evacuated and filled with N<sub>2 </sub>several times, and a H<sub>2 </sub>filled balloon was connected. The mixture was stirred at RT 3 h, and then filtered through celite. Precipitation from heptane and evaporation of residual solvents gave octadecandioyl-L-Glu(OSu) (27 mg, 61%).</div>\\n<div class=\"description-paragraph\" id=\"p-0166\" num=\"0191\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 6.32 (d, 1H), 4.70 (m, 1H), 3.70 (m, 1H), 3.06 (m, 2H), 2.88 (s, 4H), 2.62 (m, 2H), 2.35 (m, 2H), 2.24 (m, 1H), 1.74 (m, 1H), 1.64 (m, 2H), 1.50-1.20 (m, 26H).</div>\\n<heading id=\"h-0023\">Example 6</heading>\\n<heading id=\"h-0024\">Synthesis of N<sup>εB29</sup>—(N-(L-Asp-OC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0167\" num=\"0192\">This compound was prepared in analogy with example 4, via reaction of L-Asp(OtBu)-OtBu with succinimidyl octadecandioate followed by activation with TSTU, reaction with L-GluOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA.</div>\\n<div class=\"description-paragraph\" id=\"p-0168\" num=\"0193\">LCMS 6247.5, calculated 6247.3.</div>\\n<heading id=\"h-0025\">Example 7</heading>\\n<heading id=\"h-0026\">Synthesis of N<sup>εB29</sup>—N-(L-Glu-OC(CH<sub>2</sub>)<sub>14</sub>CO-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0169\" num=\"0194\">This compound was prepared in analogy with example 4, via reaction of L-Glu(OtBu)-OtBu with succinimidyl hexadecandioate followed by activation with TSTU, reaction with L-GluOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6261.3, calculated 6261.3.</div>\\n<heading id=\"h-0027\">Example 8</heading>\\n<heading id=\"h-0028\">Synthesis of N<sup>εB29</sup>—N-(L-Glu-OC(CH<sub>2</sub>)<sub>14</sub>CO—) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0170\" num=\"0195\">This compound was prepared in analogy with example 4, via reaction of L-Glu(OtBu)-OtBu with succinimidyl hexadecandioate followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6130.8, calculated 6132.2.</div>\\n<heading id=\"h-0029\">Example 9</heading>\\n<heading id=\"h-0030\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Glu)-N-(β-L-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0171\" num=\"0196\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with L-Glu(OtBu) followed by activation with TSTU, reaction with L-AspOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6246.9, calculated 6247.3.</div>\\n<heading id=\"h-0031\">Example 10</heading>\\n<heading id=\"h-0032\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>15</sub>CO-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0172\" num=\"0197\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl heptadecandioate (A. C. Cope, U. Axen, E. P. Burrows, J. Weinlich, J. Am. Chem Soc. 1966, 88, 4228) with L-GluOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6118.3, calculated 6118.1.</div>\\n<heading id=\"h-0033\">Example 11</heading>\\n<heading id=\"h-0034\">Synthesis of N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>13</sub>CO-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0173\" num=\"0198\">This compound was prepared in analogy with example 4, via reaction of L-GlyOtBu with succinimidyl pentadecandioate followed by activation with TSTU, reaction with L-GluOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6147.5, calculated 6147.1.</div>\\n<heading id=\"h-0035\">Example 12</heading>\\n<heading id=\"h-0036\">Synthesis of N<sup>εB29</sup>—(N-(L-Sar-OC(CH<sub>2</sub>)<sub>13</sub>CO-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0174\" num=\"0199\">This compound was prepared in analogy with example 4, via reaction of L-Sar-OtBu with succinimidyl octadecandioate, followed by activation with TSTU, reaction with L-GluOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6161.0, calculated 6161.1.</div>\\n<heading id=\"h-0037\">Example 13</heading>\\n<heading id=\"h-0038\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Asp)-N-(β-L-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0175\" num=\"0200\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with L-Asp(OtBu) followed by activation with TSTU, reaction with L-AspOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6233.8, calculated 6233.2.</div>\\n<heading id=\"h-0039\">Example 14</heading>\\n<heading id=\"h-0040\">Synthesis of N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>14</sub>CO-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0176\" num=\"0201\">This compound was prepared in analogy with example 4, via reaction of L-GlyOtBu with succinimidyl hexadecandioate followed by activation with TSTU, reaction with L-GluOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6160.7, calculated 6161.1.</div>\\n<heading id=\"h-0041\">Example 15</heading>\\n<heading id=\"h-0042\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-β-L-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0177\" num=\"0202\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl hexadecandioate with L-AspOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6089.8, calculated 6089.8.</div>\\n<heading id=\"h-0043\">Example 16</heading>\\n<heading id=\"h-0044\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-β-L-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0178\" num=\"0203\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with L-AspOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6117.8, calculated 6118.1.</div>\\n<heading id=\"h-0045\">Example 17</heading>\\n<heading id=\"h-0046\">Synthesis of N<sup>εB29</sup>—N-(Gly-OC(CH<sub>2</sub>)<sub>16</sub>CO-γ-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0179\" num=\"0204\">This compound was prepared in analogy with example 4, via reaction of L-GlyOtBu with succinimidyl octadecandioate followed by activation with TSTU, reaction with L-GluOtBu, activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6189.2, calculated 6189.2.</div>\\n<heading id=\"h-0047\">Example 18</heading>\\n<heading id=\"h-0048\">Synthesis of N B29—(N—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO-ε-L-LysCO—) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0180\" num=\"0205\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl hexadecandioate with L-Lys(Z)-OtBu, followed by hydrogenation over Pd/C and in-situ activation by 4-nitrophenyl chloroformate, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6189.2, calculated 6189.2.</div>\\n<heading id=\"h-0049\">Example 19</heading>\\n<heading id=\"h-0050\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0181\" num=\"0206\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with L-Glu(OtBu) followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6132.1, calculated 6132.2.</div>\\n<heading id=\"h-0051\">Example 20</heading>\\n<heading id=\"h-0052\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0182\" num=\"0207\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with L-Asp(OtBu) followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6117.8, calculated 6118.1.</div>\\n<heading id=\"h-0053\">Example 21</heading>\\n<heading id=\"h-0054\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>15</sub>CO-β-L-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0183\" num=\"0208\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl heptadecandioate with L-AspOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6104.2, calculated 6104.1.</div>\\n<heading id=\"h-0055\">Example 22</heading>\\n<heading id=\"h-0056\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-D-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0184\" num=\"0209\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with D-GluOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6132.4, calculated 6132.2.</div>\\n<heading id=\"h-0057\">Example 23</heading>\\n<heading id=\"h-0058\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-δ-L-Aad) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0185\" num=\"0210\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with L-AadOtBu (prepared from commercial L-Aad(OMe) by tert-butylation with AcOtBu/BF<sub>3</sub>.OEt<sub>2 </sub>and saponification of the methyl ester), followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6116.9, calculated 6118.1.</div>\\n<heading id=\"h-0059\">Example 24</heading>\\n<heading id=\"h-0060\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>13</sub>CO-β-L-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0186\" num=\"0211\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl pentadecandioate with L-AspOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6074.7, calculated 6076.1.</div>\\n<heading id=\"h-0061\">Example 25</heading>\\n<heading id=\"h-0062\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>13</sub>CO-β-L-Glu) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0187\" num=\"0212\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl pentadecandioate with L-GluOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. MALDI-MS 6080.6, calculated 6076.1.</div>\\n<heading id=\"h-0063\">Example 26</heading>\\n<heading id=\"h-0064\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-β-D-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0188\" num=\"0213\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl hexadecandioate with D-AspOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6089.1, calculated 6090.1.</div>\\n<heading id=\"h-0065\">Example 27</heading>\\n<heading id=\"h-0066\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-β-D-Asp) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0189\" num=\"0214\">This compound was prepared in analogy with example 4, via reaction of tert-butyl succinimidyl octadecandioate with D-AspOtBu followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6117.1, calculated 6118.1.</div>\\n<heading id=\"h-0067\">Example 28</heading>\\n<heading id=\"h-0068\">Synthesis of N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-IDA) des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0190\" num=\"0215\">This compound was prepared in analogy with example 4, via reaction of tert-butyl 3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl hexadecandioate with iminodiacetic acid followed by activation with TSTU, coupling with Des(B30) human insulin and deprotection by TFA. LCMS 6089.1, calculated 6090.1.</div>\\n<heading id=\"h-0069\">Example 29</heading>\\n<heading id=\"h-0070\">Synthesis of N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)—N-(carboxymethyl)-β-Ala] des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0191\" num=\"0216\">A1N, B1N-diBoc DesB30 Human insulin (Kurtzhals P; Havelund S; Jonassen I; Kiehr B; Larsen U D; Ribel U; Markussen J Biochemical Journal, 1995, 312, 725-731) (186 mg, 0.031 mmol) was dissolved in DMSO (1.8 ml). A solution of tert-butyl octadecandioyl-N-(tert-butoxycarbonylmethyl)-β-Ala-OSu (27 mg, 0.04 mmol) in THF (1.8 ml) and triethylamine (0.045 ml, 0.31 mmol) was added (pH was 10). After slowly stirring at room temperature for 45 min the reaction was quenched with 0.2M methylamine in THF (0,20 ml). Water (5 ml) was added and pH was adjusted to 5.5 with 1 N HCl. The isoelectric precipitate was collected by centrifugation and freeze dried to give 150 mg. The coupling yield was 74% (LCMS m/z: 2148.9 [(M+3)/3], rt 5.04.) The protected product was dissolved in TFA (2.5 ml) and left for 1 h and evaporated in vacuo. The crude product was purified by RP-HPLC on C4-column, buffer A: 0.1% TFA, buffer B: MeCN+0.1% TFA; gradient 10-70% B. The collected fractions were freeze-dried. The yield was 75 mg, 52%. The purity as evaluated by HPLC was 97.2%.</div>\\n<div class=\"description-paragraph\" id=\"p-0192\" num=\"0217\">MALDI-MS: 6132.1, calculated: 6132.2.</div>\\n<heading id=\"h-0071\">Preparation of tert-butyl octadecandioyl-N-(tert-butoxycarbonylmethyl)-β-Ala-OSu</heading>\\n<div class=\"description-paragraph\" id=\"p-0193\" num=\"0218\">Octadecanedioic acid (5.64 g, 17.9 mmol) was dissolved in toluene (80 ml) at 115° C. N,N-dimethylformamide di-tert-butylacetal (12.9 ml, 53.8 mmol) was added drop-wise over 1.5 h. After refluxing for 3 h more N,N-dimethylformamide di-tert-butylacetal (2.15 ml) was added over 20 min. Reflux was continued over night and more N,N-dimethylformamide di-tert-butylacetal (2.15 ml) was added over 20 min. After stirring for another 2 h. the reaction mixture was cooled to RT. Water and DCM was added. The diacid can was removed by filtration. The filtrate was concentrated on silica gel (40 g) and purified on a 1.5 L silicagel column using DCM/MeOH 14:1. Octadecanedioic acid mono-tert-butyl ester was isolated in 53% yield (3.52 g).</div>\\n<div class=\"description-paragraph\" id=\"p-0194\" num=\"0219\">LC-MS: 393 (M+Na), rt 6.40.</div>\\n<div class=\"description-paragraph\" id=\"p-0195\" num=\"0220\"> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): δ 1.22 (br s, 24H), 1.38 (s, 9H), 1.47 (m, 4H), 2.14 (t, 2H), 2.18 ppm (t, 2H).</div>\\n<div class=\"description-paragraph\" id=\"p-0196\" num=\"0221\">To a solution of mono-tert-butyl octadecanedioate (1.00 g, 2.7 mmol) in dry THF (8 ml), was added DIPEA (0,555 ml, 3.2 mmol) followed by TSTU (1.00 g, 3.2 mmol). The reaction mixture was stirred under nitrogen for 18 h. The solvent had evaporated. AcOEt was added to the residue and the resulting suspension was filtered. The filtrate was washed with cold 0.1 M HCl (2×) and water, dried and concentrated to give succinimidyl tert-butyl octadecandioate as a white solid.</div>\\n<div class=\"description-paragraph\" id=\"p-0197\" num=\"0222\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 1.25 (m s, 20H), 1.39 (m, 2H) 1.44 (s, 9H), 1.58 (m, 4H), 1.74 (p, 2H), 2.2 (t, 2H), 2.60 (t, 2H), 2,85 ppm (m, 2H).</div>\\n<div class=\"description-paragraph\" id=\"p-0198\" num=\"0223\">To a suspension of H-Gly-OtBu (1.00 g, 6.0 mmol) in dry DMF (6 ml) was added triethyl amine (0.835 ml, 6.0 mmol). A precipitation of triethyl amine hydrochloride was observed. A solution of benzyl acrylate (0.910 ml, 6.0 mmol) in DMF (6 ml) was added. The resulting suspension was stirred at room temperature for 2 days. The precipitate was removed by filtration and the filtrate was concentrated. The residue was dissolved in AcOEt and washed with sat. NaHCO<sub>3</sub>. The organic layer was dried (MgSO<sub>4</sub>), filtered and concentrated to give a clear oil, which was purified by flash chromatography using AcOEt/heptane 1:3 and 1:1 as eluent. N-tert-butoxycarbonylmethyl)-β-Ala-OBn was isolated in 29% yield (0.505 g).</div>\\n<div class=\"description-paragraph\" id=\"p-0199\" num=\"0224\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: ppm 1.43 (s, 9H), 2.55 (t, 2H), 2.92 (t, 2H), 3.30 (s, 2H), 5.15 (s, 2H), 7.65 (m, 5H).</div>\\n<div class=\"description-paragraph\" id=\"p-0200\" num=\"0225\">Succinimidyl tert-butyl octadecandioate (0,15 g, 0.32 mmol) and N-(tert-butoxycarbonylmethyl)-β-Ala-OBn (0.10 g, 0,32 mmol) were dissolved in dry DMF (2.5 ml) and DIEA (0,070 ml, 0.38 mmol) was added. After stirring under nitrogen for 30 min HOAt (0,045 g, 0.32 mmol) was added and the mixture turned yellow. Stirring was continued at RT under nitrogen for convenience reasons for 13 days. The reaction mixture was concentrated. The residue dissolved in AcOEt, washed with 0.1N HCl (2×) and water, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to a give tert-butyl octadecandioyl-N-(tert-butoxycarbonylmethyl)-β-Ala-OBn as a white oil. 205 mg, Yield 99%.</div>\\n<div class=\"description-paragraph\" id=\"p-0201\" num=\"0226\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: ppm 1.25 (m, 26H), 1.45 (s, 9H), 1.50 (s, 9H), 1.6 (m, 4H), 2.20 (t, 2H), 2.40 (t, 2H), 2.75 (q, 2H), 3.62 (t, 2H), 3.97 (s, 2H), 5.20 (s, 2H); 7.35 (m, 5H)</div>\\n<div class=\"description-paragraph\" id=\"p-0202\" num=\"0227\">Tert-butyl octadecandioyl-N-(tert-butoxycarbonylmethyl)-β-Ala-OBn (200 mg, 0.31 mmol) was dissolved in EtOAc (10 ml) and THF (5 ml). 10% Pd/C was added and the mixture was hydrogenated at 1 atm for 16 h. The reaction mixture was filtered and concentrated to give tert-butyl octadecandioyl-N-(tert-butoxycarbonylmethyl)-β-Ala-OH as a clear oil. Yield 180 mg, 100%.</div>\\n<div class=\"description-paragraph\" id=\"p-0203\" num=\"0228\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: ppm 1.25 (m, 26H), 1.45 (s, 9H), 1.50 (s, 9H), 1.6 (m, 4H), 2.20 (t, 2H), 2.40 (t, 2H), 2.70 (m, 2H), 3.65 (m, 2H), 4.05 (s, 2H).</div>\\n<div class=\"description-paragraph\" id=\"p-0204\" num=\"0229\">Tert-butyl octadecandioyl-N-(tert-butoxycarbonylmethyl)-β-Ala-OH (0.110 g, 0.2 mmol) was dissolved in dry THF (2 ml). DIEA (0,045 ml, 0.24 mmol) and TSTU (0.075 g, 0.24 mmol) was added. The mixture was stirred under nitrogen for 18 h. The reaction mixture was filtered. AcOEt was added to the filtrate and washed with 0.2 M HCl (2×), brine (1×), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to give tert-butyl octadecandioyl-N-(tert-butoxycarbonylmethyl)-β-Ala-OSu as a clear syrup. Yield 124 mg, 96%.</div>\\n<div class=\"description-paragraph\" id=\"p-0205\" num=\"0230\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: ppm 1.25 (m, 26H), 1.40 (s, 9H), 1.57 (s, 9H), 1.6 (m, 4H), 2.40 (m, 4H), 2.58 (br s, 4H), 3.0 (t, 2H), 3.7 (t, 2H), 4.03 (s, 2H).</div>\\n<heading id=\"h-0072\">Example 30</heading>\\n<heading id=\"h-0073\">Synthesis of N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)—N-(2-carboxyethyl)-Gly] des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0206\" num=\"0231\">A1N, B1N-diBoc DesB30 Human insulin (Kurtzhals P; Havelund S; Jonassen I; Kiehr B; Larsen U D; Ribel U; Markussen J Biochemical Journal, 1995, 312, 725-731) (120 mg, 0.020 mmol) was dissolved in DMSO (1.2 ml). A solution of tert-butyl octadecandioyl-N-(2-(tert-butoxycarbonyl)ethyl)-Gly-OSu (16 mg, 0.025 mmol) in THF (1.2 ml) and triethylamine (0.033 ml, 0.24 mmol) was added (pH was 10). After slowly stirring at room temperature for 3 h and 20 min water (4 ml) was added and pH was adjusted to 5.5 with 1 N HCl. The isoelectric precipitate was collected by centrifugation, washed with water and isolated by centrifugation. The product was freeze dried. The crude product was purified by RP-HPLC on C18-column, buffer A: 0.1% TFA, buffer B: MeCN+0.1% TFA; gradient 20-90% B. The collected fractions were freeze-dried. The unoptimized coupling yield was 15 mg, 11% (MALDI-MS 6441, calculated: 6444.5) The protected product was dissolved in TFA (1 ml) and left for 1 h and evaporated in vacuo. The crude product was purified by RP-HPLC on C4-column, buffer A: 0.1% TFA, buffer B: MeCN+0.1% TFA; gradient 10-80% B, and by RP-HPLC on C4-column, buffer A: 20% EtOH+0.1% TFA, buffer B: 80% EtOH+0.1% TFA; gradient 15-60% B, followed by HPLC on C4-column, buffer A: 10 mM Tris+15 mM ammonium sulphate in 20% EtOH, pH 7.3, buffer B: 80% EtOH, gradient 15-60% B. The collected fractions were desalted on Sep-Pak with 70% acetonitrile+0.1% TFA, neutralized by addition of ammonia and freeze-dried. The unoptimized yield was 1.8 mg, 13%. The purity as evaluated by HPLC was 96.4%.</div>\\n<div class=\"description-paragraph\" id=\"p-0207\" num=\"0232\">MALDI: 6132.1, calculated: 6132.2.</div>\\n<heading id=\"h-0074\">Preparation of tert-butyl octadecandioyl-N-(2-(tert-butoxycarbonyl)ethyl)-Gly-OSu</heading>\\n<div class=\"description-paragraph\" id=\"p-0208\" num=\"0233\">H-Gly-OBn, HCl (3.03 g, 15 mmol) was dissolved in dry DMF (15 ml) and cooled on an ice bath. TEA (2.10, 15 mmol) was added under precipitation of TEA-hydrochloride. The suspension was stirred for 5 min before t-butyl acrylate (2.20 ml, 15 mmol) was added. The cooling bath was allowed to reach RT slowly and stirring was continued under nitrogen for 2 days. The reaction mixture was filtered and the filtrate was concentrated. The residue, still containing DMF, was dissolved in AcOEt and washed with sat aq NaHCO<sub>3 </sub>(2×) and water (1×). The organic layer was filtered before drying (Na<sub>2</sub>SO<sub>4</sub>) and concentration to give a yellow oil. Purification by flash chromatography or preparative HPLC gave N-(2-(tertbutoxycarbonyl)ethyl)-Gly-OBn as a clear oil (0.739 g, 17%).</div>\\n<div class=\"description-paragraph\" id=\"p-0209\" num=\"0234\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: ppm 1.46 (s, 9H) 2.50-2.61 (m, 2H) 2.82-2.99 (m, 2H) 3.31 (s, 2H) 5.14 (s, 2H) 7.29-7.43 (m, 5H).</div>\\n<div class=\"description-paragraph\" id=\"p-0210\" num=\"0235\">N-(2-(Tert-butoxycarbonyl)ethyl)-Gly-OBn (0.030 g, 0.1 mmol) and succinimidyl tertbutyloctadecanedioate (described in example 29, 0.050 mg, 0.1 mmol) was suspended in dry DMF (1 ml). HOAt (0.014 g, 0.1 mmol) and DIEA (0.21 ml, 1.2 mmol) was added. The yellow reaction mixture was stirred under nitrogen for 42 h. The reaction mixture was concentrated. The residue was redissolved in AcOEt and washed with 0.1 N HCl (2×), water (1×), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to give tert-butyl octadecandioyl-N-(2-(tert-butoxycarbonyl)ethyl)Gly-OBn in 85% yield (55 mg).</div>\\n<div class=\"description-paragraph\" id=\"p-0211\" num=\"0236\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: ppm 1.3 (m, 26H) 1.38 (s, 9H), 1.46 (s, 9H), 1.6 (m, 4H), 2.2 (m, 2H), 2.35 (m, 2H), 2.65 (m, 2H), 2.85 (s, 2H) 3.65 (m, 2H), 5.15 (s, 2H) 7.35 (m, 5H).</div>\\n<div class=\"description-paragraph\" id=\"p-0212\" num=\"0237\">Tert-butyl octadecandioyl-N-(2-(tert-butoxycarbonyl)ethyl)-Gly-OBn (0.054 g, 0.08 mmol) was dissolved in THF (2 ml). 10% Palladium on charcoal was added and the mixture was hydrogenated at 1 atm and RT over the week-end. The dry reaction mixture was dissolved in AcOEt and filtered 3 times to remove the carbon. The filtrate was concentrated to give in tert-butyl octadecandioyl-N-(2-(tert-butoxycarbonyl)ethyl)-Gly-OH 80% yield (37 mg).</div>\\n<div class=\"description-paragraph\" id=\"p-0213\" num=\"0238\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: ppm 1.3 (m, 26H) 1.40 (s, 9H), 1.46 (s, 9H), 1.6 (m, 4H), 1.75 (p, 2H), 2.2 (m, 2H), 2.35 (m, 2H), 2.63 (m, 2H), 2.83 (s, 2H).</div>\\n<div class=\"description-paragraph\" id=\"p-0214\" num=\"0239\">Tert-butyl octadecandioyl-N-(2-(tert-butoxycarbonyl)ethyl)-Gly-OH (0.07 mmol) was dissolved in dry THF (2 ml). TSTU (24 mg, 0.08 mmol) and DIPEA (15 uL, 0.08 mmol) was added. The mixture was stirred at RT under nitrogen. After 19 h the reaction had not finished according to TLC (DCM/MeOH 10:1). More DIEA was added (20 uL, 0.11 mmol) and stirring was continued. After 42 h the reaction mixture was filtered. The filtrate was diluted with AcOEt and washed with 0.1 N HCl (2×) and brine (1×), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to a give tert-butyl octadecandioyl-N-(2-(tert-butoxycarbonyl)ethyl)-Gly-OSu as a white solid in 84% yield (36 mg).</div>\\n<div class=\"description-paragraph\" id=\"p-0215\" num=\"0240\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: ppm 1.3 (m, 26H) 1.40 (m, 2H), 1.44 (s, 9H), 1.46 (s, 9H), 1.58 (m, 2H), 1.73 (p, 2H), 2.2 (t, 2H), 2.60 (t, 2H), 2.8 (m, 6H).</div>\\n<heading id=\"h-0075\">Example 31</heading>\\n<heading id=\"h-0076\">Synthesis of N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)—N-(carboxyethyl)-Gly] des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0216\" num=\"0241\">This compound was prepared in analogy with example 30, via reaction of N-(2-(tertbutoxycarbonyl)ethyl)-Gly-OBn with succinimidyl hexadecandioate (described in example 4) followed by debenzylation, activation with TSTU, coupling with A1N, B1N-diBOC-Des(B30) human insulin and deprotection by TFA.</div>\\n<div class=\"description-paragraph\" id=\"p-0217\" num=\"0242\">MALDI-MS: 6093.0, calculated 6104.1.</div>\\n<heading id=\"h-0077\">Example 32</heading>\\n<heading id=\"h-0078\">Synthesis of N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)—N-(carboxymethyl)-β-Ala] des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0218\" num=\"0243\">This compound was prepared in analogy with example 29 via reaction of N-(tertbutoxycarbonylmethyl)-β-Ala-OBn with succinimidyl hexadecandioate (described in example 4) followed by debenzylation, activation with TSTU, coupling with A1N, B1N-diBOC-Des(B30) human insulin and deprotection by TFA.</div>\\n<div class=\"description-paragraph\" id=\"p-0219\" num=\"0244\">MALDI-MS: 6097.6, calculated 6104.1.</div>\\n<heading id=\"h-0079\">Example 33</heading>\\n<heading id=\"h-0080\">Synthesis of N<sup>εB29</sup>—[N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>3</sub>CO)-γ-L-Glu] des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0220\" num=\"0245\">This compound was prepared similarly as described in example 1 using (MeOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>3</sub>CO)-Glu(OSu)-OMe, prepared as described below, as acylating agent.</div>\\n<div class=\"description-paragraph\" id=\"p-0221\" num=\"0246\">LCMS (electrospray): M+3: 2049, calculated 2050; M+4: 1538, calculated 1537.8; M+5: 1231, calculated 1230.4.</div>\\n<div class=\"description-paragraph\" id=\"p-0222\" num=\"0247\">MALDI-TOF MS: Calculated: 6147; found: 6153.</div>\\n<heading id=\"h-0081\">Preparation of (MeOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>3</sub>CO)-Glu(OSu)-OMe</heading>\\n<div class=\"description-paragraph\" id=\"p-0223\" num=\"0248\">MeOH (40 ml) was cooled to 0-50° C., and SOCl<sub>2 </sub>(4 ml) was added drop wise with stirring during 30 minutes. 12-Aminododecanoic acid (3 g, 13.9 mmol) was added and the resulting suspension was stirred at 0-5° C. while the ice in cooling bath melted and allowed to warm to room temperature during 16 hours. The mixture was filtered and the solid was dried by suction to afford 2.23 g (60%) of 12-aminododecanoic acid methyl ester hydrochloride. From the mother liquor a further batch of 0.92 g (25%) was isolated.</div>\\n<div class=\"description-paragraph\" id=\"p-0224\" num=\"0249\"> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 7.97 (bs, 3H), 3.58 (s, 3H), 2.73 (m, 2H, 2.28 (t, 2H), 1.52 (m, 4H), 1.25 (“s”, 14H).</div>\\n<div class=\"description-paragraph\" id=\"p-0225\" num=\"0250\">The 12-aminododecanoic acid methyl ester hydrochloride (1 g, 3.8 mmol) was suspended in THF (15 ml) and added glutaric acid anhydride (1.29 g, 3.8 mmol) and TEA (0.52 ml, 3.8 mmol) and the resulting mixture (suspension) was stirred at room temperature for 16 hours. Water (75 ml) was added gradually. After 25 ml, a solution was obtained and later a suspension appeared. The mixture was stirred at room temperature for 1 hour and filtered. The solid was washed with water and dried in vacuo. This afforded 1.02 g (80%) of 12-(4-carboxybutyrylamino)dodecanoic acid methyl ester.</div>\\n<div class=\"description-paragraph\" id=\"p-0226\" num=\"0251\"> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ:12 (bs, 1H), 7.73 (t, 1H), 3.57 (s, 3H), 3.00 (q, 2H), 2.28 (t, 2H), 2.18 (t, 2H), 2.06 (t, 2H), 1.69 (p, 2H), 1.50 (p, 2H), 1.36 (p, 2H), 1.23 (“s”, 14H).</div>\\n<div class=\"description-paragraph\" id=\"p-0227\" num=\"0252\">The 12-(4-carboxybutyrylamino)dodecanoic acid methyl ester (0.33 g, 0.95 mmol) was dissolved in a mixture of THF and DMF (2:1, 6 ml), and added DIEA (0.178 ml, 1.04 mmol). The mixture was cooled to 0-5° C. and TSTU (0.314 g, 1.04 mmol) was added. The mixture was stirred at 0-5° C. for 1 hour and at room temperature for 16 hours. The mixture was concentrated to dryness in vacuo. The residue (OSu-activated 12-(4-carboxybutyrylamino)dodecanoic acid methyl ester) was dissolved in DMF (10 ml) and added DIEA (0.24 ml, 1.4 mmol) and H-Glu-OMe (0.168 g, 1.04 mmol) and the mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo and the residue was dissolved in AcOEt (100 ml) and washed with 0.2M hydrochloric acid (3×50 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. This afforded 0.358 g (78%) of (MeOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>3</sub>CO)-Glu-OMe.</div>\\n<div class=\"description-paragraph\" id=\"p-0228\" num=\"0253\"> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>), δ: 12 (bs, 1H), 8.22 (d, 1H), 7.73 (t, 1H), 4.24 (m, 1H), 3.61 (s, 3H), 3.57 (s, 3H), 3.00 (q, 2H), 2.27 (m, 4H), 2.10 (t, 2H), 2.04 (t, 2H), 1.9 (m, 1H), 1.8 (m, 1H), 1.68 (t, 2H), 1.50 (m, 2H), 1.36 (m, 2H), 1.23 (“s”, 14H).</div>\\n<div class=\"description-paragraph\" id=\"p-0229\" num=\"0254\">(MeOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>3</sub>CO)-Glu-OMe (0.36 g, 0.36 mmol) was dissolved in THF (10 ml) and cooled to 0-5° C. DIEA (0.13 ml) and TSTU (0.129 g, 0.43 mmol) were added and the mixture was stirred at 0-5° C. for some hours and at room temperature for 3 days. The mixture was concentrated in vacuo. The residue was dissolved in AcOEt (100 ml) and washed with 0.2N hydrochloric acid (3×50 ml) and saturated aqueous NaHCO<sub>3 </sub>(3×100 ml). Drying (Na<sub>2</sub>SO<sub>4</sub>) and concentration in vacuo afforded 0.17 g (84%) of (MeOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>3</sub>CO)-Glu(OSu)-OMe.</div>\\n<div class=\"description-paragraph\" id=\"p-0230\" num=\"0255\"> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>), selected peaks, δ: 8.27 (d, 1H), 7.72 (t, 1H), 4.31 (m, 1H), 3.63 (s, 3H), 3.57 (s, 3H), 3.00 (q, 2H), 2.81 (s, 4H), 2.28 (t, 2H), 2.12 (t, 2H), 2.05 (t, 2H), 1.70 (m, 2H), 1.50 (m, 2H), 1.35 (m, 2H), 1.23 (“s”, 14H).</div>\\n<heading id=\"h-0082\">Example 34</heading>\\n<heading id=\"h-0083\">Synthesis of N<sup>εB29</sup>—[N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>2</sub>CO)-γ-L-Glu] des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0231\" num=\"0256\">This compound was prepared similarly as described in example 1 using (MeOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>2</sub>CO)-Glu(OSu)-OMe, which in turn was prepared similarly as described in example 33 using succinic acid anhydride instead of glutaric acid anhydride, as acylating agent.</div>\\n<div class=\"description-paragraph\" id=\"p-0232\" num=\"0257\">MALDI-TOF MS: Calculated: 6133; found: 6134.</div>\\n<heading id=\"h-0084\">Example 35</heading>\\n<heading id=\"h-0085\">Synthesis of N<sup>εB29</sup>—[N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)]-Gly-γ-L-Glu des(B30) Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0233\" num=\"0258\">This compound was prepared similarly as described in example 4 using tert-butyl octadecandioyl-Gly-Glu(OSu)-OtBu, prepared as described below as acylating agent.</div>\\n<div class=\"description-paragraph\" id=\"p-0234\" num=\"0259\">MALDI-TOF MS: Calculated: 6189; found: 6191.</div>\\n<heading id=\"h-0086\">Preparation of tert-butyl octadecandioyl-Gly-Glu(OSu)-OtBu</heading>\\n<div class=\"description-paragraph\" id=\"p-0235\" num=\"0260\">Z-Gly-OH (1.0 g, 4.78 mmol) was added THF (10 ml), DIEA (0.98 ml, 5.74 mmol), and TSTU (1.7 g, 5.74 mmol) and the resulting mixture was stirred at room temperature for 2 hours. AcOEt (100 ml) was added and the mixture was washed with 0.2N hydrochloric acid (100 ml) and water (2×100 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to afford 1.34 g (92%) of Z-Gly-OSu as an oil.</div>\\n<div class=\"description-paragraph\" id=\"p-0236\" num=\"0261\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>), δ: 7.35 (s, 5H), 5.32 (t, 1H), 5.15 (s, 2H), 4.35 (d, 2H), 2.83 (s, 4H).</div>\\n<div class=\"description-paragraph\" id=\"p-0237\" num=\"0262\">Z-Gly-OSu (1.3 g, 4.25 mmol) was dissolved in DMF (15 ml) and DIEA (1.82 ml, 10.6 mmol) and H-Glu-O<sup>t</sup>Bu (0.949 g, 4.67 mmol) were added and the resulting mixture was stirred at room temperature for 16 hours. AcOEt (100 ml) was added and the mixture was washed with 0.2N hydrochloric acid (100 ml) and water (2×100 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to afford 1.7 g (quant.) of Z-Gly-Glu-O<sup>t</sup>Bu as an oil.</div>\\n<div class=\"description-paragraph\" id=\"p-0238\" num=\"0263\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>), δ: 7.33 (s, 5H), 7.1 (d, 1H), 5.80 (t, 1H), 5.12 (s, 2H), 4.53 (m, 1H), 3.90 (d, 2H), 2.36 (t, 2H), 2.22 (m, 1H), 1.95 (m, 1H), 1.45 (s, 9H).</div>\\n<div class=\"description-paragraph\" id=\"p-0239\" num=\"0264\">Z-Gly-Glu-O<sup>t</sup>Bu (1.7 g, 4.3 mmol) was dissolved in 1,4-dioxane (15 ml) and under N<sub>2 </sub>10% palladium black (0.6 g) was added. The mixture was hydrogenated at atmospheric pressure for 5 hours. The mixture was filtered and the palladium was stirred with water (200 ml) for 2 hours, filtered and the filtrate was lyophilized. This afforded 0.65 g (58%) of H-Gly-Glu-O<sup>t</sup>Bu.</div>\\n<div class=\"description-paragraph\" id=\"p-0240\" num=\"0265\"> <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>), selected peaks, δ: 8.31 (d, 1H), 2.20 (t, 2H), 1.91 (m, 1H), 1.80 (m, 1H), 1.40 (s, 9H).</div>\\n<div class=\"description-paragraph\" id=\"p-0241\" num=\"0266\">H-Gly-Glu-O<sup>t</sup>Bu (0.15 g, 0.58 mmol) was suspended in DMF (5 ml) and DIEA (0.15 ml, 0.86 mmol) and succinimidyl tert-butyl octadecandioate (0.27 g, 0.58 mmol) were added and the resulting mixture was stirred at room temperature for 16 hours. AcOEt (50 ml) was added and the mixture was washed with 0.2N hydrochloric acid (100 ml) and water (3×100 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to afford 0.34 g (quant.) of tert-butyl octadecandioyl-Gly-Glu-O<sup>t</sup>Bu.</div>\\n<div class=\"description-paragraph\" id=\"p-0242\" num=\"0267\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>), δ: 7.11 (d, 1H), 6.55 (t, 1H), 4.55 (dt, 1H), 4.00 (dq, 2H), 2.40 (t, 2H), 2.26 (t, 2H), 2.20 (t, 4H), 2.00 (m, 1H), 1.57-1.65 (m, 5H), 1.47 (s, 9H), 1.44 (s, 9H), 1.25 (“s”, 22H, overlap with HDO).</div>\\n<div class=\"description-paragraph\" id=\"p-0243\" num=\"0268\">Tert-butyl octadecandioyl-Gly-Glu-O<sup>t</sup>Bu (0.32 g, 0.52 mmol) was dissolved in THF (5 ml) and added DIEA (0.11 ml, 0.63 mmol) and TSTU (0.19 g, 0.63 mmol) and the resulting mixture was stirred at room temperature under N<sub>2 </sub>for 3 days. AcOEt (100 ml) was added and the mixture was washed with 0.15N hydrochloric acid (100 ml) and water (3×100 ml). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to afford 0.3 g (81%) of tert-butyl octadecandioyl-Gly-Glu(OSu)-O<sup>t</sup>Bu.</div>\\n<div class=\"description-paragraph\" id=\"p-0244\" num=\"0269\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>), selected peaks, δ: 6.89 (d, 1H), 6.44 (t, 1H), 4.60 (m, 1H), 3.95 (dq, 2H), 2.86 (s, 4H), 2.68 (q, 2H), 2.24 (t, 2H), 2.20 (t, 4H), 1.57-1.65 (m, 5H), 1.48 (s, 9H), 1.44 (s, 9H), 1.25 (“s”, 22H, overlap with HDO).</div>\\n<heading id=\"h-0087\">Example 36</heading>\\n<heading id=\"h-0088\">Synthesis of N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)—N-(2-carboxyethyl)-β-Ala] des B30 Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0245\" num=\"0270\">This compound was prepared in analogy with example 1, via coupling of 15-[[2-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-ethyl]-(2-methoxycarbonyl-ethyl)-carbamoyl]-pentadecanoic acid methyl ester with Des(B30) human insulin and deprotection by NaOH.</div>\\n<div class=\"description-paragraph\" id=\"p-0246\" num=\"0271\">LC-MS: M+4. 1530.3, calculated 1529.5</div>\\n<heading id=\"h-0089\">Preparation of methyl hexadecandioyl N-(2-(methoxycarbonyl)ethyl)-β-Ala-OSu</heading>\\n<div class=\"description-paragraph\" id=\"p-0247\" num=\"0272\">Hβ-Ala-OMe hydrochloride (5.45 g, 39 mmol) was dissolved in DMSO (100 ml) and tert-butyl acrylate (5.71 ml, 39 mmol) and DIEA (13.4 ml, 78 mmol) were added, and the resulting mixture was stirred at room temperature for 6 days. The mixture was partitioned between water (500 ml) and AcOEt (2×250 ml). The combined organic phases were washed with saturated aqueous NH<sub>4</sub>Cl, dried (MgSO<sub>4</sub>) and concentrated in vacuo. This afforded 7.24 g (80%) of N-(2-(methoxycarbonyl)ethyl)-β-Ala-OtBu.</div>\\n<div class=\"description-paragraph\" id=\"p-0248\" num=\"0273\"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 3.58 (s, 3H), 2.72 (t, 2H), 2.67 (t, 2H), 2.41 (t, 2H), 2.29 (t, 2H), 1.39 (s, 9H).</div>\\n<div class=\"description-paragraph\" id=\"p-0249\" num=\"0274\">Hexadecanedioic acid monomethyl ester (150 mg, 0.5 mmol) was dissolved in DMF (5 mL). HOAt (102 mg, 0.75 mmol) and EDAC (143 mg, 0.75 mmol) was added and the reaction was stirred at 50° C. for 1 hour. After cooling to room temperature, DIEA (0.256 mL, 1.5 mmol) and N-(2-(methoxycarbonyl)ethyl)-β-Ala-OtBu (139 mg, 0.6 mmol) was added. The reaction was stirred overnight at room temperature. The mixture was partitioned between water (2×50 mL) and AcOEt (100 mL). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to an oil. DCM (10 mL) and TFA (10 mL) was added and the mixture was stirred for 1 hour at room temperature, solvent removed in vacuo to afford 170 mg (87%) of methyl hexadecandioyl N-(2-(methoxycarbonyl)ethyl-β-Ala-OH.</div>\\n<div class=\"description-paragraph\" id=\"p-0250\" num=\"0275\">LC-MS: 458 (M+1).</div>\\n<div class=\"description-paragraph\" id=\"p-0251\" num=\"0276\">Methyl hexadecandioyl N-(2-(methoxycarbonyl)ethyl-β-Ala-OH (161 mg, 0.351 mmol) was dissolved in THF (10 mL) DIEA (0.073 mL, 0.42 mmol) and TSTU (127 mg, 0.42 mmol) was added. The mixture was stirred while cooled on an icebath for 30 min, followed by stirring for 2 hours at room temperature. The mixture was partitioned between and AcOEt (100 mL) and aqueous HCl (0.2 N, 2×80 mL). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. This afforded 140 mg (72%) of methyl hexadecandioyl N-(2-(methoxycarbonyl)ethyl)-β-Ala-OSu as an oil.</div>\\n<div class=\"description-paragraph\" id=\"p-0252\" num=\"0277\">LC-MS: 555 (M+1).</div>\\n<heading id=\"h-0090\">Example 37</heading>\\n<heading id=\"h-0091\">Synthesis of N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)—N-(2-carboxyethyl)-β-Ala] des B30 Human Insulin</heading>\\n<div class=\"description-paragraph\" id=\"p-0253\" num=\"0278\">This compound was prepared in analogy with example 1 and 36 via coupling of methyl octadecandioyl N-(2-(methoxycarbonyl)ethyl)-β-Ala-OSu with Des(B30) human insulin and deprotection by NaOH.</div>\\n<heading id=\"h-0092\">Preparation of Methyl Octadecandioyl N-(2-(methoxycarbonyl)ethyl)-β-Ala-OSu</heading>\\n<div class=\"description-paragraph\" id=\"p-0254\" num=\"0279\">This compound was synthesized in analogy with methyl hexadecandioyl N-(2-(methoxycarbonyl)ethyl)-β-Ala-OSu using octadecanedioic acid mono methyl ester.</div>\\n<div class=\"description-paragraph\" id=\"p-0255\" num=\"0280\">MALDI-TOF MS: Calculated 6146; found: 6151</div>\\n<div class=\"description-paragraph\" id=\"p-0256\" num=\"0281\">LC-MS: 583 (M+1)</div>\\n<div class=\"description-paragraph\" id=\"h-0093\" num=\"0000\">Pharmacological Methods</div>\\n<div class=\"description-paragraph\" id=\"h-0094\" num=\"0000\">Assay (I)</div>\\n<div class=\"description-paragraph\" id=\"h-0095\" num=\"0000\">Insulin Receptor Binding of the Insulin Derivatives of the Invention</div>\\n<div class=\"description-paragraph\" id=\"p-0257\" num=\"0282\">The affinity of the insulin analogues of the invention for the human insulin receptor was determined by a SPA assay (Scintillation Proximity Assay) microtiterplate antibody capture assay. SPA-PVT antibody-binding beads, anti-mouse reagent (Amersham Biosciences, Cat No. PRNQ0017) were mixed with 25 ml of binding buffer (100 mM HEPES pH 7.8; 100 mM sodium chloride, 10 mM MgSO<sub>4</sub>, 0.025% Tween-20). Reagent mix for a single Packard Optiplate (Packard No. 6005190) is composed of 2.4 μl of a 1:5000 diluted purified recombinant human insulin receptor—exon 11, an amount of a stock solution of A14 Tyr[<sup>125</sup>I]-human insulin corresponding to 5000 cpm per 100 μl of reagent mix, 12 μl of a 1:1000 dilution of F12 antibody, 3 ml of SPA-beads and binding buffer to a total of 12 ml. A total of 100 μl was then added and a dilution series is made from appropriate samples. To the dilution series was then added 100 μl of reagent mix and the samples were incubated for 16 hours while gently shaken. The phases were the then separated by centrifugation for 1 min and the plates counted in a Topcounter. The binding data were fitted using the nonlinear regression algorithm in the GraphPad Prism 2.01 (GraphPad Software, San Diego, Calif.).</div>\\n<div class=\"description-paragraph\" id=\"h-0096\" num=\"0000\">Preparation of Monoclonal mIR Antibodies</div>\\n<div class=\"description-paragraph\" id=\"p-0258\" num=\"0283\">Specific antibodies (F12) were produced by monoclonal technique: RBF mice were immunized by injecting 50 μg of purified mIR in FCA subcutaneously followed by two injections with 20 μg of mIR in FIA. Highresponder mice were boosted intravenously with 25 μg of mIR and the spleens were harvested after 3 days. Spleen cells were fused with the myeloma Fox cell line (Köhler, G &amp; Milstein C. (1976), European J. Immunology, 6:511-19; Taggart R T et al (1983), Science 219:1228-30). Supernatants were screened for antibody production in a mIR specific ELISA. Positive wells were cloned and tested in Western blotting.</div>\\n<div class=\"description-paragraph\" id=\"p-0259\" num=\"0284\"> <tables id=\"TABLE-US-00003\" num=\"00003\"> <patent-tables colsep=\"0\" frame=\"none\" pgwide=\"1\" rowsep=\"0\"> <table align=\"left\" class=\"description-table\" cols=\"2\" colsep=\"0\" rowsep=\"0\" width=\"100%\"> <thead> <tr class=\"description-tr\"> <td class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\">TABLE 2</td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\"> </td> <td class=\"description-td\">Receptor binding</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">Product</td> <td class=\"description-td\">(% of human insulin)</td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> </thead> <tbody><tr class=\"description-tr\"> <td class=\"description-td\"> </td> </tr> </tbody></table> <table align=\"left\" class=\"description-table\" cols=\"2\" colsep=\"0\" rowsep=\"0\" width=\"100%\"> <tbody><tr class=\"description-tr\"> <td class=\"description-td\">Human insulin</td> <td class=\"description-td\">100</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">26</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">9.2</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-Glu-N-(γ-Glu) des(B30) human</td> <td class=\"description-td\">11</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Asp-OC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">13</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Glu-OC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">13</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-) des(B30) human insulin</td> <td class=\"description-td\">9.4</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-Glu)-N-(β-Glu) des(B30) human</td> <td class=\"description-td\">11</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>13</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">22</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Sar-OC(CH<sub>2</sub>)<sub>13</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">20</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Asp)-N-(β-L-Asp) des(B30)</td> <td class=\"description-td\">14</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">human insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">32</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>15</sub>CO-γ-Glu) des(B30) human insulin</td> <td class=\"description-td\">4</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-β-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">16</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">0525 N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-β-D-Asp) des(B30) human</td> <td class=\"description-td\">37</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>13</sub>CO-β-L-Glu) des(B30) human insulin</td> <td class=\"description-td\">15</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>13</sub>CO-β-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">11</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-δ-L-Aad) des(B30) human insulin</td> <td class=\"description-td\">7</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-D-Glu) des(B30) human insulin</td> <td class=\"description-td\">13</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>15</sub>CO-β-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">5.4</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">13</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-L-Glu) des(B30) human insulin</td> <td class=\"description-td\">16</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO-ε-L-LysCO—) des(B30) human insulin</td> <td class=\"description-td\">5.7</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-β-L-Asp) des(B30) human insulin</td> <td class=\"description-td\">11</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—(Gly-OC(CH<sub>2</sub>)<sub>16</sub>CO-γ-L-Glu) des(B30) human insulin</td> <td class=\"description-td\">9.1</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—[N—(HOOC(CH<sub>2</sub>)<sub>16</sub>CO)-N-(carboxymethyl)-β-Ala]</td> <td class=\"description-td\">9.4</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">des(B30) human insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—[N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>11</sub>)NHCO(CH<sub>2</sub>)<sub>3</sub>CO)-γ-L-Glu] des(B30)</td> <td class=\"description-td\">46</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">human insulin</td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> </tbody></table> </patent-tables> </tables> <br/>\\nAssay (II)\\n<br/>\\nPotency of the Insulin Derivatives of the Invention Relative to Human Insulin\\n</div>\\n<div class=\"description-paragraph\" id=\"p-0260\" num=\"0285\">Sprague Dawley male rats weighing 238-383 g on the experimental day were used for the clamp experiment. The rats had free access to feed under controlled ambient conditions and were fasted overnight (from 3 pm) prior to the clamp experiment.</div>\\n<div class=\"description-paragraph\" id=\"h-0097\" num=\"0000\">Experimental Protocol</div>\\n<div class=\"description-paragraph\" id=\"p-0261\" num=\"0286\">The rats were acclimatized in the animal facilities for at least 1 week prior to the surgical procedure. Approximately 1 week prior to the clamp experiment Tygon catheters were inserted under halothane anaesthesia into the jugular vein (for infusion) and the carotid artery (for blood sampling) and exteriorised and fixed on the back of the neck. The rats were given Streptocilin vet. (Boehringer Ingelheim; 0.15 ml/rat, i.m.) post-surgically and placed in an animal care unit (25° C.) during the recovery period. In order to obtain analgesia, Anorphin (0.06 mg/rat, s.c.) was administered during anaesthesia and Rimadyl (1.5 mg/kg, s.c.) was administered after full recovery from the anaesthesia (2-3 h) and again once daily for 2 days.</div>\\n<div class=\"description-paragraph\" id=\"p-0262\" num=\"0287\">The clamp technique employed was adapted from (1). At 7 am on the experimental day overnight fasted (from 3 pm the previous day) rats were weighed and connected to the sampling syringes and infusion system (Harvard 22 Basic pumps, Harvard, and Perfectum Hypodermic glass syringe, Aldrich) and then placed into individual clamp cages where they rested for ca. 45 min before start of experiment. The rats were able to move freely on their usual bedding during the entire experiment and had free access to drinking water. After a 30 min basal period during which plasma glucose levels were measured at 10 min intervals, the insulin derivative to be tested and human insulin (one dose level per rat, n=6-7 per dose level) were infused (i.v.) at a constant rate for 300 min. Plasma glucose levels were measured at 10 min intervals throughout and infusion of 20% aqueous glucose was adjusted accordingly in order to maintain euglyceamia. Samples of re-suspended erythrocytes were pooled from each rat and returned in about ½ ml volumes via the carotid catheter.</div>\\n<div class=\"description-paragraph\" id=\"p-0263\" num=\"0288\">On each experimental day, samples of the solutions of the individual insulin derivatives to be tested and the human insulin solution were taken before and at the end of the clamp experiments and the concentrations of the peptides were confirmed by HPLC. Plasma concentrations of rat insulin and C-peptide as well as of the insulin derivative to be tested and human insulin were measured at relevant time points before and at the end of the studies. Rats were killed at the end of experiment using a pentobarbital overdose.</div>\\n<div class=\"description-paragraph\" id=\"p-0264\" num=\"0289\">Test compounds and doses: Insulins to be tested were diluted from a stock solution containing 97 μM of the insulin derivative in 5 mM phosphate pH 7.7. The final concentration in the solution ready for use was 0.45 μM of the insulin derivative, 5 mM of phosphate, 100 mM of sodium chloride, 0.007% of polysorbate 20. The pH was 7.7 and the i.v. infusion rate was 15 and 20 pmol·min<sup>−1</sup>·kg<sup>−1</sup>.</div>\\n<div class=\"description-paragraph\" id=\"p-0265\" num=\"0290\">A stock solution of human insulin that was used as reference compound was formulated in a similar medium and infused i.v. at 6, 15 or 30 pmol·min<sup>−1</sup>·kg<sup>−1</sup>.</div>\\n<div class=\"description-paragraph\" id=\"p-0266\" num=\"0291\">Both stock solutions were stored at −20° C. and thawed overnight at 4° C. before use. The solutions were gently turned upside down several times 15 min before they were transferred to the infusion syringes.</div>\\n<div class=\"description-paragraph\" id=\"p-0267\" num=\"0292\"> <tables id=\"TABLE-US-00004\" num=\"00004\"> <patent-tables colsep=\"0\" frame=\"none\" rowsep=\"0\"> <table align=\"left\" class=\"description-table\" cols=\"2\" colsep=\"0\" rowsep=\"0\" width=\"100%\"> <thead> <tr class=\"description-tr\"> <td class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\">TABLE 3</td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\"> </td> <td class=\"description-td\">Potency relative</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">Insulin derivative</td> <td class=\"description-td\">to human insulin</td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> </thead> <tbody><tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu)</td> <td class=\"description-td\">&gt;50%</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">des(B30) human insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-Glu)</td> <td class=\"description-td\">&gt;50%</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">des(B30) human insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-Glu-N-(γ-Glu)</td> <td class=\"description-td\">&gt;50%</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">des(B30) human insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-β-L-Asp)</td> <td class=\"description-td\">&gt;50%</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">des(B30) human insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N-(Gly-OC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu)</td> <td class=\"description-td\">&gt;50%</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">des(B30) human insulin</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-β-L-Asp)</td> <td class=\"description-td\">&gt;50%</td> </tr> <tr class=\"description-tr\"> <td class=\"description-td\">des(B30) human insulin</td> </tr> <tr class=\"description-tr\"> <td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td> </tr> </tbody></table> </patent-tables> </tables> <br/>\\nAssay (III)\\n<br/>\\nDetermination in pigs of T<sub>50% </sub>of the Insulin Derivatives of the Invention\\n</div>\\n<div class=\"description-paragraph\" id=\"p-0268\" num=\"0293\">T<sub>50% </sub>is the time when 50% of an injected amount of the A14 Tyr[<sup>125</sup>I] labelled derivative of an insulin to be tested has disappeared from the injection site as measured with an external γ-counter.</div>\\n<div class=\"description-paragraph\" id=\"p-0269\" num=\"0294\">The principles of laboratory animal care were followed, Specific pathogen-free LYYD, non-diabetic female pigs, cross-breed of Danish Landrace, Yorkshire and Duroc, were used (Holmeniund, Haarloev, Denmark) for pharmacokinetic and pharmacodynamic studies. The pigs were conscious, 4-5 months of age and weighing 70-95 kg. The animals were fasted overnight for 18 h before the experiment.</div>\\n<div class=\"description-paragraph\" id=\"p-0270\" num=\"0295\">Formulated preparations of insulin derivatives labelled in Tyr<sup>A14 </sup>with <sup>125</sup>I were injected sc. in pigs as previously described (Ribel, U., Jorgensen, K, Brange, J, and Henriksen, U. The pig as a model for subcutaneous insulin absorption in man. Serrano-Rios, M and Lefèbvre, P. J. 891-896. 1985. Amsterdam; New York; Oxford, Elsevier Science Publishers. 1985 (Conference Proceeding)).</div>\\n<div class=\"description-paragraph\" id=\"p-0271\" num=\"0296\">At the beginning of the experiments a dose of 60 nmol of the insulin derivative according to the invention (test compound) and a dose of 60 nmol of insulin detemir (both <sup>125</sup>I labelled in Tyr A14) were injected at two separate sites in the neck of each pig.</div>\\n<div class=\"description-paragraph\" id=\"p-0272\" num=\"0297\">The disappearance of the radioactive label from the site of sc. injection was monitored using a modification of the traditional external gamma-counting method (Ribel, U. Subcutaneous absorption of insulin analogues. Berger, M. and Gries, F. A. 70-77 (1993). Stuttgart; New York, Georg Thime Verlag (Conference Proceeding)). With this modified method it was possible to measure continuously the disappearance of radioactivity from a subcutaneous depot for several days using cordless portable device (Scancys Laboratorieteknik, Værløse, DK-3500, Denmark). The measurements were performed at 1-min intervals, and the counted values were corrected for background activity.</div>\\n<div class=\"description-paragraph\" id=\"p-0273\" num=\"0298\">In Table 4, the column “test/detemir” shows the T<sub>50% </sub>found for each of the compounds tested (“test”) and the T<sub>50% </sub>found for insulin detemir (“detemir”) in the same experiment.</div>\\n<div class=\"description-paragraph\" id=\"p-0274\" num=\"0299\">\\n<tables id=\"TABLE-US-00005\" num=\"00005\">\\n<patent-tables colsep=\"0\" frame=\"none\" rowsep=\"0\">\\n<table align=\"left\" class=\"description-table\" cols=\"2\" colsep=\"0\" rowsep=\"0\" width=\"100%\">\\n<thead>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\">TABLE 4</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\"> </td>\\n<td class=\"description-td\">T<sub>50%</sub>, hours</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">Insulin derivative</td>\\n<td class=\"description-td\">test/detemir</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td>\\n</tr>\\n</thead>\\n<tbody><tr class=\"description-tr\">\\n<td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>14</sub>CO-γ-Glu)</td>\\n<td class=\"description-td\">9.0/9.5</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">des(B30) human insulin</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-Glu)</td>\\n<td class=\"description-td\">10.6/9.7\\u2002</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">des(B30) human insulin</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-γ-Glu-N-(γ-Glu)</td>\\n<td class=\"description-td\">7.8/7.4</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">des(B30) human insulin</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">N<sup>εB29</sup>—(N-(Asp-OC(CH<sub>2</sub>)<sub>16</sub>CO)-γ-Glu)</td>\\n<td class=\"description-td\">3.5/7.4</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">des(B30) human insulin</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">N<sup>εB29</sup>—(N-(Asp-OC(CH<sub>2</sub>)<sub>16</sub>CO—)</td>\\n<td class=\"description-td\">4.1/7.4</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">des(B30) human insulin</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">N<sup>εB29</sup>—(N—HOOC(CH<sub>2</sub>)<sub>16</sub>CO-α-Glu)-N-(β-Asp)</td>\\n<td class=\"description-td\">8.7/9.1</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td class=\"description-td\">des(B30) human insulin</td>\\n</tr>\\n<tr class=\"description-tr\">\\n<td align=\"center\" class=\"description-td\" colspan=\"2\" nameend=\"2\" namest=\"1\" rowsep=\"1\"> </td>\\n</tr>\\n</tbody></table>\\n</patent-tables>\\n</tables>\\n</div>\\n</div>\\n</div>\\n</section>\\n',\n",
       " '<section itemprop=\"claims\" itemscope=\"\">\\n<h2>Claims (<span itemprop=\"count\">12</span>)</h2>\\n<div html=\"\" itemprop=\"content\"><div class=\"claims\" lang=\"EN\" load-source=\"patent-office\" mxw-id=\"PCLM27324978\">\\n<div class=\"claim\"> <div class=\"claim\" id=\"CLM-00001\" num=\"00001\">\\n<div class=\"claim-text\">1. An insulin derivative which is a naturally occurring insulin or an analogue thereof which has a side chain attached to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula:\\n<div class=\"claim-text\"> <br/>-W-X—Y-Z</div>\\n</div>\\n<div class=\"claim-text\">wherein W is:\\n<div class=\"claim-text\">an α-amino acid residue having a carboxylic acid group in the side chain which amino acid is selected from the group consisting of α-Asp, β-Asp, α-Glu, γ-Glu, α-hGlu and δ-hGlu and which residue forms, with one of its carboxylic acid groups, an amide group together with the α-amino group of the N-terminal amino acid residue of the B chain or together with the ε-amino group of a Lys residue present in the B chain of the parent insulin;</div>\\n</div>\\n<div class=\"claim-text\">X is:\\n<div class=\"claim-text\">—CO—;</div>\\n</div>\\n<div class=\"claim-text\">Y is:\\n<div class=\"claim-text\">—(CH<sub>2</sub>)<sub>m</sub>— where m is an integer in the range of 6 to 32;</div>\\n</div>\\n<div class=\"claim-text\">Z is:\\n<div class=\"claim-text\">—COOH;</div>\\n</div>\\n<div class=\"claim-text\">and any Zn<sup>2+</sup> complexes thereof.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00002\" num=\"00002\">\\n<div class=\"claim-text\">2. An insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref>, wherein side chain -W-X—Y-Z is attached to the ε-amino group of a Lys residue present in the B chain of the parent insulin.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00003\" num=\"00003\">\\n<div class=\"claim-text\">3. An insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref>, wherein Y is —(CH<sub>2</sub>)<sub>m</sub>— where m is an integer in the range of from 12-16.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00004\" num=\"00004\">\\n<div class=\"claim-text\">4. An insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref>, wherein the parent insulin is; des(B30) human insulin.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00005\" num=\"00005\">\\n<div class=\"claim-text\">5. An insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref>, wherein the insulin derivative is N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)-γ-Glu) des(B30) human insulin.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00006\" num=\"00006\">\\n<div class=\"claim-text\">6. A zinc complex of an insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref>, wherein each insulin hexamer in said complex binds two zinc ions.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00007\" num=\"00007\">\\n<div class=\"claim-text\">7. A zinc complex of an insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref>, wherein each insulin hexamer in said complex binds three zinc ions.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00008\" num=\"00008\">\\n<div class=\"claim-text\">8. A zinc complex of an insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref>, wherein each insulin hexamer in said complex binds four zinc ions.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00009\" num=\"00009\">\\n<div class=\"claim-text\">9. A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment, said composition comprising a therapeutically effective amount of an insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref> together with a pharmaceutically acceptable carrier.</div>\\n</div>\\n</div> <div class=\"claim-dependent\"> <div class=\"claim\" id=\"CLM-00010\" num=\"00010\">\\n<div class=\"claim-text\">10. A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment, said composition comprising a therapeutically effective amount of an insulin derivative according to <claim-ref idref=\"CLM-00001\">claim 1</claim-ref> in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier.</div>\\n</div>\\n</div> <div class=\"claim\"> <div class=\"claim\" id=\"CLM-00011\" num=\"00011\">\\n<div class=\"claim-text\">11. A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment, said composition comprising a therapeutically effective amount of an insulin derivative with a pharmaceutically acceptable carrier, wherein said insulin derivative is N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)-γ-Glu) des(B30) human insulin.</div>\\n</div>\\n</div> <div class=\"claim\"> <div class=\"claim\" id=\"CLM-00012\" num=\"00012\">\\n<div class=\"claim-text\">12. A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment, said composition comprising a therapeutically effective amount of an insulin derivative in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier, wherein said insulin derivative is N<sup>εB29</sup>—(N<sup>α</sup>—(HOOC(CH<sub>2</sub>)<sub>14</sub>CO)—γ-Glu) des(B30) human insulin.</div>\\n</div>\\n</div> </div>\\n</div>\\n</section>\\n',\n",
       " '<section itemprop=\"application\" itemscope=\"\">\\n<section itemprop=\"metadata\" itemscope=\"\">\\n<span itemprop=\"applicationNumber\">US11/343,005</span>\\n<span itemprop=\"priorityDate\">2003-08-05</span>\\n<span itemprop=\"filingDate\">2006-01-30</span>\\n<span itemprop=\"title\">Insulin derivatives \\n       </span>\\n<span itemprop=\"ifiStatus\">Active</span>\\n<span itemprop=\"ifiExpiration\">2030-05-10</span>\\n<a href=\"/patent/US7615532B2/en\">\\n<span itemprop=\"representativePublication\">US7615532B2</span>\\n        (<span itemprop=\"primaryLanguage\">en</span>)\\n      </a>\\n</section>\\n<h2>Priority Applications (3)</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Application Number</th>\\n<th>Priority Date</th>\\n<th>Filing Date</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"priorityApps\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US11/343,005</span>\\n<a href=\"/patent/US7615532B2/en\">\\n<span itemprop=\"representativePublication\">US7615532B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2006-01-30</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"priorityApps\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US12/560,833</span>\\n<a href=\"/patent/US8828923B2/en\">\\n<span itemprop=\"representativePublication\">US8828923B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2009-09-16</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"priorityApps\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US14/453,276</span>\\n<a href=\"/patent/US20140349925A1/en\">\\n<span itemprop=\"representativePublication\">US20140349925A1</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2014-08-06</td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Applications Claiming Priority (5)</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Application Number</th>\\n<th>Priority Date</th>\\n<th>Filing Date</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"appsClaimingPriority\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">DKPA200301129</span>\\n</td>\\n<td itemprop=\"priorityDate\"></td>\\n<td itemprop=\"filingDate\">2003-08-05</td>\\n<td itemprop=\"title\"></td>\\n</tr>\\n<tr itemprop=\"appsClaimingPriority\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">DKPA200301129</span>\\n</td>\\n<td itemprop=\"priorityDate\"></td>\\n<td itemprop=\"filingDate\">2003-08-05</td>\\n<td itemprop=\"title\"></td>\\n</tr>\\n<tr itemprop=\"appsClaimingPriority\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US49545103P</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-14</td>\\n<td itemprop=\"filingDate\">2003-08-14</td>\\n<td itemprop=\"title\"></td>\\n</tr>\\n<tr itemprop=\"appsClaimingPriority\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">PCT/DK2004/000511</span>\\n<a href=\"/patent/WO2005012347A2/en\">\\n<span itemprop=\"representativePublication\">WO2005012347A2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2004-07-22</td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"appsClaimingPriority\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US11/343,005</span>\\n<a href=\"/patent/US7615532B2/en\">\\n<span itemprop=\"representativePublication\">US7615532B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2006-01-30</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Related Parent Applications (1)</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Application Number</th>\\n<th>Title</th>\\n<th>Priority Date</th>\\n<th>Filing Date</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"parentApps\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">PCT/DK2004/000511</span>\\n<span itemprop=\"relationType\">Continuation</span>\\n<a href=\"/patent/WO2005012347A2/en\">\\n<span itemprop=\"representativePublication\">WO2005012347A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2004-07-22</td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Related Child Applications (1)</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Application Number</th>\\n<th>Title</th>\\n<th>Priority Date</th>\\n<th>Filing Date</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"childApps\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US12/560,833</span>\\n<span itemprop=\"relationType\">Continuation</span>\\n<a href=\"/patent/US8828923B2/en\">\\n<span itemprop=\"representativePublication\">US8828923B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2009-09-16</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Publications (2)</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Publication Number</th>\\n<th>Publication Date</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"pubs\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"publicationNumber\">US20060183668A1</span>\\n<a href=\"/patent/US20060183668A1/en\">\\n              US20060183668A1\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-08-17</td>\\n</tr>\\n<tr itemprop=\"pubs\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"publicationNumber\">US7615532B2</span>\\n<span itemprop=\"thisPatent\">true</span>\\n<a href=\"/patent/US7615532B2/en\">\\n              US7615532B2\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2009-11-10</td>\\n</tr>\\n</tbody>\\n</table>\\n</section>\\n',\n",
       " '<section itemprop=\"family\" itemscope=\"\">\\n<h1>Family</h1>\\n<h2>ID=34117520</h2>\\n<h2>Family Applications (3)</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Application Number</th>\\n<th>Title</th>\\n<th>Priority Date</th>\\n<th>Filing Date</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"applications\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US11/343,005</span>\\n<span itemprop=\"ifiStatus\">Active</span>\\n<span itemprop=\"ifiExpiration\">2030-05-10</span>\\n<a href=\"/patent/US7615532B2/en\">\\n<span itemprop=\"representativePublication\">US7615532B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2006-01-30</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"applications\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US12/560,833</span>\\n<span itemprop=\"ifiStatus\">Active</span>\\n<a href=\"/patent/US8828923B2/en\">\\n<span itemprop=\"representativePublication\">US8828923B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2009-09-16</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"applications\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US14/453,276</span>\\n<span itemprop=\"ifiStatus\">Abandoned</span>\\n<a href=\"/patent/US20140349925A1/en\">\\n<span itemprop=\"representativePublication\">US20140349925A1</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2014-08-06</td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Family Applications After (2)</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Application Number</th>\\n<th>Title</th>\\n<th>Priority Date</th>\\n<th>Filing Date</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"afterApplications\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US12/560,833</span>\\n<span itemprop=\"ifiStatus\">Active</span>\\n<a href=\"/patent/US8828923B2/en\">\\n<span itemprop=\"representativePublication\">US8828923B2</span>\\n                  (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2009-09-16</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"afterApplications\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"applicationNumber\">US14/453,276</span>\\n<span itemprop=\"ifiStatus\">Abandoned</span>\\n<a href=\"/patent/US20140349925A1/en\">\\n<span itemprop=\"representativePublication\">US20140349925A1</span>\\n                  (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"filingDate\">2014-08-06</td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Country Status (17)</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Country</th>\\n<th>Link</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">US</span>\\n            (<span itemprop=\"num\">3</span>)\\n            <meta content=\"true\" itemprop=\"thisCountry\"/>\\n</td>\\n<td>\\n<a href=\"/patent/US7615532B2/en\">\\n<span itemprop=\"representativePublication\">US7615532B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">EP</span>\\n            (<span itemprop=\"num\">3</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/EP1660531A2/en\">\\n<span itemprop=\"representativePublication\">EP1660531A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">JP</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/JP4463814B2/en\">\\n<span itemprop=\"representativePublication\">JP4463814B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">KR</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/KR101159559B1/en\">\\n<span itemprop=\"representativePublication\">KR101159559B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">AU</span>\\n            (<span itemprop=\"num\">2</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/AU2004261353B2/en\">\\n<span itemprop=\"representativePublication\">AU2004261353B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">BE</span>\\n            (<span itemprop=\"num\">2</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/BE2013C035I2/en\">\\n<span itemprop=\"representativePublication\">BE2013C035I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">BR</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/BRPI0413276B8/en\">\\n<span itemprop=\"representativePublication\">BRPI0413276B8</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">CA</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/CA2531988C/en\">\\n<span itemprop=\"representativePublication\">CA2531988C</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">CY</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/CY1113850T1/en\">\\n<span itemprop=\"representativePublication\">CY1113850T1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">HU</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/HUS1300033I1/en\">\\n<span itemprop=\"representativePublication\">HUS1300033I1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">IL</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/IL172980A/en\">\\n<span itemprop=\"representativePublication\">IL172980A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">LU</span>\\n            (<span itemprop=\"num\">2</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/LU92213I2/en\">\\n<span itemprop=\"representativePublication\">LU92213I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">MX</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/MXPA06001283A/en\">\\n<span itemprop=\"representativePublication\">MXPA06001283A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">NO</span>\\n            (<span itemprop=\"num\">3</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/NO340925B1/en\">\\n<span itemprop=\"representativePublication\">NO340925B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">PL</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/PL2107069T3/en\">\\n<span itemprop=\"representativePublication\">PL2107069T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">RU</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/RU2518460C2/en\">\\n<span itemprop=\"representativePublication\">RU2518460C2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n<tr itemprop=\"countryStatus\" itemscope=\"\" repeat=\"\">\\n<td>\\n<span itemprop=\"countryCode\">WO</span>\\n            (<span itemprop=\"num\">1</span>)\\n            \\n          </td>\\n<td>\\n<a href=\"/patent/WO2005012347A2/en\">\\n<span itemprop=\"representativePublication\">WO2005012347A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Cited By (19)</h2>\\n<table>\\n<caption>* Cited by examiner, † Cited by third party</caption>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Priority date</th>\\n<th>Publication date</th>\\n<th>Assignee</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090074882A1/en\">\\n<span itemprop=\"publicationNumber\">US20090074882A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2005-12-28</td>\\n<td itemprop=\"publicationDate\">2009-03-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin compositions and method of making a composition \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090105121A1/en\">\\n<span itemprop=\"publicationNumber\">US20090105121A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2009-04-23</td>\\n<td><span itemprop=\"assigneeOriginal\">Ib Jonassen</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090137454A1/en\">\\n<span itemprop=\"publicationNumber\">US20090137454A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-02-27</td>\\n<td itemprop=\"publicationDate\">2009-05-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090239785A1/en\">\\n<span itemprop=\"publicationNumber\">US20090239785A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2009-09-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20100009899A1/en\">\\n<span itemprop=\"publicationNumber\">US20100009899A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2010-01-14</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel Insulin Derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20100279931A1/en\">\\n<span itemprop=\"publicationNumber\">US20100279931A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-11-08</td>\\n<td itemprop=\"publicationDate\">2010-11-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US9034818B2/en\">\\n<span itemprop=\"publicationNumber\">US9034818B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2007-06-13</td>\\n<td itemprop=\"publicationDate\">2015-05-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Pharmaceutical formulations comprising an insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2015071368A1/en\">\\n<span itemprop=\"publicationNumber\">WO2015071368A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-11-14</td>\\n<td itemprop=\"publicationDate\">2015-05-21</td>\\n<td><span itemprop=\"assigneeOriginal\">You-Ping Chan</span></td>\\n<td itemprop=\"title\">Long-acting insulin glargine analogue \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/USRE46170E1/en\">\\n<span itemprop=\"publicationNumber\">USRE46170E1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2005-02-02</td>\\n<td itemprop=\"publicationDate\">2016-10-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20160296602A1/en\">\\n<span itemprop=\"publicationNumber\">US20160296602A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2013-03-20</td>\\n<td itemprop=\"publicationDate\">2016-10-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Dosing Regimen \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US9603904B2/en\">\\n<span itemprop=\"publicationNumber\">US9603904B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2008-10-30</td>\\n<td itemprop=\"publicationDate\">2017-03-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Treating diabetes melitus using insulin injections with less than daily injection frequency \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10040839B2/en\">\\n<span itemprop=\"publicationNumber\">US10040839B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-02-28</td>\\n<td itemprop=\"publicationDate\">2018-08-07</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives and the medical uses hereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10137172B2/en\">\\n<span itemprop=\"publicationNumber\">US10137172B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-04-30</td>\\n<td itemprop=\"publicationDate\">2018-11-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Administration regime \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2018217573A1/en\">\\n<span itemprop=\"publicationNumber\">WO2018217573A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2017-05-26</td>\\n<td itemprop=\"publicationDate\">2018-11-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Eli Lilly And Company</span></td>\\n<td itemprop=\"title\">Acylated insulin compound \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10335464B1/en\">\\n<span itemprop=\"publicationNumber\">US10335464B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-06-26</td>\\n<td itemprop=\"publicationDate\">2019-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Device for titrating basal insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020032422A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020032422A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-08-08</td>\\n<td itemprop=\"publicationDate\">2020-02-13</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 대웅제약</span></td>\\n<td itemprop=\"title\">Long-acting insulin analogue and complex thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10596229B2/en\">\\n<span itemprop=\"publicationNumber\">US10596229B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-10-27</td>\\n<td itemprop=\"publicationDate\">2020-03-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020138953A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020138953A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">Insulin precursor purifying method using anion exchange chromatography \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020138952A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020138952A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">Composition for converting insulin precursor into insulin enzyme and method for converting insulin precursor into insulin by using same \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Families Citing this family (76)</h2>\\n<table>\\n<caption>* Cited by examiner, † Cited by third party</caption>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Priority date</th>\\n<th>Publication date</th>\\n<th>Assignee</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DE602004021603D1/en\">\\n<span itemprop=\"publicationNumber\">DE602004021603D1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-07-25</td>\\n<td itemprop=\"publicationDate\">2009-07-30</td>\\n<td><span itemprop=\"assigneeOriginal\">Conjuchem Biotechnologies Inc</span></td>\\n<td itemprop=\"title\">\\n  INSULIN DERIVATIVES WITH LONG-LASTING EFFECT AND METHOD FOR THE PRODUCTION THEREOF\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ES2490243T3/en\">\\n<span itemprop=\"publicationNumber\">ES2490243T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2005-02-02</td>\\n<td itemprop=\"publicationDate\">2014-09-03</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">\\n  Insulin derivatives\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2007104736A2/en\">\\n<span itemprop=\"publicationNumber\">WO2007104736A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-03-13</td>\\n<td itemprop=\"publicationDate\">2007-09-20</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Acylated single chain insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2015722B1/en\">\\n<span itemprop=\"publicationNumber\">EP2015722B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-04-28</td>\\n<td itemprop=\"publicationDate\">2016-11-16</td>\\n<td><span itemprop=\"assigneeOriginal\">Avent, Inc.</span></td>\\n<td itemprop=\"title\">Antimicrobial site dressings \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN101437849B/en\">\\n<span itemprop=\"publicationNumber\">CN101437849B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2015-09-30</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃-诺迪斯克有限公司</span></td>\\n<td itemprop=\"title\">Insulin derivates \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP5097900B2/en\">\\n<span itemprop=\"publicationNumber\">JP5097900B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-06-27</td>\\n<td itemprop=\"publicationDate\">2012-12-12</td>\\n<td><span itemprop=\"assigneeOriginal\">独立行政法人物質・材料研究機構</span></td>\\n<td itemprop=\"title\">\\n  Method for producing active ester of organic acid or derivative thereof\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN101573133B/en\">\\n<span itemprop=\"publicationNumber\">CN101573133B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-07-31</td>\\n<td itemprop=\"publicationDate\">2014-08-27</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃-诺迪斯克有限公司</span></td>\\n<td itemprop=\"title\">PEGylated, extended insulins \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CA2663074A1/en\">\\n<span itemprop=\"publicationNumber\">CA2663074A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-09-22</td>\\n<td itemprop=\"publicationDate\">2008-03-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Protease resistant insulin analogues \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2008132224A2/en\">\\n<span itemprop=\"publicationNumber\">WO2008132224A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2007-04-30</td>\\n<td itemprop=\"publicationDate\">2008-11-06</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2164466A1/en\">\\n<span itemprop=\"publicationNumber\">EP2164466A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2007-06-01</td>\\n<td itemprop=\"publicationDate\">2010-03-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2497462A1/en\">\\n<span itemprop=\"publicationNumber\">EP2497462A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-06-01</td>\\n<td itemprop=\"publicationDate\">2012-09-12</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Stable non-aqueous pharmaceutical compositions \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN101784562B/en\">\\n<span itemprop=\"publicationNumber\">CN101784562B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2007-08-15</td>\\n<td itemprop=\"publicationDate\">2016-07-13</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃-诺迪斯克有限公司</span></td>\\n<td itemprop=\"title\">There is the insulin analog of acyl group and aklylene glycol moiety \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8962794B2/en\">\\n<span itemprop=\"publicationNumber\">US8962794B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2007-08-15</td>\\n<td itemprop=\"publicationDate\">2015-02-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN101157725B/en\">\\n<span itemprop=\"publicationNumber\">CN101157725B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-10-24</td>\\n<td itemprop=\"publicationDate\">2012-07-25</td>\\n<td><span itemprop=\"assigneeOriginal\">中国药科大学</span></td>\\n<td itemprop=\"title\">Preparation method of human insulin analogue and usage thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BRPI0820535B8/en\">\\n<span itemprop=\"publicationNumber\">BRPI0820535B8</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2007-11-16</td>\\n<td itemprop=\"publicationDate\">2021-05-25</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  pharmaceutical compositions containing insulin and an insulinotropic peptide\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN101970477B/en\">\\n<span itemprop=\"publicationNumber\">CN101970477B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2008-03-14</td>\\n<td itemprop=\"publicationDate\">2014-12-31</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃-诺迪斯克有限公司</span></td>\\n<td itemprop=\"title\">Protease-stabilized insulin analogues \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/HUE032287T2/en\">\\n<span itemprop=\"publicationNumber\">HUE032287T2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2008-03-18</td>\\n<td itemprop=\"publicationDate\">2017-09-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">Protease stabilized, acylated insulin analogues \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2010029159A1/en\">\\n<span itemprop=\"publicationNumber\">WO2010029159A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2008-09-12</td>\\n<td itemprop=\"publicationDate\">2010-03-18</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Method of acylating a peptide or protein \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP5599822B2/en\">\\n<span itemprop=\"publicationNumber\">JP5599822B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2009-01-23</td>\\n<td itemprop=\"publicationDate\">2014-10-01</td>\\n<td><span itemprop=\"assigneeOriginal\">ノヴォ  ノルディスク  アー／エス</span></td>\\n<td itemprop=\"title\">\\n  FGF21 derivatives having albumin binder ABCDE and their use\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2493919A1/en\">\\n<span itemprop=\"publicationNumber\">EP2493919A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2009-10-30</td>\\n<td itemprop=\"publicationDate\">2012-09-05</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Derivatives of cgrp \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/MX2012007806A/en\">\\n<span itemprop=\"publicationNumber\">MX2012007806A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-01-12</td>\\n<td itemprop=\"publicationDate\">2012-08-01</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">Pharmaceutical compositions for oral administration of insulin peptides. \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN102812039B/en\">\\n<span itemprop=\"publicationNumber\">CN102812039B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-02-16</td>\\n<td itemprop=\"publicationDate\">2016-01-20</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃—诺迪斯克有限公司</span></td>\\n<td itemprop=\"title\">Conjugated protein \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2536434B1/en\">\\n<span itemprop=\"publicationNumber\">EP2536434B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-02-16</td>\\n<td itemprop=\"publicationDate\">2016-04-20</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Purification method \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BR112012028766A2/en\">\\n<span itemprop=\"publicationNumber\">BR112012028766A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-05-10</td>\\n<td itemprop=\"publicationDate\">2017-06-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  process for the preparation of insulin and zinc complexes\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2011146972A1/en\">\\n<span itemprop=\"publicationNumber\">WO2011146972A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-05-25</td>\\n<td itemprop=\"publicationDate\">2011-12-01</td>\\n<td><span itemprop=\"assigneeOriginal\">Monash University</span></td>\\n<td itemprop=\"title\">Methods for the synthesis of dicarba bridges in peptides \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2011161124A1/en\">\\n<span itemprop=\"publicationNumber\">WO2011161124A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-06-23</td>\\n<td itemprop=\"publicationDate\">2011-12-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin analogues containing additional disulfide bonds \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2011161083A1/en\">\\n<span itemprop=\"publicationNumber\">WO2011161083A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-06-23</td>\\n<td itemprop=\"publicationDate\">2011-12-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Human insulin containing additional disulfide bonds \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN102985440B/en\">\\n<span itemprop=\"publicationNumber\">CN102985440B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2010-06-23</td>\\n<td itemprop=\"publicationDate\">2016-10-26</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃-诺迪斯克有限公司</span></td>\\n<td itemprop=\"title\">Comprise the insulin derivates of extra disulfide bond \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20140315797A1/en\">\\n<span itemprop=\"publicationNumber\">US20140315797A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-10-15</td>\\n<td itemprop=\"publicationDate\">2014-10-23</td>\\n<td><span itemprop=\"assigneeOriginal\">Peter Madsen</span></td>\\n<td itemprop=\"title\">Novel N-Terminally Modified Insulin Derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/PL2632478T3/en\">\\n<span itemprop=\"publicationNumber\">PL2632478T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-10-27</td>\\n<td itemprop=\"publicationDate\">2020-03-31</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Treating diabetes melitus using insulin injections administered with varying injection intervals \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP2013545782A/en\">\\n<span itemprop=\"publicationNumber\">JP2013545782A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-12-14</td>\\n<td itemprop=\"publicationDate\">2013-12-26</td>\\n<td><span itemprop=\"assigneeOriginal\">ノヴォ  ノルディスク  アー／エス</span></td>\\n<td itemprop=\"title\">\\n  Fast-acting insulin combined with long-acting insulin\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN103370075A/en\">\\n<span itemprop=\"publicationNumber\">CN103370075A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2011-02-15</td>\\n<td itemprop=\"publicationDate\">2013-10-23</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃—诺迪斯克有限公司</span></td>\\n<td itemprop=\"title\">Long-acting IL-1 receptor antagonists \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2691108A1/en\">\\n<span itemprop=\"publicationNumber\">EP2691108A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2011-03-28</td>\\n<td itemprop=\"publicationDate\">2014-02-05</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel glucagon analogues \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP6030630B2/en\">\\n<span itemprop=\"publicationNumber\">JP6030630B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2011-04-14</td>\\n<td itemprop=\"publicationDate\">2016-11-24</td>\\n<td><span itemprop=\"assigneeOriginal\">ノヴォ ノルディスク アー／エス</span></td>\\n<td itemprop=\"title\">\\n  Fatty acylated amino acids for oral peptide delivery\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN103596584B/en\">\\n<span itemprop=\"publicationNumber\">CN103596584B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2011-06-15</td>\\n<td itemprop=\"publicationDate\">2016-12-14</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃—诺迪斯克有限公司</span></td>\\n<td itemprop=\"title\">Polysubstituted insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2012311484B2/en\">\\n<span itemprop=\"publicationNumber\">AU2012311484B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2011-09-23</td>\\n<td itemprop=\"publicationDate\">2017-04-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel glucagon analogues \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN103443122B/en\">\\n<span itemprop=\"publicationNumber\">CN103443122B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2011-12-15</td>\\n<td itemprop=\"publicationDate\">2016-05-11</td>\\n<td><span itemprop=\"assigneeOriginal\">上海恒瑞医药有限公司</span></td>\\n<td itemprop=\"title\">Human insulin analogue and acylated derivatives thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20140357838A1/en\">\\n<span itemprop=\"publicationNumber\">US20140357838A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2011-12-21</td>\\n<td itemprop=\"publicationDate\">2014-12-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">N-Terminally Modified Insulin Derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP6199956B2/en\">\\n<span itemprop=\"publicationNumber\">JP6199956B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2012-04-11</td>\\n<td itemprop=\"publicationDate\">2017-09-20</td>\\n<td><span itemprop=\"assigneeOriginal\">ノヴォ ノルディスク アー／エス</span></td>\\n<td itemprop=\"title\">\\n  Insulin preparations\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20160031962A1/en\">\\n<span itemprop=\"publicationNumber\">US20160031962A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2012-04-20</td>\\n<td itemprop=\"publicationDate\">2016-02-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Kleomenis K. Barlos</span></td>\\n<td itemprop=\"title\">Solid phase peptide synthesis of insulin using side chain achored lysine \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2013255880B2/en\">\\n<span itemprop=\"publicationNumber\">AU2013255880B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2012-05-01</td>\\n<td itemprop=\"publicationDate\">2017-07-20</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Pharmaceutical composition \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2869830B1/en\">\\n<span itemprop=\"publicationNumber\">EP2869830B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2012-07-09</td>\\n<td itemprop=\"publicationDate\">2016-10-12</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel use of insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/UA116217C2/en\">\\n<span itemprop=\"publicationNumber\">UA116217C2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2012-10-09</td>\\n<td itemprop=\"publicationDate\">2018-02-26</td>\\n<td><span itemprop=\"assigneeOriginal\">Санофі</span></td>\\n<td itemprop=\"title\">Exendin-4 derivatives as dual glp1/glucagon agonists \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2908846A1/en\">\\n<span itemprop=\"publicationNumber\">EP2908846A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2012-10-17</td>\\n<td itemprop=\"publicationDate\">2015-08-26</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Fatty acid acylated d-amino acids for oral peptide delivery \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2934569A1/en\">\\n<span itemprop=\"publicationNumber\">EP2934569A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2012-12-21</td>\\n<td itemprop=\"publicationDate\">2015-10-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Sanofi</span></td>\\n<td itemprop=\"title\">Exendin-4 derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/RU2683039C2/en\">\\n<span itemprop=\"publicationNumber\">RU2683039C2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-04-18</td>\\n<td itemprop=\"publicationDate\">2019-03-26</td>\\n<td><span itemprop=\"assigneeOriginal\">Ново Нордиск А/С</span></td>\\n<td itemprop=\"title\">Stable protracted glp-1/glucagon receptor co-antagonists for medical use \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/GB201315335D0/en\">\\n<span itemprop=\"publicationNumber\">GB201315335D0</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-08-29</td>\\n<td itemprop=\"publicationDate\">2013-10-09</td>\\n<td><span itemprop=\"assigneeOriginal\">Of Singapore</span></td>\\n<td itemprop=\"title\">Amino diacids containing peptide modifiers \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP6499184B2/en\">\\n<span itemprop=\"publicationNumber\">JP6499184B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-10-07</td>\\n<td itemprop=\"publicationDate\">2019-04-10</td>\\n<td><span itemprop=\"assigneeOriginal\">ノヴォ ノルディスク アー／エス</span></td>\\n<td itemprop=\"title\">\\n  Novel derivatives of insulin analogues\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/TW201609796A/en\">\\n<span itemprop=\"publicationNumber\">TW201609796A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-12-13</td>\\n<td itemprop=\"publicationDate\">2016-03-16</td>\\n<td><span itemprop=\"assigneeOriginal\">賽諾菲公司</span></td>\\n<td itemprop=\"title\">Non-acylated EXENDIN-4 peptide analogues \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP3080154B1/en\">\\n<span itemprop=\"publicationNumber\">EP3080154B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-12-13</td>\\n<td itemprop=\"publicationDate\">2018-02-07</td>\\n<td><span itemprop=\"assigneeOriginal\">Sanofi</span></td>\\n<td itemprop=\"title\">Dual glp-1/gip receptor agonists \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP3080149A1/en\">\\n<span itemprop=\"publicationNumber\">EP3080149A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-12-13</td>\\n<td itemprop=\"publicationDate\">2016-10-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Sanofi</span></td>\\n<td itemprop=\"title\">Dual glp-1/glucagon receptor agonists \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP3080150B1/en\">\\n<span itemprop=\"publicationNumber\">EP3080150B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-12-13</td>\\n<td itemprop=\"publicationDate\">2018-08-01</td>\\n<td><span itemprop=\"assigneeOriginal\">Sanofi</span></td>\\n<td itemprop=\"title\">Exendin-4 peptide analogues as dual glp-1/gip receptor agonists \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AR100306A1/en\">\\n<span itemprop=\"publicationNumber\">AR100306A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-02-18</td>\\n<td itemprop=\"publicationDate\">2016-09-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  GLUCAGON ANALOGS STABLE AND USE FOR THE TREATMENT OF HYPOGLUCEMIA\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/TW201625670A/en\">\\n<span itemprop=\"publicationNumber\">TW201625670A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-04-07</td>\\n<td itemprop=\"publicationDate\">2016-07-16</td>\\n<td><span itemprop=\"assigneeOriginal\">賽諾菲公司</span></td>\\n<td itemprop=\"title\">Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/TW201625668A/en\">\\n<span itemprop=\"publicationNumber\">TW201625668A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-04-07</td>\\n<td itemprop=\"publicationDate\">2016-07-16</td>\\n<td><span itemprop=\"assigneeOriginal\">賽諾菲公司</span></td>\\n<td itemprop=\"title\">Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/TW201625669A/en\">\\n<span itemprop=\"publicationNumber\">TW201625669A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-04-07</td>\\n<td itemprop=\"publicationDate\">2016-07-16</td>\\n<td><span itemprop=\"assigneeOriginal\">賽諾菲公司</span></td>\\n<td itemprop=\"title\">Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP3151852A1/en\">\\n<span itemprop=\"publicationNumber\">EP3151852A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-06-04</td>\\n<td itemprop=\"publicationDate\">2017-04-12</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Glp-1/glucagon receptor co-agonists for medical use \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US9932381B2/en\">\\n<span itemprop=\"publicationNumber\">US9932381B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-06-18</td>\\n<td itemprop=\"publicationDate\">2018-04-03</td>\\n<td><span itemprop=\"assigneeOriginal\">Sanofi</span></td>\\n<td itemprop=\"title\">Exendin-4 derivatives as selective glucagon receptor agonists \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AR105319A1/en\">\\n<span itemprop=\"publicationNumber\">AR105319A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2015-06-05</td>\\n<td itemprop=\"publicationDate\">2017-09-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Sanofi Sa</span></td>\\n<td itemprop=\"title\">\\n  PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/TW201706291A/en\">\\n<span itemprop=\"publicationNumber\">TW201706291A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2015-07-10</td>\\n<td itemprop=\"publicationDate\">2017-02-16</td>\\n<td><span itemprop=\"assigneeOriginal\">賽諾菲公司</span></td>\\n<td itemprop=\"title\">New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20190010206A1/en\">\\n<span itemprop=\"publicationNumber\">US20190010206A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2015-08-25</td>\\n<td itemprop=\"publicationDate\">2019-01-10</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel Insulin Derivatives and the Medical Uses Hereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP3341402A1/en\">\\n<span itemprop=\"publicationNumber\">EP3341402A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2015-08-25</td>\\n<td itemprop=\"publicationDate\">2018-07-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel insulin derivatives and the medical uses hereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10815287B2/en\">\\n<span itemprop=\"publicationNumber\">US10815287B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2016-08-02</td>\\n<td itemprop=\"publicationDate\">2020-10-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Jiangsu Hengrui Medicine Co., Ltd.</span></td>\\n<td itemprop=\"title\">Acylated derivative of human insulin or analogue thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2018096164A1/en\">\\n<span itemprop=\"publicationNumber\">WO2018096164A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2016-11-28</td>\\n<td itemprop=\"publicationDate\">2018-05-31</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin degludec for treating diabetes \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP3544682A1/en\">\\n<span itemprop=\"publicationNumber\">EP3544682A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2016-11-28</td>\\n<td itemprop=\"publicationDate\">2019-10-02</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/MA46897A/en\">\\n<span itemprop=\"publicationNumber\">MA46897A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2016-11-28</td>\\n<td itemprop=\"publicationDate\">2021-04-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  INSULIN DEGLUDEC USED IN CARDIOVASCULAR CONDITIONS\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/IL267224B2/en\">\\n<span itemprop=\"publicationNumber\">IL267224B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2016-12-16</td>\\n<td itemprop=\"publicationDate\">2023-10-01</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">Insulin containing pharmaceutical compositions \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP3750998A4/en\">\\n<span itemprop=\"publicationNumber\">EP3750998A4</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-02-09</td>\\n<td itemprop=\"publicationDate\">2022-02-23</td>\\n<td><span itemprop=\"assigneeOriginal\">Jiangsu Hengrui Medicine Co., Ltd.</span></td>\\n<td itemprop=\"title\">Codon optimized precursor gene and signal peptide gene of human insulin analogue \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CA3100869A1/en\">\\n<span itemprop=\"publicationNumber\">CA3100869A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-05-24</td>\\n<td itemprop=\"publicationDate\">2019-11-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Jiangsu Hengrui Medicine Co., Ltd.</span></td>\\n<td itemprop=\"title\">Method for preparing precursor of recombinant human insulin or analogue thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP3815106A1/en\">\\n<span itemprop=\"publicationNumber\">EP3815106A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-06-26</td>\\n<td itemprop=\"publicationDate\">2021-05-05</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">System providing dose recommendations for basal insulin titration \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/TW202120536A/en\">\\n<span itemprop=\"publicationNumber\">TW202120536A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2019-07-31</td>\\n<td itemprop=\"publicationDate\">2021-06-01</td>\\n<td><span itemprop=\"assigneeOriginal\">美商美國禮來大藥廠</span></td>\\n<td itemprop=\"title\">Relaxin analogs and methods of using the same \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN114901682A/en\">\\n<span itemprop=\"publicationNumber\">CN114901682A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2019-12-30</td>\\n<td itemprop=\"publicationDate\">2022-08-12</td>\\n<td><span itemprop=\"assigneeOriginal\">甘李药业股份有限公司</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP4180060A1/en\">\\n<span itemprop=\"publicationNumber\">EP4180060A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2021-11-15</td>\\n<td itemprop=\"publicationDate\">2023-05-17</td>\\n<td><span itemprop=\"assigneeOriginal\">Adocia</span></td>\\n<td itemprop=\"title\">Solid compositions comprising a peptide or a protein and an acylated amino acid \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2023084118A1/en\">\\n<span itemprop=\"publicationNumber\">WO2023084118A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2021-11-15</td>\\n<td itemprop=\"publicationDate\">2023-05-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Adocia</span></td>\\n<td itemprop=\"title\">Solid compositions comprising a peptide or a protein and an acylated amino acid \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP4299057A1/en\">\\n<span itemprop=\"publicationNumber\">EP4299057A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2022-06-30</td>\\n<td itemprop=\"publicationDate\">2024-01-03</td>\\n<td><span itemprop=\"assigneeOriginal\">Adocia</span></td>\\n<td itemprop=\"title\">Solid compositions comprising a peptide or a protein and an acylated amino acid \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP4299071A1/en\">\\n<span itemprop=\"publicationNumber\">EP4299071A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2022-07-01</td>\\n<td itemprop=\"publicationDate\">2024-01-03</td>\\n<td><span itemprop=\"assigneeOriginal\">Adocia</span></td>\\n<td itemprop=\"title\">Compositions comprising a peptide or a protein and an acylated amino acid \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Citations (8)</h2>\\n<table>\\n<caption>* Cited by examiner, † Cited by third party</caption>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Priority date</th>\\n<th>Publication date</th>\\n<th>Assignee</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"backwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US3528960A/en\">\\n<span itemprop=\"publicationNumber\">US3528960A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1968-10-07</td>\\n<td itemprop=\"publicationDate\">1970-09-15</td>\\n<td>\\n<span itemprop=\"assigneeOriginal\">Lilly Co Eli</span>\\n</td>\\n<td itemprop=\"title\">N-carboxyaroyl insulins \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/GB1492997A/en\">\\n<span itemprop=\"publicationNumber\">GB1492997A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1976-07-21</td>\\n<td itemprop=\"publicationDate\">1977-11-23</td>\\n<td>\\n<span itemprop=\"assigneeOriginal\">Nat Res Dev</span>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO1991012817A1/en\">\\n<span itemprop=\"publicationNumber\">WO1991012817A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1990-02-21</td>\\n<td itemprop=\"publicationDate\">1991-09-05</td>\\n<td>\\n<span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span>\\n</td>\\n<td itemprop=\"title\">Novel insulin compositions \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO1995007931A1/en\">\\n<span itemprop=\"publicationNumber\">WO1995007931A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1993-09-17</td>\\n<td itemprop=\"publicationDate\">1995-03-23</td>\\n<td>\\n<span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span>\\n</td>\\n<td itemprop=\"title\">Acylated insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO1998002460A1/en\">\\n<span itemprop=\"publicationNumber\">WO1998002460A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1996-07-11</td>\\n<td itemprop=\"publicationDate\">1998-01-22</td>\\n<td>\\n<span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span>\\n</td>\\n<td itemprop=\"title\">Selective acylation method \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP0894095A1/en\">\\n<span itemprop=\"publicationNumber\">EP0894095A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1996-02-21</td>\\n<td itemprop=\"publicationDate\">1999-02-03</td>\\n<td>\\n<span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives and their use \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5898067A/en\">\\n<span itemprop=\"publicationNumber\">US5898067A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1997-02-07</td>\\n<td itemprop=\"publicationDate\">1999-04-27</td>\\n<td>\\n<span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span>\\n</td>\\n<td itemprop=\"title\">Crystallization of proteins \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesOrig\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US6251856B1/en\">\\n<span itemprop=\"publicationNumber\">US6251856B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1995-03-17</td>\\n<td itemprop=\"publicationDate\">2001-06-26</td>\\n<td>\\n<span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<h2>Family Cites Families (87)</h2>\\n<table>\\n<caption>* Cited by examiner, † Cited by third party</caption>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Priority date</th>\\n<th>Publication date</th>\\n<th>Assignee</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DE1212679B/en\">\\n<span itemprop=\"publicationNumber\">DE1212679B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1957-08-03</td>\\n<td itemprop=\"publicationDate\">1966-03-17</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Terapeutisk Labor As</span></td>\\n<td itemprop=\"title\">\\n  Process for the preparation of insulin solutions\\n \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/GB1042194A/en\">\\n<span itemprop=\"publicationNumber\">GB1042194A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1962-04-30</td>\\n<td itemprop=\"publicationDate\">1966-09-14</td>\\n<td><span itemprop=\"assigneeOriginal\">Olin Mathieson</span></td>\\n<td itemprop=\"title\">Insulin preparations \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US3868358A/en\">\\n<span itemprop=\"publicationNumber\">US3868358A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1971-04-30</td>\\n<td itemprop=\"publicationDate\">1975-02-25</td>\\n<td><span itemprop=\"assigneeOriginal\">Lilly Co Eli</span></td>\\n<td itemprop=\"title\">Protamine-insulin product \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JPS5767548A/en\">\\n<span itemprop=\"publicationNumber\">JPS5767548A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1980-10-14</td>\\n<td itemprop=\"publicationDate\">1982-04-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Shionogi &amp; Co Ltd</span></td>\\n<td itemprop=\"title\">Insulin analog and its preparation \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/FI78616C/en\">\\n<span itemprop=\"publicationNumber\">FI78616C</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1982-02-05</td>\\n<td itemprop=\"publicationDate\">1989-09-11</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Industri As</span></td>\\n<td itemprop=\"title\">\\n  Process for preparing an infused stabilized insulin solution having an elevated zinc content\\n \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/PH25772A/en\">\\n<span itemprop=\"publicationNumber\">PH25772A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1985-08-30</td>\\n<td itemprop=\"publicationDate\">1991-10-18</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Industri As</span></td>\\n<td itemprop=\"title\">Insulin analogues, process for their preparation \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NZ222907A/en\">\\n<span itemprop=\"publicationNumber\">NZ222907A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1986-12-16</td>\\n<td itemprop=\"publicationDate\">1990-08-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Industri As</span></td>\\n<td itemprop=\"title\">Preparation for intranasal administration containing a phospholipid absorption enhancing system \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5605884A/en\">\\n<span itemprop=\"publicationNumber\">US5605884A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1987-10-29</td>\\n<td itemprop=\"publicationDate\">1997-02-25</td>\\n<td><span itemprop=\"assigneeOriginal\">Rhone-Poulenc Rorer Pharmaceuticals Inc.</span></td>\\n<td itemprop=\"title\">Factor VIII formulations in high ionic strength media \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US4877608A/en\">\\n<span itemprop=\"publicationNumber\">US4877608A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1987-11-09</td>\\n<td itemprop=\"publicationDate\">1989-10-31</td>\\n<td><span itemprop=\"assigneeOriginal\">Rorer Pharmaceutical Corporation</span></td>\\n<td itemprop=\"title\">Pharmaceutical plasma protein formulations in low ionic strength media \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JPH01254699A/en\">\\n<span itemprop=\"publicationNumber\">JPH01254699A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1988-04-05</td>\\n<td itemprop=\"publicationDate\">1989-10-11</td>\\n<td><span itemprop=\"assigneeOriginal\">Kodama Kk</span></td>\\n<td itemprop=\"title\">Insulin derivative and use thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DE3827533A1/en\">\\n<span itemprop=\"publicationNumber\">DE3827533A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1988-08-13</td>\\n<td itemprop=\"publicationDate\">1990-02-15</td>\\n<td><span itemprop=\"assigneeOriginal\">Hoechst Ag</span></td>\\n<td itemprop=\"title\">\\n  PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU641631B2/en\">\\n<span itemprop=\"publicationNumber\">AU641631B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1988-12-23</td>\\n<td itemprop=\"publicationDate\">1993-09-30</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Human insulin analogues \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NZ232375A/en\">\\n<span itemprop=\"publicationNumber\">NZ232375A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1989-02-09</td>\\n<td itemprop=\"publicationDate\">1992-04-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Lilly Co Eli</span></td>\\n<td itemprop=\"title\">Insulin analogues modified at b29 \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/IT1240314B/en\">\\n<span itemprop=\"publicationNumber\">IT1240314B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1989-09-28</td>\\n<td itemprop=\"publicationDate\">1993-12-07</td>\\n<td><span itemprop=\"assigneeOriginal\">Immunobiology Research Institutes, Inc.</span></td>\\n<td itemprop=\"title\">\\n  STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DK0506792T3/en\">\\n<span itemprop=\"publicationNumber\">DK0506792T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1989-12-21</td>\\n<td itemprop=\"publicationDate\">1995-10-09</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  Insulin preparation containing nicotinic acid or nicotinamide\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP3193398B2/en\">\\n<span itemprop=\"publicationNumber\">JP3193398B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1991-07-23</td>\\n<td itemprop=\"publicationDate\">2001-07-30</td>\\n<td><span itemprop=\"assigneeOriginal\">サンデン株式会社</span></td>\\n<td itemprop=\"title\">\\n  Showcase\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DE69233704T2/en\">\\n<span itemprop=\"publicationNumber\">DE69233704T2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1991-12-20</td>\\n<td itemprop=\"publicationDate\">2008-05-21</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">\\n  Stabilized pharmaceutical formulation comprising growth hormone and histidine\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US6869930B1/en\">\\n<span itemprop=\"publicationNumber\">US6869930B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1993-09-17</td>\\n<td itemprop=\"publicationDate\">2005-03-22</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Acylated insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US6011007A/en\">\\n<span itemprop=\"publicationNumber\">US6011007A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1993-09-17</td>\\n<td itemprop=\"publicationDate\">2000-01-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Acylated insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5652216A/en\">\\n<span itemprop=\"publicationNumber\">US5652216A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1994-05-26</td>\\n<td itemprop=\"publicationDate\">1997-07-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Pharmaceutical preparation \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO1996010417A1/en\">\\n<span itemprop=\"publicationNumber\">WO1996010417A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1994-10-04</td>\\n<td itemprop=\"publicationDate\">1996-04-11</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5646242A/en\">\\n<span itemprop=\"publicationNumber\">US5646242A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1994-11-17</td>\\n<td itemprop=\"publicationDate\">1997-07-08</td>\\n<td><span itemprop=\"assigneeOriginal\">Eli Lilly And Company</span></td>\\n<td itemprop=\"title\">Selective acylation of epsilon-amino groups \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5830999A/en\">\\n<span itemprop=\"publicationNumber\">US5830999A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1995-01-26</td>\\n<td itemprop=\"publicationDate\">1998-11-03</td>\\n<td><span itemprop=\"assigneeOriginal\">Regents Of The University Of California</span></td>\\n<td itemprop=\"title\">Stabilization of insulin through ligand binding interations \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN1196061A/en\">\\n<span itemprop=\"publicationNumber\">CN1196061A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1995-03-17</td>\\n<td itemprop=\"publicationDate\">1998-10-14</td>\\n<td><span itemprop=\"assigneeOriginal\">诺沃挪第克公司</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DK2275119T3/en\">\\n<span itemprop=\"publicationNumber\">DK2275119T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1995-07-27</td>\\n<td itemprop=\"publicationDate\">2013-11-11</td>\\n<td><span itemprop=\"assigneeOriginal\">Genentech Inc</span></td>\\n<td itemprop=\"title\">\\n  Stable, isotonic lyophilized protein formulation\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5898267A/en\">\\n<span itemprop=\"publicationNumber\">US5898267A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1996-04-10</td>\\n<td itemprop=\"publicationDate\">1999-04-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Mcdermott; Kevin</span></td>\\n<td itemprop=\"title\">Parabolic axial lighting device \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5866538A/en\">\\n<span itemprop=\"publicationNumber\">US5866538A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1996-06-20</td>\\n<td itemprop=\"publicationDate\">1999-02-02</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin preparations containing NaCl \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5905140A/en\">\\n<span itemprop=\"publicationNumber\">US5905140A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1996-07-11</td>\\n<td itemprop=\"publicationDate\">1999-05-18</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S, Novo Alle</span></td>\\n<td itemprop=\"title\">Selective acylation method \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5763401A/en\">\\n<span itemprop=\"publicationNumber\">US5763401A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1996-07-12</td>\\n<td itemprop=\"publicationDate\">1998-06-09</td>\\n<td><span itemprop=\"assigneeOriginal\">Bayer Corporation</span></td>\\n<td itemprop=\"title\">Stabilized albumin-free recombinant factor VIII preparation having a low sugar content \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DK0821006T3/en\">\\n<span itemprop=\"publicationNumber\">DK0821006T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1996-07-26</td>\\n<td itemprop=\"publicationDate\">2004-08-16</td>\\n<td><span itemprop=\"assigneeOriginal\">Aventis Pharma Gmbh</span></td>\\n<td itemprop=\"title\">\\n  Insulin derivatives with increased zinc binding\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/IL119029A0/en\">\\n<span itemprop=\"publicationNumber\">IL119029A0</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1996-08-07</td>\\n<td itemprop=\"publicationDate\">1996-11-14</td>\\n<td><span itemprop=\"assigneeOriginal\">Yeda Res &amp; Dev</span></td>\\n<td itemprop=\"title\">Long-acting drugs and pharamaceutical compositions comprising them \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO1998042368A1/en\">\\n<span itemprop=\"publicationNumber\">WO1998042368A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1997-03-20</td>\\n<td itemprop=\"publicationDate\">1998-10-01</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Therapeutic powder formulation for pulmonary administration, containing crystalline insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP2001518915A/en\">\\n<span itemprop=\"publicationNumber\">JP2001518915A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1997-03-20</td>\\n<td itemprop=\"publicationDate\">2001-10-16</td>\\n<td><span itemprop=\"assigneeOriginal\">ノボ  ノルディスク  アクティーゼルスカブ</span></td>\\n<td itemprop=\"title\">\\n  Preparation of therapeutic powder by co-precipitation of insulin and absorption enhancer\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BR9808285A/en\">\\n<span itemprop=\"publicationNumber\">BR9808285A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1997-03-20</td>\\n<td itemprop=\"publicationDate\">2000-05-16</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  Zinc-free insulin crystals, therapeutic powder formulation, process for preparing zinc-free insulin crystals, use of zinc-free crystals, and process for the treatment of diabetes mellitus\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US7097845B2/en\">\\n<span itemprop=\"publicationNumber\">US7097845B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1997-04-23</td>\\n<td itemprop=\"publicationDate\">2006-08-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Jacob Sten Petersen</span></td>\\n<td itemprop=\"title\">Combinations of antigen and mucosal binding component for inducing specific immunological tolerance \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/SI0884053T1/en\">\\n<span itemprop=\"publicationNumber\">SI0884053T1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1997-06-13</td>\\n<td itemprop=\"publicationDate\">2003-02-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Eli Lilly And Company</span></td>\\n<td itemprop=\"title\">Stable insulin formulations \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US6451762B1/en\">\\n<span itemprop=\"publicationNumber\">US6451762B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1997-10-24</td>\\n<td itemprop=\"publicationDate\">2002-09-17</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Aggregates of human insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20020155994A1/en\">\\n<span itemprop=\"publicationNumber\">US20020155994A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1997-10-24</td>\\n<td itemprop=\"publicationDate\">2002-10-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Svend Havelund</span></td>\\n<td itemprop=\"title\">Aggregates of human insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU747926B2/en\">\\n<span itemprop=\"publicationNumber\">AU747926B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1997-10-24</td>\\n<td itemprop=\"publicationDate\">2002-05-30</td>\\n<td><span itemprop=\"assigneeOriginal\">Eli Lilly And Company</span></td>\\n<td itemprop=\"title\">Insoluble insulin compositions \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU757933B2/en\">\\n<span itemprop=\"publicationNumber\">AU757933B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1997-10-24</td>\\n<td itemprop=\"publicationDate\">2003-03-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Aggregates of human insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ZA989744B/en\">\\n<span itemprop=\"publicationNumber\">ZA989744B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1997-10-31</td>\\n<td itemprop=\"publicationDate\">2000-04-26</td>\\n<td><span itemprop=\"assigneeOriginal\">Lilly Co Eli</span></td>\\n<td itemprop=\"title\">Method for administering acylated insulin. \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US6531448B1/en\">\\n<span itemprop=\"publicationNumber\">US6531448B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1997-12-23</td>\\n<td itemprop=\"publicationDate\">2003-03-11</td>\\n<td><span itemprop=\"assigneeOriginal\">Eli Lilly And Company</span></td>\\n<td itemprop=\"title\">Insoluble compositions for controlling blood glucose \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ATE290877T1/en\">\\n<span itemprop=\"publicationNumber\">ATE290877T1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1998-01-09</td>\\n<td itemprop=\"publicationDate\">2005-04-15</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  STABILIZED INSULIN PREPARATIONS\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DK1172114T3/en\">\\n<span itemprop=\"publicationNumber\">DK1172114T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1998-10-16</td>\\n<td itemprop=\"publicationDate\">2005-01-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  Stable concentrated insulin preparations for pulmonary administration\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US6211144B1/en\">\\n<span itemprop=\"publicationNumber\">US6211144B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1998-10-16</td>\\n<td itemprop=\"publicationDate\">2001-04-03</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Stable concentrated insulin preparations for pulmonary delivery \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CZ307715B6/en\">\\n<span itemprop=\"publicationNumber\">CZ307715B6</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">1999-02-22</td>\\n<td itemprop=\"publicationDate\">2019-03-06</td>\\n<td><span itemprop=\"assigneeOriginal\">University Of Connecticut</span></td>\\n<td itemprop=\"title\">A process for lyophilizing an aqueous albumin-free pharmaceutical formulations of factor VIII \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP2002543092A/en\">\\n<span itemprop=\"publicationNumber\">JP2002543092A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1999-04-27</td>\\n<td itemprop=\"publicationDate\">2002-12-17</td>\\n<td><span itemprop=\"assigneeOriginal\">イーライ・リリー・アンド・カンパニー</span></td>\\n<td itemprop=\"title\">\\n  Insulin crystals for pulmonary administration\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/GB9930882D0/en\">\\n<span itemprop=\"publicationNumber\">GB9930882D0</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1999-12-30</td>\\n<td itemprop=\"publicationDate\">2000-02-23</td>\\n<td><span itemprop=\"assigneeOriginal\">Nps Allelix Corp</span></td>\\n<td itemprop=\"title\">GLP-2 formulations \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DE10022092A1/en\">\\n<span itemprop=\"publicationNumber\">DE10022092A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2000-05-08</td>\\n<td itemprop=\"publicationDate\">2001-11-15</td>\\n<td><span itemprop=\"assigneeOriginal\">Aventis Behring Gmbh</span></td>\\n<td itemprop=\"title\">\\n  Stabilized protein preparation and process for its preparation\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US6652886B2/en\">\\n<span itemprop=\"publicationNumber\">US6652886B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2001-02-16</td>\\n<td itemprop=\"publicationDate\">2003-11-25</td>\\n<td><span itemprop=\"assigneeOriginal\">Expression Genetics</span></td>\\n<td itemprop=\"title\">Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DE10114178A1/en\">\\n<span itemprop=\"publicationNumber\">DE10114178A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2001-03-23</td>\\n<td itemprop=\"publicationDate\">2002-10-10</td>\\n<td><span itemprop=\"assigneeOriginal\">Aventis Pharma Gmbh</span></td>\\n<td itemprop=\"title\">\\n  Zinc-free and low-zinc insulin preparations with improved stability\\n \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20030119734A1/en\">\\n<span itemprop=\"publicationNumber\">US20030119734A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2001-06-28</td>\\n<td itemprop=\"publicationDate\">2003-06-26</td>\\n<td><span itemprop=\"assigneeOriginal\">Flink James M.</span></td>\\n<td itemprop=\"title\">Stable formulation of modified GLP-1 \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/HU0700126A2/en\">\\n<span itemprop=\"publicationNumber\">HU0700126A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2001-12-20</td>\\n<td itemprop=\"publicationDate\">2007-06-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Lilly Co Eli</span></td>\\n<td itemprop=\"title\">Insulin molecule having protracted time action \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2003075950A1/en\">\\n<span itemprop=\"publicationNumber\">WO2003075950A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2002-03-13</td>\\n<td itemprop=\"publicationDate\">2003-09-18</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Minimising body weight gain in insulin treatment \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ATE496064T1/en\">\\n<span itemprop=\"publicationNumber\">ATE496064T1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2002-05-07</td>\\n<td itemprop=\"publicationDate\">2011-02-15</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  SOLUBLE FORMULATIONS CONTAINING MONOMERIC INSULIN AND ACYLATED INSULIN\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20050232899A1/en\">\\n<span itemprop=\"publicationNumber\">US20050232899A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2002-05-31</td>\\n<td itemprop=\"publicationDate\">2005-10-20</td>\\n<td><span itemprop=\"assigneeOriginal\">Aradigm Corporation</span></td>\\n<td itemprop=\"title\">Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20040002451A1/en\">\\n<span itemprop=\"publicationNumber\">US20040002451A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2002-06-20</td>\\n<td itemprop=\"publicationDate\">2004-01-01</td>\\n<td><span itemprop=\"assigneeOriginal\">Bruce Kerwin</span></td>\\n<td itemprop=\"title\">Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR100615389B1/en\">\\n<span itemprop=\"publicationNumber\">KR100615389B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2002-08-23</td>\\n<td itemprop=\"publicationDate\">2006-08-25</td>\\n<td><span itemprop=\"assigneeOriginal\">(주)헬릭서</span></td>\\n<td itemprop=\"title\">Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NZ539811A/en\">\\n<span itemprop=\"publicationNumber\">NZ539811A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2002-10-29</td>\\n<td itemprop=\"publicationDate\">2008-08-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Alza Corp</span></td>\\n<td itemprop=\"title\">Solid-state polypeptide particles that facilitate the loading of an implant delivery system with a concentration of stabilised, therapeutic polypeptide sufficiently high to enable delivery of therapeutic doses of the polypeptide over an extended period of time \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20040138099A1/en\">\\n<span itemprop=\"publicationNumber\">US20040138099A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2002-11-29</td>\\n<td itemprop=\"publicationDate\">2004-07-15</td>\\n<td><span itemprop=\"assigneeOriginal\">Draeger Eberhard Kurt</span></td>\\n<td itemprop=\"title\">Insulin administration regimens for the treatment of subjects with diabetes \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/MXPA05008363A/en\">\\n<span itemprop=\"publicationNumber\">MXPA05008363A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-02-07</td>\\n<td itemprop=\"publicationDate\">2005-12-06</td>\\n<td><span itemprop=\"assigneeOriginal\">Ajinomoto Kk</span></td>\\n<td itemprop=\"title\">Remedy for diabetes. \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP2007523836A/en\">\\n<span itemprop=\"publicationNumber\">JP2007523836A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-02-19</td>\\n<td itemprop=\"publicationDate\">2007-08-23</td>\\n<td><span itemprop=\"assigneeOriginal\">ノバルティス  アクチエンゲゼルシャフト</span></td>\\n<td itemprop=\"title\">\\n  Glycoprotein antigen SIMA135 expressed in metastatic human tumor cells\\n \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20060014027A/en\">\\n<span itemprop=\"publicationNumber\">KR20060014027A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-03-04</td>\\n<td itemprop=\"publicationDate\">2006-02-14</td>\\n<td><span itemprop=\"assigneeOriginal\">더 테크놀로지 디벨로프먼트 컴퍼니 리미티드</span></td>\\n<td itemprop=\"title\">Long acting injectable insulin composition and methods of making and using thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2004112828A1/en\">\\n<span itemprop=\"publicationNumber\">WO2004112828A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-06-25</td>\\n<td itemprop=\"publicationDate\">2004-12-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk Health Care Ag</span></td>\\n<td itemprop=\"title\">Liquid composition of factor vii polypeptides \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20050054818A1/en\">\\n<span itemprop=\"publicationNumber\">US20050054818A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-07-02</td>\\n<td itemprop=\"publicationDate\">2005-03-10</td>\\n<td><span itemprop=\"assigneeOriginal\">Brader Mark Laurence</span></td>\\n<td itemprop=\"title\">Crystalline compositions for controlling blood glucose \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR101159559B1/en\">\\n<span itemprop=\"publicationNumber\">KR101159559B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2012-06-26</td>\\n<td><span itemprop=\"assigneeOriginal\">노보 노르디스크 에이/에스</span></td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2287184A3/en\">\\n<span itemprop=\"publicationNumber\">EP2287184A3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2011-08-10</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ES2574581T3/en\">\\n<span itemprop=\"publicationNumber\">ES2574581T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-14</td>\\n<td itemprop=\"publicationDate\">2016-06-20</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk Health Care Ag</span></td>\\n<td itemprop=\"title\">\\n  Aqueous liquid pharmaceutical composition of Factor VII polypeptides\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2005021022A2/en\">\\n<span itemprop=\"publicationNumber\">WO2005021022A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-09-01</td>\\n<td itemprop=\"publicationDate\">2005-03-10</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Stable formulations of peptides \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ES2229931B1/en\">\\n<span itemprop=\"publicationNumber\">ES2229931B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-10-03</td>\\n<td itemprop=\"publicationDate\">2006-01-16</td>\\n<td><span itemprop=\"assigneeOriginal\">Grifols, S.A.</span></td>\\n<td itemprop=\"title\">\\n  BILOGICALLY STABLE LIQUID COMPOSITION OF FVIII, FVW OR HUMAN FVIII / FVW COMPLEX.\\n \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP1687428A1/en\">\\n<span itemprop=\"publicationNumber\">EP1687428A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-11-14</td>\\n<td itemprop=\"publicationDate\">2006-08-09</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Processes for making acylated insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2005063298A1/en\">\\n<span itemprop=\"publicationNumber\">WO2005063298A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-12-23</td>\\n<td itemprop=\"publicationDate\">2005-07-14</td>\\n<td><span itemprop=\"assigneeOriginal\">Pharmacia Corporation</span></td>\\n<td itemprop=\"title\">Stable growth hormone liquid formulation \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ES2398318T3/en\">\\n<span itemprop=\"publicationNumber\">ES2398318T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2004-03-12</td>\\n<td itemprop=\"publicationDate\">2013-03-15</td>\\n<td><span itemprop=\"assigneeOriginal\">Biodel, Inc.</span></td>\\n<td itemprop=\"title\">\\n  Fast-acting drug delivery compositions\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2005117948A1/en\">\\n<span itemprop=\"publicationNumber\">WO2005117948A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2004-06-01</td>\\n<td itemprop=\"publicationDate\">2005-12-15</td>\\n<td><span itemprop=\"assigneeOriginal\">Ares Trading S.A.</span></td>\\n<td itemprop=\"title\">Method of stabilizing proteins \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP1796647B1/en\">\\n<span itemprop=\"publicationNumber\">EP1796647B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2004-08-12</td>\\n<td itemprop=\"publicationDate\">2010-08-11</td>\\n<td><span itemprop=\"assigneeOriginal\">Schering Corporation</span></td>\\n<td itemprop=\"title\">Stable pegylated interferon formulation \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US7365165B2/en\">\\n<span itemprop=\"publicationNumber\">US7365165B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2004-08-17</td>\\n<td itemprop=\"publicationDate\">2008-04-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Regeneron Pharmaceuticals, Inc.</span></td>\\n<td itemprop=\"title\">IL-1 antagonist formulations \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ES2575984T3/en\">\\n<span itemprop=\"publicationNumber\">ES2575984T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2004-11-12</td>\\n<td itemprop=\"publicationDate\">2016-07-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">\\n  Stable formulations of peptides containing an acylated GLP-1 analogue and a basal insulin\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CN101060856B/en\">\\n<span itemprop=\"publicationNumber\">CN101060856B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2004-11-22</td>\\n<td itemprop=\"publicationDate\">2011-01-19</td>\\n<td><span itemprop=\"assigneeOriginal\">诺和诺德公司</span></td>\\n<td itemprop=\"title\">Soluble, stable insulin-containing formulations with a protamine salt \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP1838290A2/en\">\\n<span itemprop=\"publicationNumber\">EP1838290A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2005-01-21</td>\\n<td itemprop=\"publicationDate\">2007-10-03</td>\\n<td><span itemprop=\"assigneeOriginal\">Alza Corporation</span></td>\\n<td itemprop=\"title\">Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP1846446B1/en\">\\n<span itemprop=\"publicationNumber\">EP1846446B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2005-02-02</td>\\n<td itemprop=\"publicationDate\">2013-06-26</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/ES2371361T3/en\">\\n<span itemprop=\"publicationNumber\">ES2371361T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2005-12-28</td>\\n<td itemprop=\"publicationDate\">2011-12-30</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">\\n  COMPOSITIONS THAT INCLUDE AN INSULIN ACILADA AND ZINC AND METHOD OF PRODUCTION OF SUCH COMPOSITIONS.\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/DE602007009496D1/en\">\\n<span itemprop=\"publicationNumber\">DE602007009496D1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-02-27</td>\\n<td itemprop=\"publicationDate\">2010-11-11</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  INSULIN DERIVATIVES\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2007238114B2/en\">\\n<span itemprop=\"publicationNumber\">AU2007238114B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-04-12</td>\\n<td itemprop=\"publicationDate\">2010-10-14</td>\\n<td><span itemprop=\"assigneeOriginal\">Biodel, Inc.</span></td>\\n<td itemprop=\"title\">Rapid acting and long acting insulin combination formulations \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP5269767B2/en\">\\n<span itemprop=\"publicationNumber\">JP5269767B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2013-08-21</td>\\n<td><span itemprop=\"assigneeOriginal\">ノボ・ノルデイスク・エー／エス</span></td>\\n<td itemprop=\"title\">\\n  Insulin derivative\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US9034818B2/en\">\\n<span itemprop=\"publicationNumber\">US9034818B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-06-13</td>\\n<td itemprop=\"publicationDate\">2015-05-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Pharmaceutical formulations comprising an insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BRPI0820535B8/en\">\\n<span itemprop=\"publicationNumber\">BRPI0820535B8</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-11-16</td>\\n<td itemprop=\"publicationDate\">2021-05-25</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk As</span></td>\\n<td itemprop=\"title\">\\n  pharmaceutical compositions containing insulin and an insulinotropic peptide\\n \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferencesFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/TWI451876B/en\">\\n<span itemprop=\"publicationNumber\">TWI451876B</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2008-06-13</td>\\n<td itemprop=\"publicationDate\">2014-09-11</td>\\n<td><span itemprop=\"assigneeOriginal\">Lilly Co Eli</span></td>\\n<td itemprop=\"title\">Pegylated insulin lispro compounds \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<ul>\\n<li itemprop=\"applicationsByYear\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"year\">2004</span>\\n<ul>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">KR</span>\\n<span itemprop=\"applicationNumber\">KR1020067002551A</span>\\n<a href=\"/patent/KR101159559B1/en\"><span itemprop=\"documentId\">patent/KR101159559B1/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Protection Beyond IP Right Term</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">BR</span>\\n<span itemprop=\"applicationNumber\">BRPI0413276A</span>\\n<a href=\"/patent/BRPI0413276B8/en\"><span itemprop=\"documentId\">patent/BRPI0413276B8/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">IP Right Grant</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">PL</span>\\n<span itemprop=\"applicationNumber\">PL09165072T</span>\\n<a href=\"/patent/PL2107069T3/en\"><span itemprop=\"documentId\">patent/PL2107069T3/en</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">AU</span>\\n<span itemprop=\"applicationNumber\">AU2004261353A</span>\\n<a href=\"/patent/AU2004261353B2/en\"><span itemprop=\"documentId\">patent/AU2004261353B2/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Active</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">EP</span>\\n<span itemprop=\"applicationNumber\">EP04739008A</span>\\n<a href=\"/patent/EP1660531A2/en\"><span itemprop=\"documentId\">patent/EP1660531A2/en</span></a>\\n<span itemprop=\"legalStatusCat\">not_active</span>\\n<span itemprop=\"legalStatus\">Withdrawn</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">MX</span>\\n<span itemprop=\"applicationNumber\">MXPA06001283A</span>\\n<a href=\"/patent/MXPA06001283A/en\"><span itemprop=\"documentId\">patent/MXPA06001283A/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">IP Right Grant</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">WO</span>\\n<span itemprop=\"applicationNumber\">PCT/DK2004/000511</span>\\n<a href=\"/patent/WO2005012347A2/en\"><span itemprop=\"documentId\">patent/WO2005012347A2/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Application Filing</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">JP</span>\\n<span itemprop=\"applicationNumber\">JP2006522233A</span>\\n<a href=\"/patent/JP4463814B2/en\"><span itemprop=\"documentId\">patent/JP4463814B2/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Active</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">CA</span>\\n<span itemprop=\"applicationNumber\">CA2531988A</span>\\n<a href=\"/patent/CA2531988C/en\"><span itemprop=\"documentId\">patent/CA2531988C/en</span></a>\\n<span itemprop=\"legalStatusCat\">not_active</span>\\n<span itemprop=\"legalStatus\">Expired - Fee Related</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">EP</span>\\n<span itemprop=\"applicationNumber\">EP10174490.2A</span>\\n<a href=\"/patent/EP2264065B1/en\"><span itemprop=\"documentId\">patent/EP2264065B1/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Active</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2004-07-22</span>\\n<span itemprop=\"countryCode\">EP</span>\\n<span itemprop=\"applicationNumber\">EP09165072A</span>\\n<a href=\"/patent/EP2107069B1/en\"><span itemprop=\"documentId\">patent/EP2107069B1/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Active</span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"applicationsByYear\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"year\">2006</span>\\n<ul>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2006-01-05</span>\\n<span itemprop=\"countryCode\">IL</span>\\n<span itemprop=\"applicationNumber\">IL172980A</span>\\n<a href=\"/patent/IL172980A/en\"><span itemprop=\"documentId\">patent/IL172980A/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Protection Beyond IP Right Term</span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2006-01-30</span>\\n<span itemprop=\"countryCode\">US</span>\\n<span itemprop=\"applicationNumber\">US11/343,005</span>\\n<a href=\"/patent/US7615532B2/en\"><span itemprop=\"documentId\">patent/US7615532B2/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Active</span>\\n<span bool=\"\" content=\"true\" itemprop=\"thisApp\"></span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2006-03-02</span>\\n<span itemprop=\"countryCode\">NO</span>\\n<span itemprop=\"applicationNumber\">NO20061026A</span>\\n<a href=\"/patent/NO340925B1/en\"><span itemprop=\"documentId\">patent/NO340925B1/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Protection Beyond IP Right Term</span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"applicationsByYear\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"year\">2008</span>\\n<ul>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2008-12-29</span>\\n<span itemprop=\"countryCode\">RU</span>\\n<span itemprop=\"applicationNumber\">RU2008152033/04A</span>\\n<a href=\"/patent/RU2518460C2/en\"><span itemprop=\"documentId\">patent/RU2518460C2/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"applicationsByYear\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"year\">2009</span>\\n<ul>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2009-09-16</span>\\n<span itemprop=\"countryCode\">US</span>\\n<span itemprop=\"applicationNumber\">US12/560,833</span>\\n<a href=\"/patent/US8828923B2/en\"><span itemprop=\"documentId\">patent/US8828923B2/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Active</span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"applicationsByYear\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"year\">2010</span>\\n<ul>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2010-02-10</span>\\n<span itemprop=\"countryCode\">AU</span>\\n<span itemprop=\"applicationNumber\">AU2010200497A</span>\\n<a href=\"/patent/AU2010200497B2/en\"><span itemprop=\"documentId\">patent/AU2010200497B2/en</span></a>\\n<span itemprop=\"legalStatusCat\">active</span>\\n<span itemprop=\"legalStatus\">Active</span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"applicationsByYear\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"year\">2013</span>\\n<ul>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2013-03-28</span>\\n<span itemprop=\"countryCode\">CY</span>\\n<span itemprop=\"applicationNumber\">CY20131100259T</span>\\n<a href=\"/patent/CY1113850T1/en\"><span itemprop=\"documentId\">patent/CY1113850T1/en</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2013-06-10</span>\\n<span itemprop=\"countryCode\">LU</span>\\n<span itemprop=\"applicationNumber\">LU92213C</span>\\n<a href=\"/patent/LU92213I2/en\"><span itemprop=\"documentId\">patent/LU92213I2/en</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2013-06-11</span>\\n<span itemprop=\"countryCode\">BE</span>\\n<span itemprop=\"applicationNumber\">BE2013C035C</span>\\n<a href=\"/patent/BE2013C035I2/fr\"><span itemprop=\"documentId\">patent/BE2013C035I2/fr</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2013-06-19</span>\\n<span itemprop=\"countryCode\">LU</span>\\n<span itemprop=\"applicationNumber\">LU92226C</span>\\n<a href=\"/patent/LU92226I2/en\"><span itemprop=\"documentId\">patent/LU92226I2/en</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2013-06-19</span>\\n<span itemprop=\"countryCode\">BE</span>\\n<span itemprop=\"applicationNumber\">BE2013C038C</span>\\n<a href=\"/patent/BE2013C038I2/fr\"><span itemprop=\"documentId\">patent/BE2013C038I2/fr</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2013-07-18</span>\\n<span itemprop=\"countryCode\">HU</span>\\n<span itemprop=\"applicationNumber\">HUS1300033C</span>\\n<a href=\"/patent/HUS1300033I1/en\"><span itemprop=\"documentId\">patent/HUS1300033I1/en</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"applicationsByYear\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"year\">2014</span>\\n<ul>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2014-08-06</span>\\n<span itemprop=\"countryCode\">US</span>\\n<span itemprop=\"applicationNumber\">US14/453,276</span>\\n<a href=\"/patent/US20140349925A1/en\"><span itemprop=\"documentId\">patent/US20140349925A1/en</span></a>\\n<span itemprop=\"legalStatusCat\">not_active</span>\\n<span itemprop=\"legalStatus\">Abandoned</span>\\n</li>\\n</ul>\\n</li>\\n<li itemprop=\"applicationsByYear\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"year\">2018</span>\\n<ul>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2018-01-11</span>\\n<span itemprop=\"countryCode\">NO</span>\\n<span itemprop=\"applicationNumber\">NO2018002C</span>\\n<a href=\"/patent/NO2018002I2/en\"><span itemprop=\"documentId\">patent/NO2018002I2/en</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n<li itemprop=\"application\" itemscope=\"\" repeat=\"\">\\n<span itemprop=\"filingDate\">2018-01-11</span>\\n<span itemprop=\"countryCode\">NO</span>\\n<span itemprop=\"applicationNumber\">NO2018003C</span>\\n<a href=\"/patent/NO2018003I1/en\"><span itemprop=\"documentId\">patent/NO2018003I1/en</span></a>\\n<span itemprop=\"legalStatusCat\">unknown</span>\\n<span itemprop=\"legalStatus\"></span>\\n</li>\\n</ul>\\n</li>\\n</ul>\\n</section>\\n',\n",
       " '<section>\\n<h2>Patent Citations (9)</h2>\\n<table>\\n<caption>* Cited by examiner, † Cited by third party</caption>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Priority date</th>\\n<th>Publication date</th>\\n<th>Assignee</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US3528960A/en\">\\n<span itemprop=\"publicationNumber\">US3528960A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1968-10-07</td>\\n<td itemprop=\"publicationDate\">1970-09-15</td>\\n<td><span itemprop=\"assigneeOriginal\">Lilly Co Eli</span></td>\\n<td itemprop=\"title\">N-carboxyaroyl insulins \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/GB1492997A/en\">\\n<span itemprop=\"publicationNumber\">GB1492997A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1976-07-21</td>\\n<td itemprop=\"publicationDate\">1977-11-23</td>\\n<td><span itemprop=\"assigneeOriginal\">Nat Res Dev</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n     </td>\\n</tr>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO1991012817A1/en\">\\n<span itemprop=\"publicationNumber\">WO1991012817A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1990-02-21</td>\\n<td itemprop=\"publicationDate\">1991-09-05</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel insulin compositions \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO1995007931A1/en\">\\n<span itemprop=\"publicationNumber\">WO1995007931A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1993-09-17</td>\\n<td itemprop=\"publicationDate\">1995-03-23</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Acylated insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US6251856B1/en\">\\n<span itemprop=\"publicationNumber\">US6251856B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1995-03-17</td>\\n<td itemprop=\"publicationDate\">2001-06-26</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP0894095A1/en\">\\n<span itemprop=\"publicationNumber\">EP0894095A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1996-02-21</td>\\n<td itemprop=\"publicationDate\">1999-02-03</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives and their use \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20020045731A1/en\">\\n<span itemprop=\"publicationNumber\">US20020045731A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1996-02-21</td>\\n<td itemprop=\"publicationDate\">2002-04-18</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk Of North America, Inc.</span></td>\\n<td itemprop=\"title\">Peptide derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO1998002460A1/en\">\\n<span itemprop=\"publicationNumber\">WO1998002460A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1996-07-11</td>\\n<td itemprop=\"publicationDate\">1998-01-22</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Selective acylation method \\n       </td>\\n</tr>\\n<tr itemprop=\"backwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US5898067A/en\">\\n<span itemprop=\"publicationNumber\">US5898067A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"priorityDate\">1997-02-07</td>\\n<td itemprop=\"publicationDate\">1999-04-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Crystallization of proteins \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n</section>\\n<h2>Cited By (30)</h2>\\n<table>\\n<caption>* Cited by examiner, † Cited by third party</caption>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Priority date</th>\\n<th>Publication date</th>\\n<th>Assignee</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20140349925A1/en\">\\n<span itemprop=\"publicationNumber\">US20140349925A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2014-11-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20100009899A1/en\">\\n<span itemprop=\"publicationNumber\">US20100009899A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2010-01-14</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel Insulin Derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8828923B2/en\">\\n<span itemprop=\"publicationNumber\">US8828923B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2014-09-09</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/USRE46170E1/en\">\\n<span itemprop=\"publicationNumber\">USRE46170E1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2005-02-02</td>\\n<td itemprop=\"publicationDate\">2016-10-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090074882A1/en\">\\n<span itemprop=\"publicationNumber\">US20090074882A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2005-12-28</td>\\n<td itemprop=\"publicationDate\">2009-03-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin compositions and method of making a composition \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US11167035B2/en\">\\n<span itemprop=\"publicationNumber\">US11167035B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2005-12-28</td>\\n<td itemprop=\"publicationDate\">2021-11-09</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin compositions and method of making a composition \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8722620B2/en\">\\n<span itemprop=\"publicationNumber\">US8722620B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-02-27</td>\\n<td itemprop=\"publicationDate\">2014-05-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090137454A1/en\">\\n<span itemprop=\"publicationNumber\">US20090137454A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-02-27</td>\\n<td itemprop=\"publicationDate\">2009-05-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8796205B2/en\">\\n<span itemprop=\"publicationNumber\">US8796205B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2014-08-05</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090239785A1/en\">\\n<span itemprop=\"publicationNumber\">US20090239785A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2009-09-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8933021B2/en\">\\n<span itemprop=\"publicationNumber\">US8933021B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2015-01-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090105121A1/en\">\\n<span itemprop=\"publicationNumber\">US20090105121A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2009-04-23</td>\\n<td><span itemprop=\"assigneeOriginal\">Ib Jonassen</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US9034818B2/en\">\\n<span itemprop=\"publicationNumber\">US9034818B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2007-06-13</td>\\n<td itemprop=\"publicationDate\">2015-05-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Pharmaceutical formulations comprising an insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8710000B2/en\">\\n<span itemprop=\"publicationNumber\">US8710000B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-11-08</td>\\n<td itemprop=\"publicationDate\">2014-04-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20100279931A1/en\">\\n<span itemprop=\"publicationNumber\">US20100279931A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-11-08</td>\\n<td itemprop=\"publicationDate\">2010-11-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US9603904B2/en\">\\n<span itemprop=\"publicationNumber\">US9603904B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2008-10-30</td>\\n<td itemprop=\"publicationDate\">2017-03-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Treating diabetes melitus using insulin injections with less than daily injection frequency \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10596229B2/en\">\\n<span itemprop=\"publicationNumber\">US10596229B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-10-27</td>\\n<td itemprop=\"publicationDate\">2020-03-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20160296602A1/en\">\\n<span itemprop=\"publicationNumber\">US20160296602A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2013-03-20</td>\\n<td itemprop=\"publicationDate\">2016-10-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Dosing Regimen \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10137172B2/en\">\\n<span itemprop=\"publicationNumber\">US10137172B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-04-30</td>\\n<td itemprop=\"publicationDate\">2018-11-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Administration regime \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2015071368A1/en\">\\n<span itemprop=\"publicationNumber\">WO2015071368A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-11-14</td>\\n<td itemprop=\"publicationDate\">2015-05-21</td>\\n<td><span itemprop=\"assigneeOriginal\">You-Ping Chan</span></td>\\n<td itemprop=\"title\">Long-acting insulin glargine analogue \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10040839B2/en\">\\n<span itemprop=\"publicationNumber\">US10040839B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-02-28</td>\\n<td itemprop=\"publicationDate\">2018-08-07</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives and the medical uses hereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2018217573A1/en\">\\n<span itemprop=\"publicationNumber\">WO2018217573A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2017-05-26</td>\\n<td itemprop=\"publicationDate\">2018-11-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Eli Lilly And Company</span></td>\\n<td itemprop=\"title\">Acylated insulin compound \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10335464B1/en\">\\n<span itemprop=\"publicationNumber\">US10335464B1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-06-26</td>\\n<td itemprop=\"publicationDate\">2019-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Device for titrating basal insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020032422A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020032422A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-08-08</td>\\n<td itemprop=\"publicationDate\">2020-02-13</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 대웅제약</span></td>\\n<td itemprop=\"title\">Long-acting insulin analogue and complex thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20200017078A/en\">\\n<span itemprop=\"publicationNumber\">KR20200017078A</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-08-08</td>\\n<td itemprop=\"publicationDate\">2020-02-18</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 대웅제약</span></td>\\n<td itemprop=\"title\">Long-acting Insulin Analog and Derivatives Thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US11566059B2/en\">\\n<span itemprop=\"publicationNumber\">US11566059B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-08-08</td>\\n<td itemprop=\"publicationDate\">2023-01-31</td>\\n<td><span itemprop=\"assigneeOriginal\">Daewoong Pharmaceutical Co., Ltd.</span></td>\\n<td itemprop=\"title\">Long-acting insulin analogues and derivatives thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020138953A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020138953A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">Insulin precursor purifying method using anion exchange chromatography \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020138952A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020138952A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">Composition for converting insulin precursor into insulin enzyme and method for converting insulin precursor into insulin by using same \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20200080748A/en\">\\n<span itemprop=\"publicationNumber\">KR20200080748A</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-07</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">A Method for Purifying Proinsulin Using Anion Exchange Chromatography \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20200080747A/en\">\\n<span itemprop=\"publicationNumber\">KR20200080747A</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-07</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n',\n",
       " '<section>\\n<h2>Also Published As</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Publication date</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20060132543A/en\">\\n<span itemprop=\"publicationNumber\">KR20060132543A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-12-21</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/MXPA06001283A/en\">\\n<span itemprop=\"publicationNumber\">MXPA06001283A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-04-11</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BRPI0413276B1/en\">\\n<span itemprop=\"publicationNumber\">BRPI0413276B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2020-03-03</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO20061026L/en\">\\n<span itemprop=\"publicationNumber\">NO20061026L</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-03-02</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2010200497B2/en\">\\n<span itemprop=\"publicationNumber\">AU2010200497B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2014-10-23</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO340925B1/en\">\\n<span itemprop=\"publicationNumber\">NO340925B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2017-07-17</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP2007523881A/en\">\\n<span itemprop=\"publicationNumber\">JP2007523881A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2007-08-23</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2264065A3/en\">\\n<span itemprop=\"publicationNumber\">EP2264065A3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2011-07-27</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/LU92213I9/en\">\\n<span itemprop=\"publicationNumber\">LU92213I9</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-11-19</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR101159559B1/en\">\\n<span itemprop=\"publicationNumber\">KR101159559B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2012-06-26</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/RU2008152033A/en\">\\n<span itemprop=\"publicationNumber\">RU2008152033A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-07-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2107069A3/en\">\\n<span itemprop=\"publicationNumber\">EP2107069A3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2009-11-25</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20060183668A1/en\">\\n<span itemprop=\"publicationNumber\">US20060183668A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-08-17</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/LU92213I2/en\">\\n<span itemprop=\"publicationNumber\">LU92213I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2013-08-23</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO2018002I2/en\">\\n<span itemprop=\"publicationNumber\">NO2018002I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-08-20</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20100009899A1/en\">\\n<span itemprop=\"publicationNumber\">US20100009899A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-01-14</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BRPI0413276A/en\">\\n<span itemprop=\"publicationNumber\">BRPI0413276A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-10-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2004261353B2/en\">\\n<span itemprop=\"publicationNumber\">AU2004261353B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2009-12-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CA2531988A1/en\">\\n<span itemprop=\"publicationNumber\">CA2531988A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2005-02-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/IL172980A/en\">\\n<span itemprop=\"publicationNumber\">IL172980A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2013-10-31</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/LU92226I2/en\">\\n<span itemprop=\"publicationNumber\">LU92226I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2015-04-29</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BRPI0413276B8/en\">\\n<span itemprop=\"publicationNumber\">BRPI0413276B8</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2021-05-25</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/LU92226I9/en\">\\n<span itemprop=\"publicationNumber\">LU92226I9</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-11-19</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8828923B2/en\">\\n<span itemprop=\"publicationNumber\">US8828923B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2014-09-09</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2264065B1/en\">\\n<span itemprop=\"publicationNumber\">EP2264065B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2017-03-08</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CA2531988C/en\">\\n<span itemprop=\"publicationNumber\">CA2531988C</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2016-06-28</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2010200497A1/en\">\\n<span itemprop=\"publicationNumber\">AU2010200497A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-03-04</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2107069B1/en\">\\n<span itemprop=\"publicationNumber\">EP2107069B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2013-01-16</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2264065A2/en\">\\n<span itemprop=\"publicationNumber\">EP2264065A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-12-22</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/PL2107069T3/en\">\\n<span itemprop=\"publicationNumber\">PL2107069T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2013-06-28</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP1660531A2/en\">\\n<span itemprop=\"publicationNumber\">EP1660531A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-05-31</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2005012347A3/en\">\\n<span itemprop=\"publicationNumber\">WO2005012347A3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2005-04-14</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO2018002I1/en\">\\n<span itemprop=\"publicationNumber\">NO2018002I1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-01-11</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BE2013C035I2/en\">\\n<span itemprop=\"publicationNumber\">BE2013C035I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2023-12-14</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CY1113850T1/en\">\\n<span itemprop=\"publicationNumber\">CY1113850T1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2015-11-04</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2004261353A1/en\">\\n<span itemprop=\"publicationNumber\">AU2004261353A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2005-02-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP4463814B2/en\">\\n<span itemprop=\"publicationNumber\">JP4463814B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-05-19</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BE2013C038I2/en\">\\n<span itemprop=\"publicationNumber\">BE2013C038I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2023-12-14</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2005012347A2/en\">\\n<span itemprop=\"publicationNumber\">WO2005012347A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2005-02-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2107069A2/en\">\\n<span itemprop=\"publicationNumber\">EP2107069A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2009-10-07</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO2018003I1/en\">\\n<span itemprop=\"publicationNumber\">NO2018003I1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-01-11</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/HUS1300033I1/en\">\\n<span itemprop=\"publicationNumber\">HUS1300033I1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2016-08-29</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20140349925A1/en\">\\n<span itemprop=\"publicationNumber\">US20140349925A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2014-11-27</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/RU2518460C2/en\">\\n<span itemprop=\"publicationNumber\">RU2518460C2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2014-06-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/IL172980A0/en\">\\n<span itemprop=\"publicationNumber\">IL172980A0</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-06-11</td>\\n</tr>\\n</tbody>\\n</table>\\n</section>\\n',\n",
       " '<section>\\n<h2>Similar Documents</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Publication</th>\\n<th>Publication Date</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US7615532B2/en\">\\n<span itemprop=\"publicationNumber\">US7615532B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2009-11-10\" itemprop=\"publicationDate\">2009-11-10</time>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/EP2275439B1/en\">\\n<span itemprop=\"publicationNumber\">EP2275439B1</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2014-03-26\" itemprop=\"publicationDate\">2014-03-26</time>\\n</td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US11167035B2/en\">\\n<span itemprop=\"publicationNumber\">US11167035B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2021-11-09\" itemprop=\"publicationDate\">2021-11-09</time>\\n</td>\\n<td itemprop=\"title\">Insulin compositions and method of making a composition \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US6869930B1/en\">\\n<span itemprop=\"publicationNumber\">US6869930B1</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2005-03-22\" itemprop=\"publicationDate\">2005-03-22</time>\\n</td>\\n<td itemprop=\"title\">Acylated insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US8067362B2/en\">\\n<span itemprop=\"publicationNumber\">US8067362B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2011-11-29\" itemprop=\"publicationDate\">2011-11-29</time>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US8722620B2/en\">\\n<span itemprop=\"publicationNumber\">US8722620B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2014-05-13\" itemprop=\"publicationDate\">2014-05-13</time>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/CZ287945B6/en\">\\n<span itemprop=\"publicationNumber\">CZ287945B6</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2001-03-14\" itemprop=\"publicationDate\">2001-03-14</time>\\n</td>\\n<td itemprop=\"title\">Insulin derivative and pharmaceutical preparation in which it is comprised and which is intended for treating diabetes mellitus \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n</section>\\n']"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'<h2>Cited By (30)</h2>\\n<table>\\n<caption>* Cited by examiner, † Cited by third party</caption>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Priority date</th>\\n<th>Publication date</th>\\n<th>Assignee</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20140349925A1/en\">\\n<span itemprop=\"publicationNumber\">US20140349925A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2014-11-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20100009899A1/en\">\\n<span itemprop=\"publicationNumber\">US20100009899A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2010-01-14</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Novel Insulin Derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8828923B2/en\">\\n<span itemprop=\"publicationNumber\">US8828923B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2003-08-05</td>\\n<td itemprop=\"publicationDate\">2014-09-09</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/USRE46170E1/en\">\\n<span itemprop=\"publicationNumber\">USRE46170E1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2005-02-02</td>\\n<td itemprop=\"publicationDate\">2016-10-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090074882A1/en\">\\n<span itemprop=\"publicationNumber\">US20090074882A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2005-12-28</td>\\n<td itemprop=\"publicationDate\">2009-03-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin compositions and method of making a composition \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US11167035B2/en\">\\n<span itemprop=\"publicationNumber\">US11167035B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2005-12-28</td>\\n<td itemprop=\"publicationDate\">2021-11-09</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin compositions and method of making a composition \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8722620B2/en\">\\n<span itemprop=\"publicationNumber\">US8722620B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-02-27</td>\\n<td itemprop=\"publicationDate\">2014-05-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090137454A1/en\">\\n<span itemprop=\"publicationNumber\">US20090137454A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-02-27</td>\\n<td itemprop=\"publicationDate\">2009-05-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8796205B2/en\">\\n<span itemprop=\"publicationNumber\">US8796205B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2014-08-05</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090239785A1/en\">\\n<span itemprop=\"publicationNumber\">US20090239785A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2009-09-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8933021B2/en\">\\n<span itemprop=\"publicationNumber\">US8933021B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2015-01-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20090105121A1/en\">\\n<span itemprop=\"publicationNumber\">US20090105121A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2006-05-09</td>\\n<td itemprop=\"publicationDate\">2009-04-23</td>\\n<td><span itemprop=\"assigneeOriginal\">Ib Jonassen</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US9034818B2/en\">\\n<span itemprop=\"publicationNumber\">US9034818B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2007-06-13</td>\\n<td itemprop=\"publicationDate\">2015-05-19</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Pharmaceutical formulations comprising an insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8710000B2/en\">\\n<span itemprop=\"publicationNumber\">US8710000B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-11-08</td>\\n<td itemprop=\"publicationDate\">2014-04-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20100279931A1/en\">\\n<span itemprop=\"publicationNumber\">US20100279931A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2007-11-08</td>\\n<td itemprop=\"publicationDate\">2010-11-04</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin Derivative \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US9603904B2/en\">\\n<span itemprop=\"publicationNumber\">US9603904B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2008-10-30</td>\\n<td itemprop=\"publicationDate\">2017-03-28</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Treating diabetes melitus using insulin injections with less than daily injection frequency \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10596229B2/en\">\\n<span itemprop=\"publicationNumber\">US10596229B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2010-10-27</td>\\n<td itemprop=\"publicationDate\">2020-03-24</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20160296602A1/en\">\\n<span itemprop=\"publicationNumber\">US20160296602A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n<span itemprop=\"examinerCited\">*</span>\\n</td>\\n<td itemprop=\"priorityDate\">2013-03-20</td>\\n<td itemprop=\"publicationDate\">2016-10-13</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Dosing Regimen \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10137172B2/en\">\\n<span itemprop=\"publicationNumber\">US10137172B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-04-30</td>\\n<td itemprop=\"publicationDate\">2018-11-27</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Administration regime \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2015071368A1/en\">\\n<span itemprop=\"publicationNumber\">WO2015071368A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2013-11-14</td>\\n<td itemprop=\"publicationDate\">2015-05-21</td>\\n<td><span itemprop=\"assigneeOriginal\">You-Ping Chan</span></td>\\n<td itemprop=\"title\">Long-acting insulin glargine analogue \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10040839B2/en\">\\n<span itemprop=\"publicationNumber\">US10040839B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2014-02-28</td>\\n<td itemprop=\"publicationDate\">2018-08-07</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Insulin derivatives and the medical uses hereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2018217573A1/en\">\\n<span itemprop=\"publicationNumber\">WO2018217573A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2017-05-26</td>\\n<td itemprop=\"publicationDate\">2018-11-29</td>\\n<td><span itemprop=\"assigneeOriginal\">Eli Lilly And Company</span></td>\\n<td itemprop=\"title\">Acylated insulin compound \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US10335464B1/en\">\\n<span itemprop=\"publicationNumber\">US10335464B1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-06-26</td>\\n<td itemprop=\"publicationDate\">2019-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">Novo Nordisk A/S</span></td>\\n<td itemprop=\"title\">Device for titrating basal insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020032422A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020032422A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-08-08</td>\\n<td itemprop=\"publicationDate\">2020-02-13</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 대웅제약</span></td>\\n<td itemprop=\"title\">Long-acting insulin analogue and complex thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20200017078A/en\">\\n<span itemprop=\"publicationNumber\">KR20200017078A</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-08-08</td>\\n<td itemprop=\"publicationDate\">2020-02-18</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 대웅제약</span></td>\\n<td itemprop=\"title\">Long-acting Insulin Analog and Derivatives Thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US11566059B2/en\">\\n<span itemprop=\"publicationNumber\">US11566059B2</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-08-08</td>\\n<td itemprop=\"publicationDate\">2023-01-31</td>\\n<td><span itemprop=\"assigneeOriginal\">Daewoong Pharmaceutical Co., Ltd.</span></td>\\n<td itemprop=\"title\">Long-acting insulin analogues and derivatives thereof \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020138953A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020138953A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">Insulin precursor purifying method using anion exchange chromatography \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2020138952A1/en\">\\n<span itemprop=\"publicationNumber\">WO2020138952A1</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-02</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">Composition for converting insulin precursor into insulin enzyme and method for converting insulin precursor into insulin by using same \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20200080748A/en\">\\n<span itemprop=\"publicationNumber\">KR20200080748A</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-07</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">A Method for Purifying Proinsulin Using Anion Exchange Chromatography \\n       </td>\\n</tr>\\n<tr itemprop=\"forwardReferences\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20200080747A/en\">\\n<span itemprop=\"publicationNumber\">KR20200080747A</span>\\n            (<span itemprop=\"primaryLanguage\">en</span>)\\n          </a>\\n</td>\\n<td itemprop=\"priorityDate\">2018-12-27</td>\\n<td itemprop=\"publicationDate\">2020-07-07</td>\\n<td><span itemprop=\"assigneeOriginal\">주식회사 폴루스</span></td>\\n<td itemprop=\"title\">An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n<section>\\n<h2>Also Published As</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Publication number</th>\\n<th>Publication date</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR20060132543A/en\">\\n<span itemprop=\"publicationNumber\">KR20060132543A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-12-21</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/MXPA06001283A/en\">\\n<span itemprop=\"publicationNumber\">MXPA06001283A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-04-11</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BRPI0413276B1/en\">\\n<span itemprop=\"publicationNumber\">BRPI0413276B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2020-03-03</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO20061026L/en\">\\n<span itemprop=\"publicationNumber\">NO20061026L</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-03-02</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2010200497B2/en\">\\n<span itemprop=\"publicationNumber\">AU2010200497B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2014-10-23</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO340925B1/en\">\\n<span itemprop=\"publicationNumber\">NO340925B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2017-07-17</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP2007523881A/en\">\\n<span itemprop=\"publicationNumber\">JP2007523881A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2007-08-23</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2264065A3/en\">\\n<span itemprop=\"publicationNumber\">EP2264065A3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2011-07-27</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/LU92213I9/en\">\\n<span itemprop=\"publicationNumber\">LU92213I9</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-11-19</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/KR101159559B1/en\">\\n<span itemprop=\"publicationNumber\">KR101159559B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2012-06-26</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/RU2008152033A/en\">\\n<span itemprop=\"publicationNumber\">RU2008152033A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-07-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2107069A3/en\">\\n<span itemprop=\"publicationNumber\">EP2107069A3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2009-11-25</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20060183668A1/en\">\\n<span itemprop=\"publicationNumber\">US20060183668A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-08-17</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/LU92213I2/en\">\\n<span itemprop=\"publicationNumber\">LU92213I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2013-08-23</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO2018002I2/en\">\\n<span itemprop=\"publicationNumber\">NO2018002I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-08-20</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20100009899A1/en\">\\n<span itemprop=\"publicationNumber\">US20100009899A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-01-14</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BRPI0413276A/en\">\\n<span itemprop=\"publicationNumber\">BRPI0413276A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-10-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2004261353B2/en\">\\n<span itemprop=\"publicationNumber\">AU2004261353B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2009-12-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CA2531988A1/en\">\\n<span itemprop=\"publicationNumber\">CA2531988A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2005-02-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/IL172980A/en\">\\n<span itemprop=\"publicationNumber\">IL172980A</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2013-10-31</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/LU92226I2/en\">\\n<span itemprop=\"publicationNumber\">LU92226I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2015-04-29</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BRPI0413276B8/en\">\\n<span itemprop=\"publicationNumber\">BRPI0413276B8</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2021-05-25</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/LU92226I9/en\">\\n<span itemprop=\"publicationNumber\">LU92226I9</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-11-19</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US8828923B2/en\">\\n<span itemprop=\"publicationNumber\">US8828923B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2014-09-09</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2264065B1/en\">\\n<span itemprop=\"publicationNumber\">EP2264065B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2017-03-08</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CA2531988C/en\">\\n<span itemprop=\"publicationNumber\">CA2531988C</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2016-06-28</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2010200497A1/en\">\\n<span itemprop=\"publicationNumber\">AU2010200497A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-03-04</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2107069B1/en\">\\n<span itemprop=\"publicationNumber\">EP2107069B1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2013-01-16</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2264065A2/en\">\\n<span itemprop=\"publicationNumber\">EP2264065A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-12-22</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/PL2107069T3/en\">\\n<span itemprop=\"publicationNumber\">PL2107069T3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2013-06-28</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP1660531A2/en\">\\n<span itemprop=\"publicationNumber\">EP1660531A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-05-31</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2005012347A3/en\">\\n<span itemprop=\"publicationNumber\">WO2005012347A3</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2005-04-14</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO2018002I1/en\">\\n<span itemprop=\"publicationNumber\">NO2018002I1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-01-11</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BE2013C035I2/en\">\\n<span itemprop=\"publicationNumber\">BE2013C035I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2023-12-14</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/CY1113850T1/en\">\\n<span itemprop=\"publicationNumber\">CY1113850T1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2015-11-04</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/AU2004261353A1/en\">\\n<span itemprop=\"publicationNumber\">AU2004261353A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2005-02-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/JP4463814B2/en\">\\n<span itemprop=\"publicationNumber\">JP4463814B2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2010-05-19</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/BE2013C038I2/en\">\\n<span itemprop=\"publicationNumber\">BE2013C038I2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2023-12-14</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/WO2005012347A2/en\">\\n<span itemprop=\"publicationNumber\">WO2005012347A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2005-02-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/EP2107069A2/en\">\\n<span itemprop=\"publicationNumber\">EP2107069A2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2009-10-07</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/NO2018003I1/en\">\\n<span itemprop=\"publicationNumber\">NO2018003I1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2018-01-11</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/HUS1300033I1/en\">\\n<span itemprop=\"publicationNumber\">HUS1300033I1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2016-08-29</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/US20140349925A1/en\">\\n<span itemprop=\"publicationNumber\">US20140349925A1</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2014-11-27</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/RU2518460C2/en\">\\n<span itemprop=\"publicationNumber\">RU2518460C2</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2014-06-10</td>\\n</tr>\\n<tr itemprop=\"docdbFamily\" itemscope=\"\" repeat=\"\">\\n<td>\\n<a href=\"/patent/IL172980A0/en\">\\n<span itemprop=\"publicationNumber\">IL172980A0</span>\\n              (<span itemprop=\"primaryLanguage\">en</span>)\\n            </a>\\n</td>\\n<td itemprop=\"publicationDate\">2006-06-11</td>\\n</tr>\\n</tbody>\\n</table>\\n</section>\\n<section>\\n<h2>Similar Documents</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Publication</th>\\n<th>Publication Date</th>\\n<th>Title</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US7615532B2/en\">\\n<span itemprop=\"publicationNumber\">US7615532B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2009-11-10\" itemprop=\"publicationDate\">2009-11-10</time>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/EP2275439B1/en\">\\n<span itemprop=\"publicationNumber\">EP2275439B1</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2014-03-26\" itemprop=\"publicationDate\">2014-03-26</time>\\n</td>\\n<td itemprop=\"title\">Novel insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US11167035B2/en\">\\n<span itemprop=\"publicationNumber\">US11167035B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2021-11-09\" itemprop=\"publicationDate\">2021-11-09</time>\\n</td>\\n<td itemprop=\"title\">Insulin compositions and method of making a composition \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US6869930B1/en\">\\n<span itemprop=\"publicationNumber\">US6869930B1</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2005-03-22\" itemprop=\"publicationDate\">2005-03-22</time>\\n</td>\\n<td itemprop=\"title\">Acylated insulin \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US8067362B2/en\">\\n<span itemprop=\"publicationNumber\">US8067362B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2011-11-29\" itemprop=\"publicationDate\">2011-11-29</time>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/US8722620B2/en\">\\n<span itemprop=\"publicationNumber\">US8722620B2</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2014-05-13\" itemprop=\"publicationDate\">2014-05-13</time>\\n</td>\\n<td itemprop=\"title\">Insulin derivatives \\n       </td>\\n</tr>\\n<tr itemprop=\"similarDocuments\" itemscope=\"\" repeat=\"\">\\n<td>\\n<meta content=\"true\" itemprop=\"isPatent\"/>\\n<a href=\"/patent/CZ287945B6/en\">\\n<span itemprop=\"publicationNumber\">CZ287945B6</span>\\n                (<span itemprop=\"primaryLanguage\">en</span>)\\n              </a>\\n</td>\\n<td>\\n<time datetime=\"2001-03-14\" itemprop=\"publicationDate\">2001-03-14</time>\\n</td>\\n<td itemprop=\"title\">Insulin derivative and pharmaceutical preparation in which it is comprised and which is intended for treating diabetes mellitus \\n       </td>\\n</tr>\\n</tbody>\\n</table>\\n</section>\\n<section>\\n<h2>Legal Events</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Date</th>\\n<th>Code</th>\\n<th>Title</th>\\n<th>Description</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2006-04-27\" itemprop=\"date\">2006-04-27</time></td>\\n<td itemprop=\"code\">AS</td>\\n<td itemprop=\"title\">Assignment</td>\\n<td>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Owner name</strong>:\\n              <span itemprop=\"value\">NOVO NORDISK A/S, DENMARK</span>\\n</p>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Free format text</strong>:\\n              <span itemprop=\"value\">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JONASSEN, IB;HOEG-JENSEN, THOMAS;HAVELUND, SVEND;AND OTHERS;REEL/FRAME:017550/0278;SIGNING DATES FROM 20060224 TO 20060314</span>\\n</p>\\n</td>\\n</tr>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2009-10-21\" itemprop=\"date\">2009-10-21</time></td>\\n<td itemprop=\"code\">STCF</td>\\n<td itemprop=\"title\">Information on status: patent grant</td>\\n<td>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Free format text</strong>:\\n              <span itemprop=\"value\">PATENTED CASE</span>\\n</p>\\n</td>\\n</tr>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2013-03-06\" itemprop=\"date\">2013-03-06</time></td>\\n<td itemprop=\"code\">FPAY</td>\\n<td itemprop=\"title\">Fee payment</td>\\n<td>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Year of fee payment</strong>:\\n              <span itemprop=\"value\">4</span>\\n</p>\\n</td>\\n</tr>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2015-11-12\" itemprop=\"date\">2015-11-12</time></td>\\n<td itemprop=\"code\">PTEF</td>\\n<td itemprop=\"title\">Application for a patent term extension</td>\\n<td>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Free format text</strong>:\\n              <span itemprop=\"value\">PRODUCT NAME: TRESIBA (INSULIN DEGLUDEC INJECTION); REQUESTED FOR 1803 DAYS</span>\\n</p>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Filing date</strong>:\\n              <span itemprop=\"value\">20151112</span>\\n</p>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Expiry date</strong>:\\n              <span itemprop=\"value\">20250525</span>\\n</p>\\n</td>\\n</tr>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2016-03-01\" itemprop=\"date\">2016-03-01</time></td>\\n<td itemprop=\"code\">CC</td>\\n<td itemprop=\"title\">Certificate of correction</td>\\n<td>\\n</td>\\n</tr>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2016-06-07\" itemprop=\"date\">2016-06-07</time></td>\\n<td itemprop=\"code\">CC</td>\\n<td itemprop=\"title\">Certificate of correction</td>\\n<td>\\n</td>\\n</tr>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2017-04-14\" itemprop=\"date\">2017-04-14</time></td>\\n<td itemprop=\"code\">FPAY</td>\\n<td itemprop=\"title\">Fee payment</td>\\n<td>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Year of fee payment</strong>:\\n              <span itemprop=\"value\">8</span>\\n</p>\\n</td>\\n</tr>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2018-09-06\" itemprop=\"date\">2018-09-06</time></td>\\n<td itemprop=\"code\">PTEG</td>\\n<td itemprop=\"title\">Grant of a patent term extension</td>\\n<td>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Free format text</strong>:\\n              <span itemprop=\"value\">PRODUCT NAME: TRESIBA (INSULIN DEGLUDEC INJECTION)</span>\\n</p>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Filing date</strong>:\\n              <span itemprop=\"value\">20151112</span>\\n</p>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Expiry date</strong>:\\n              <span itemprop=\"value\">20250525</span>\\n</p>\\n</td>\\n</tr>\\n<tr itemprop=\"legalEvents\" itemscope=\"\" repeat=\"\">\\n<td><time datetime=\"2021-04-21\" itemprop=\"date\">2021-04-21</time></td>\\n<td itemprop=\"code\">MAFP</td>\\n<td itemprop=\"title\">Maintenance fee payment</td>\\n<td>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Free format text</strong>:\\n              <span itemprop=\"value\">PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>\\n</p>\\n<p itemprop=\"attributes\" itemscope=\"\" repeat=\"\">\\n<strong itemprop=\"label\">Year of fee payment</strong>:\\n              <span itemprop=\"value\">12</span>\\n</p>\\n</td>\\n</tr>\\n</tbody>\\n</table>\\n</section>\\n'"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "101"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list(soup.find(\"h2\").next_siblings))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "bs4.element.Tag"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(tag)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "import lxml.html\n",
    "import requests\n",
    "\n",
    "response = requests.get(url.format(patent_number=patent_number), stream=True)\n",
    "response.raw.decode_content = True\n",
    "tree = lxml.html.parse(response.raw)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# title = soup.title.string\n",
    "# description = soup.find(\"meta\", {\"name\": \"description\"})[\"content\"]\n",
    "# soup.select_one('//*[@id=\"abstract\"]')\n",
    "tree.xpath('//*[@id=\"abstract\"]/patent-text')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<lxml.etree._ElementTree at 0x1398c49ae80>"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "paper",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
